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Abstract 
Inflammatory bowel disease, namely Crohn’s disease and ulcerative colitis, are chronic 
diseases, which require a lifelong symptomatic treatment associated with adverse effects and 
lacking curative approaches.  
The present work evaluates the potential of nano- and microparticulate drug delivery systems 
based on the biodegradable and biocompatible poly (lactic-co-glycolic acid) for oral/rectal 
administration to improve therapy of inflammatory bowel disease. A design of experiments 
approach was applied to achieve reproducible and controllable drug delivery system preparation 
to guarantee consistent quality.  
Both nanoparticles and microparticles were loaded with the immunosuppressant cyclosporine A 
and the corticosteroid budesonide. The formulations were characterized for physico-chemical 
and biopharmaceutical properties. These properties, cytotoxicity and immunotoxicity were 
evaluated in different in vitro cell culture systems including a three-dimensional cell culture 
model of the inflamed intestine. In vivo animal tests were performed with selected cyclosporine A 
formulations in a chemically induced colitis model in mice. In particular, cyclosporine A loaded 
nanoparticles showed, due to reduced systemic bioavailability, a significant improvement of 
disease characteristic parameters colon length and colon weight/length ratio, and in the 
histological analysis, compared to a commercially available product (Sandimmun® Neoral) and 
diseased control, respectively. 
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Zusammenfassung 
Chronisch-entzündliche Darmerkrankungen, Morbus Crohn und Colitis ulcerosa, benötigen eine 
lebenslange, symptomatische, medikamentöse Behandlung, die mit erheblichen 
Nebenwirkungen assoziiert ist. 
Die vorliegende Arbeit evaluiert das Potenzial von aus Polylactid-co-Glycolid hergestellten, für 
rektale/orale Applikation geeigneten, nano- und mikropartikulären Arzneistoffträgersystemen für 
eine verbesserte Behandlung. Die Herstellungsmethoden wurden durch statistische 
Versuchsplanung optimiert, um reproduzierbare, kontrollierbare Prozesse sowie gleichbleibende 
Qualität zu gewährleisten. 
Die Arzneistoffträgersysteme wurden anschließend mit dem Immunsuppressivum Cyclosporin A 
und dem Kortikosteroid Budesonid beladen, die physikochemischen und biopharmazeutischen 
Eigenschaften bestimmt sowie diese, die Zytotoxizität und die Immuntoxizität in verschiedenen 
Zellkulturmodellen, insbesondere auf einen in vitro Zellkulturmodell der entzündeten 
Darmmukosa, charakterisiert. Aufgrund der Resultate wurden die mit Cyclosporin A beladenen 
Arzneistoffträgersysteme in einem Mausmodell der chemisch induzierten Kolitis getestet. Vor 
allem die Cyclosporin A beladenen Nanopartikel zeigten, durch eine reduzierte systemische 
Verfügbarkeit des Arzneistoffes, eine signifikante Verbesserung in den charakteristischen 
Parametern Kolonlänge, Kolon Gewichts/Längenverhältnis und in der histologischen Analyse im 
Vergleich zu einem kommerziellen Produkt (Sandimmun®Neoral) und zu erkrankten, 
unbehandelten Mäusen. 
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1. Introduction 
1.1. Inflammatory bowel disease – Clinical manifestation and pathogenesis  
Currently around 320.000 patients in Germany suffer from inflammatory bowel disease (IBD) 
with increasing incidence in Northern Europe, United Kingdom and North America [1], [2]. IBD 
includes Crohn’s disease (CD) and ulcerative colitis (UC). Both forms differ in clinical 
manifestation, pathogenesis, severity level and progression.  
CD is characterized by a chronic transmural inflammation, which affects the entire wall of the 
bowel down to the serosal layer and can involve all parts of the gastrointestinal tract (GIT) 
from the mouth to the anus. The often discontinuous inflammation in CD is pre-dominantly 
situated in the small or/and large intestine, usually with a focus in the distal ileum [3], [4]. CD 
can be associated with intestinal granulomas, strictures and fistulas. On the other hand, UC 
affects the innermost mucosa, while the deeper tissue layers of submucosa, muscularis or 
serosa are not involved. The entire colon is inflamed continuously including a constant 
involvement of the rectum and a variable involvement of proximal segments of the colon, 
cecum, ascending and transverse colon. 25%-50% of the patients with UC only show an 
involvement of the rectum (proctitis) and 25% show an inflammation of the whole extension of 
the colon [5]. Furthermore, patients suffering from UC have a higher risk of developing colon 
cancer, because the colonic inflammation plays a key role for colon cancer [6]. A special form 
of IBD is the indeterminate colitis, which is characterized by an inflammation of the colon and 
shares clinical characteristics of both UC and CD [5]. Patients with IBD in general have a 
higher risk of primary sclerosis cholangitis, ankylosing spondylitis and psoriasis [7]. For 
patients suffering from UC a life time reduction has been observed [5]. 
IBD patients show common symptoms such as abdominal pain, cramping, bloody stool, 
diarrhea, fever, fatigue and weight loss [8]. Both IBD forms have an episodic progression of 
the disease. Diseased phases alternate with phases of remission. Active disease is 
characterized by an exaggerated immune response with a dominant T-cell activity [3]. CD is 
dominated by T helper cell 1 (TH1) and TH17 immune response, which is triggered by 
increased synthesis of interleukin (IL)-12 [9]. Therefore, the cytokine profile in CD is 
dominated by interferon (IFN)-γ, IL-17 and IL-22 [10]. In contrast, UC is mainly TH2 mediated, 
resulting in an expansion of natural killer cells producing IL-13 [10]. The difference in the 
immune response can be associated with the susceptibility of both disease forms to different 
kinds of treatment.  
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The hyperactivation of effector immune cells leads to high levels of pro-inflammatory 
cytokines and mediators including tumor necrosis factor-ɑ (TNF-ɑ), IL-6, IL-8, IFN-γ and 
cyclooxygenase-2 (COX-2), inducible nitric oxide synthases (iNOS) and metalloproteinase 
expression, which are involved in the mechanism of tissue damage [11], [12]. The common 
histological changes associated with IBD occur. They include e.g. villus atrophy, loss of 
crypts and ulcerations. Moreover, the activation of T-cells and macrophages leads to an 
uncontrolled inflammation and to inflammatory cycles. The nuclear transcription factor 
kappaB (NF-κB) was identified as one key regulator in the pathogenesis. The activation of 
NF-κB leads to increased levels of inflammatory mediators (TNF-ɑ, IL-6 and IFN-γ) in both CD 
and UC.  
CD and UC are assumed to be initiated by the interplay of different genetic and 
environmental factors. These factors deregulate the anti- and pro-inflammatory balance in the 
gut influencing the intestinal commensal flora and triggering the inappropriate immune 
response [1], [8], [13]. 99 non-overlapping genetic risk loci, 28 of which are common between 
CD and UC, were identified in genome wide association studies (GWAS) [14]. These genes 
are responsible for e.g. the barrier function, epithelial restitution, microbial defence, innate 
immune regulation, reactive oxygen species generation, autophagy, regulation of adaptive 
immunity and metabolic pathways associated with cellular homeostasis [14]. A monogenetic 
mutation in the NOD2 gene was further associated with CD [15]. Homozygous gene carriers 
have an 11 to 27 times higher probability of developing CD compared to heterozygous gene 
carriers. Heterozygous gene carriers themselves have a risk factor of 1.75 to 4 compared to 
non-carriers [15], [16]. NOD2 is a putative intracellular receptor for bacterial peptidoglycan, 
which is part of the bacterial membrane and induces a protective cascade. The cascade ends 
in the expression of human ɑ-defensins. ɑ-Defensins are antibiotic effector molecules 
predominantly expressed in the Paneth cells of the ileum. The mutation of the NOD2 gene 
leads to a reduced defensin expression. That is why patients carrying a NOD2 mutation show 
a high inflammation in the ileum [14], [17]. 
Several environmental risk factors, which contribute to the development of IBD, were 
proposed and investigated, but due to inconsistent data the role of some of these is still under 
discussion [13]. Environmental risk factors e.g. excessive childhood hygiene, use of oral 
contraceptives or diet are associated with an increased risk, whereas appendectomy, 
breastfeeding and infections/vaccination seem to have a protective effect [1], [13], [17].  
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Case studies and meta analyses revealed consistent data for the risk factor smoking [18]–
[21]. A meta-analysis has demonstrated that smokers have a two times higher risk especially 
of developing CD [22]. Moreover, CD patients who smoke show more frequent relapses and 
need more medical treatment and more often surgery to control the disease [22]. For patients 
suffering from UC smoking seems to have a protective effect supposedly due to an increased 
mucus and defensin production induced by nicotine [17]. 
 
1.2. Medical therapy of inflammatory bowel disease 
There is no cure for IBD. Along with that, the patients need a lifelong application of the 
medical treatment, which is based on mainly corticosteroids, aminosalicylates and 
immunosuppressants. Currently, the main aims of this symptomatic treatment of IBD are: (a) 
to reduce the inflammation, (b) to bring the patients into remission, (c) to maintain remission, 
and (d) to improve the quality of life. Finally, 70%-80% of the patients with CD and 25%-40% 
of the patients with UC however need surgery to control the disease [3], [8].  
Aminosalicylates, e.g. mesalazine, are used in order to treat mild to moderate active CD, UC 
and to maintain remission in UC [17]. The anti-inflammatory effect of aminosalicylates is 
based on the reduction of leukotriene production, inhibition of synthesis of pro-inflammatory 
cytokines and cellular release of IL-1, IL-2 and NF-κB [23]. Furthermore, aminosalicylates 
reduce the long-term risk of colon cancer in UC [12]. Several chemical modifications of 
mesalazine (5-amino-salicylic acid), e.g. olsalazine (5-amino-salicylic acid dimer) and 
balsalazide (5-amino-salicylic acid linked to 4-aminobenzoyl-β-alanine), are on the market to 
reduce the resorption in the upper parts of the intestine in comparison to mesalazine. 
Therefore, the systemic side effects, e.g. nausea, vomiting and headache, can be reduced 
[4], [23].  
Corticosteroids modulate the immune response via the glucocorticoid receptor in the nucleus 
and inhibit the expression of adhesion molecules and trafficking of immune cells to target 
tissues [23]. In the last decades they have primarily been used for the treatment of moderate 
to severe active CD and severe UC, also in combination with aminosalicylates [24]. The 
therapy induces in 60-92% of cases a remission after 4-6 weeks [17]. The application of 
corticosteroids is limited due to short-term and long-term adverse effects, e.g. systemic 
immunosuppression, risk of opportunistic infections, Cushing's syndrome including diabetes 
mellitus and osteoporosis [25]. 
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Moreover, some patients do not respond to corticosteroids, named as steroid-refractory 
disease, or the corticosteroids cannot be tapered without relapse, named as steroid-
dependent. The significant morbidity under treatment with corticosteroids for CD patients 
caused a change to newer agents including biologicals [4]. Unfortunately, neither 
aminosalicylates nor corticosteroids can reduce relapses in CD which is the main goal of the 
medical treatment in CD. 
Azathioprine, methotrexate und biologicals (infliximab, adalimumab, cetrolizumab) are used in 
order to treat steroid-refractory or steroid-dependent patients and severe disease, in case 
other therapy options failed to induce remission [4]. As azathioprine, which can cause bone 
marrow suppression and pancreatitis, needs 2-3 months to reach the full therapeutic efficacy, 
it is often combined with biologicals (“bridging”) [3], [17]. This combination also reduces the 
development of antibodies against the biologicals, which is a drawback of a biological therapy 
[26]. 
Infliximab, a chimeric monoclonal antibody to TNF-α, was introduced to the medical therapy 
of CD in 1997 [5], [27]. TNF-α mediates multiple pro-inflammatory processes implemented in 
the pathogenesis of IBD. Adalimumab and certolizumab pegol are also approved by the 
American Food and Drug Administration (FDA) and showed efficacy in the treatment of CD 
[5]. Adalimumab is a recombinant human IgG1 monoclonal antibody that binds with high 
specificity and affinity to human TNF-α [5]. Certolizumab pegol is a monoclonal humanized 
anti-TNF-α antibody Fab’ fragment linked chemically to polyethylene glycol (PEG) [5]. All 
these biologicals have to be applied intravenously or subcutaneously, resulting in a reduced 
patient compliance. Although these therapies generally demonstrated efficacy in inducing and 
maintaining remission, they failed in inducing remission in about 50% of the CD patients [4], 
[23], [26], [28], [29]. Plus, the use of biologicals is further associated with infections and 
increased risk of neoplasia in combination with immunosuppressive drugs [26].  
 
1.2.1. Cyclosporine A and budesonide as drugs for the treatment of inflammatory 
 bowel disease 
The cyclosporine A (CYA) is a cyclic peptide of 11 amino acids (Figure 1.1a), which are 
partially untypical or rarely encountered in nature, e.g. D-alanine [30]. CYA is a very potent 
immunosuppressive drug and can be isolated from the fungus Tolypocladium inflatum Gams 
(Beauveria nivea) or chemically synthesised. 
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In the treatment of IBD CYA is applied to UC patients suffering from fulminant colitis or who 
being steroid-refractory. The therapy is started intravenously for three to five days 
(2 mg/kg/day) and is typically continued after reaching remission with oral CYA (5-
8 mg/kg/day, in two doses per day), often in co-medication with azathioprine and 
methotrexate for maintenance therapy [17].  
a 
 
b 
 
Figure 1.1. Chemical structure of (a) cyclosporine A (Mr 1206.6) as tertiary structure (-- = hydrogen bond) and (b) 
budesonide (Mr 430.53) (adapted and modified from Steinhilber et al. [31]). 
CYA inhibits the production of cytokines secreted by lymphocytes e.g. IL-1 and IL-2 at a high 
selectivity [30]. Furthermore, CYA inhibits nitric oxide synthesis induced by IL-1ɑ, 
lipopolysaccharides and TNF-ɑ. Through the inhibition of IL-2 the expansion of antigen-
specific T-cells and the maturation to cytotoxic T-cells is stopped and, therefore, the immune 
reaction is suppressed [30]. CYA binds on the intracellular receptor cyclophilin, a proline-
cis/trans-isomerase [23]. The complex (CYA/cyclophilin) inhibits afterward the 
calcium/calmodulin depending phosphatase, calcineurin, and blocks the signal transduction. 
This prevents the activation of transcription factors, e.g. NFAT (nuclear factor of activated 
T cells) and NF-κB hindering the synthesis of cytokines in T-cells. NFAT is mostly located in 
T cells. This explains the high selectivity of CYA and the specific, reversible effect on 
lymphocytes, especially TH cells, whereas phagocytic cells of the reticuloendothelial system 
are not affected [23], [31], [32]. 
CYA is an inhibitor and substrate of cytochrome P450 3A4 (CYP3A4) and inhibitor of the 
multidrug efflux transporter p-glycoprotein. Therefore, CYA may increase plasma 
concentrations of co-medications that are substrates of CYP3A4 or p-glycoprotein or both, 
e.g. verapamil, carbamazepine resulting in overdosing [17], [31].  
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The physico-chemical, pharmacokinetic and pharmacodynamic properties of CYA are 
summarized in Table 1.1. The therapeutic window of CYA is narrow (0.15-0.25 µg/ml [31]) 
and the plasma levels should be monitored during the therapy to avoid overdosing as well as 
underdosing and consequently inefficiency. The CYA therapy is associated with adverse 
effects, e.g. neurological toxicity (tremor), opportunistic infections, renal dysfunction and 
hypertension, hirsutism and gum hyperplasia [23]. Lifelong application of CYA may lead to 
hypertension, diabetes mellitus, hyperlipidemia and adiposity [23].  
Table 1.1. Physico-chemical, pharmacodynamic and pharmacokinetik properties [23], [33], [34]. 
substance cyclosporine A budesonide 
physico-chemical properties 
solubility  
soluble in DMSO (25 mg/ml), 
acetone ethanol, chloroform; 
practically insoluble in water 
freely soluble in methylene chloride; 
sparingly soluble in ethanol 
(30 mg/ml); 
partially soluble in water (saturation 
concentration 14 µg/ml) 
partition coefficient log Poctanol/water 2.92 [35] log Poctanol/water 3.2 [36] 
pharmacodynamic and pharmacokinetik properties 
absolute bioavailability 
10-90%  
(depends on the patient population); 
increased by fatty meals 
11% 
plasma protein binding 90% 88% 
apparent volume of 
distribution 
3.5-13 l/kg 3 l/kg 
terminal half-life 5-19 h 2.5 h 
maximum plasm 
concentration after oral 
application 
1.5-2.0 h 5 h 
elimination biliary renally 
 
Budesonide (BU), a corticosteroid (Figure 1.1b), is a strong antiphlogistic drug with strong 
local effectiveness. The affinity of BU to the glucocorticoid receptor is 100 fold higher than of 
hydrocortisone. Like other glucocorticoids BU inhibits the activation of NF-κB. The anti-
inflammatory effect results from the inhibition of genes responsible for the synthesis of pro-
inflammatory mediators, e.g. IL-1, COX-2 and the activation of the anti-inflammatory IL-1 
receptor agonist and IL-10. 
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The physico-chemical, pharmacokinetic and pharmacodynamic properties of BU are 
summarized in Table 1.1. BU is metabolized up to 90% during first liver passage to 
metabolites with less effectiveness (<1% compared to BU), in particular 6-beta-
hydroxybudesonide and 16-alpha-hydroxyprednisolon. The metabolites are eliminated 
renally.  
In the therapy of CD BU is a first-line agent for the treatment of affected ileum and/or 
ascending colon [17], [37], [38]. It can be applied orally (9 mg/day) and locally as foam, 
suppositories or enema (2 mg/day) in order to target the descending colon and rectum [17]. 
The extensive first-pass metabolism reduces the systemic bioavailability of BU after oral 
administration [39], [40]. Therefore, also side effects comparable to other corticosteroids, e.g. 
weight gain and cushingoid, occur in a reduced pattern. Apart from this, steroid-refractory 
disease can also not be overcome with BU therapy.  
 
1.3. Dosage forms for the therapy of inflammatory bowel disease 
A major issue in the therapy of the local inflammation is the systemic absorption of those 
highly active drugs which cause adverse effects, especially due to the required lifelong 
treatment. This effect can be enhanced by the increased permeability of the upper intestinal 
mucosa during the active state of IBD [41], [42]. 
IBD differs in its manifestation and the therapy has to be individualized in the applied drug 
and the drug delivery strategy depending on the location of the inflammation. To achieve an 
optimal treatment, the drug should ideally be applied locally at the site of inflammation to 
obtain high concentrations in the affected tissues and to reduce the access to the systemic 
circulation [43]. Several drugs and a multitude of simple as well as advanced formulations are 
available on the market for the therapy of IBD. Dosage forms are available to target the 
inflamed areas via rectal route or which release the encapsulated drugs pH- or time-
dependently to target different parts of the GIT via oral route. However, the used galenic 
strategies are not fully adapted to the pathophysiological changes in IBD.  
Proctitis and left-sided colitis, which is characterized by an inflammation of the descending 
colon, are treated rectally with foams, enemas and suppositories containing either 
aminosalicylates (mesalazine; Salofalk®, Claversal®) or corticosteroids (betamethasone; 
Betnesol®). In CD, where the inflammation is more distributed and often the ileum involved, 
the rectal therapy with foams, enemas and suppositories is less suitable.  
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In general, the oral route is more tolerated by patients, but the solid oral dosage forms require 
advanced galenic approaches [44]. However, the application of solid oral dosage forms such 
as capsules, granules, pellets and tablets is often inefficient due to accelerated elimination by 
diarrhea in IBD. Furthermore, UC patients show a decreased contractility of the colon leading 
to variable gastrointestinal transit times [45]. Nonetheless, this is the only chance of delivering 
drugs to the upper parts of the intestine [43].  
Coatings of oral dosage forms releasing the encapsulated drug in pH-dependent manner are 
used in order to target different parts of the intestine [4], [46]. For example mesalazine 
containing tablets with a stomach resistant coating (Claversal®, Salofalk®) and with colon 
targeting coating (Asacolitin®) have been developed to target the terminal ileum and the 
colon, respectively [4], [46]. Unfortunately, 20-40% of the released mesalazine is systemically 
available from these with poly(meth)acrylates (Eudragit®) coated tablets and, thus, 
responsible for observed side effects [4], [46], [47]. Furthermore, several studies revealed a 
pH change in the GIT depending on the disease state of the patients [48]. In detail, the 
colonic pH in active and inactive CD was investigated to be ~5.3 in both the proximal and in 
the distal part. The pH of the small intestine seems not to be affected [49], [50]. For UC 
proximal colonic pH values ranging individually from 2.3-3.4 have been reported [51]. These 
pathophysiological changes could influence the drug release resulting either in an incomplete 
drug release or in an release apart from the targeted part of the GIT [49]. Therefore, these 
pH-dependent release strategies have been controversially discussed [44], [52].  
Moreover, the optimum size range of dosage forms to avoid the accelerated elimination by 
diarrhea and to increase transit times is so far not finally determined [43]. Hardy et al. 
investigated options for influencing the residence time in the large intestine even for patients 
suffering from diarrhea. By reducing the diameter of an oral dosage form (capsule vs. pellet 
system) an increased residence time in the large intestine could be achieved [53]. Thus, 
sugar matrix based pellet systems containing BU, which are coated with Eudragit®L 100 
(Entocort®) or a combination of Eudragit®S 100 and Eudragit®L 100 (Budenofalk®), were 
successfully commercialized for IBD treatment to target the terminal ileum or ascending colon 
[17], [23], [54], [55]. As they release the BU at pH >5.5 and pH 6.4, respectively, at the 
moment only patients with inflammation located in the respective parts of the colon benefit 
from this galenic modification. 
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Furthermore, efforts have been made to develop controlled release oral dosage forms with a 
lag phase in the drug release to treat patients with affected parts in the small and large 
intestine [56]. One of these systems is based on a tablet, which disintegrates in the stomach 
and releases microgranules (Pentasa®). The microgranules coated with ethyl cellulose 
release the encapsulated mesalazine time-dependently and diffusion controlled [47].  
Due to the low solubility of CYA special dosage forms had to be developed in order to deliver 
CYA orally and intravenously. For example CYA was formulated in a dispersed system, 
consisting of aqueous phase, lipid phase and surfactant, which forms a microemulsion in 
contact with water (Sandimmun® Neoral) [57]. The small size of the emulsion droplets 
(<100 nm) supports the fast adsorption and, thus, increases the bioavailability [34]. 
Nevertheless, the CYA is systemically available from this dosage form causing adverse 
effects. 
CYA and BU were selected as drugs for the presented work, leading to adverse effects when 
systemically available. Furthermore, with the current dosage forms the drug is also available 
in healthy parts of the intestine. Therefore, patients would benefit from a dosage form that 
would deliver the encapsulated CYA and BU directly to the inflamed areas of the intestine. 
Such a local treatment aimed to reduce the applied dose due to high drug concentrations in 
the affected tissues. Furthermore, high systemic concentrations would ideally be avoided 
and, therefore, the side effects of the used drugs could be reduced.  
 
1.4. State of the art - Polymeric nano- and microparticles for the therapy of 
inflammatory bowel disease 
Several well-known properties of particulate formulations in the micro- or nanometer size 
range (nanoparticles and microparticles) suggest them as a very promising strategy for the 
therapy of IBD. Preferentially biodegradable and biocompatible polymers, e.g. poly (lactic-co-
glycolic acid), (PLGA), and natural compounds such as proteins and lipids are used in order 
to fabricate nanoparticles (NPs) and microparticles (MPs) in the medical and pharmaceutical 
context [58]. The selection of material for the formulation of drug delivery systems (DDS) is 
furthermore a key factor for a (a) successful encapsulation and delivery of drugs, and (b) 
compatibility in the applied organism.  
In the production and development of NPs and MPs as DDS the synthetic, biocompatible and 
biodegradable polymer PLGA is due to several characteristics the most attractive choice. 
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PLGA is approved by the FDA in the medical field for the use as implants and surgical 
sutures [59]. Furthermore, in the human body PLGA will be degraded through hydrolysis of 
the ester-bonds into its two non-toxic components, lactic acid and glycolic acid, which can be 
metabolized in the citric cycle [59], [60]. The fastest degradation of PLGA is reached with a 
50/50 (wt/wt) ratio of lactic and glycolic acids. In this ratio, PLGA is amorphous and, 
therefore, optimal for DDS as it decomposes within two months [61], [62]. The degradation 
proceeds more slowly with higher ratios of lactic acid, which increase the hydrophobic 
characteristics forcing a reduced water adsorption [61], [62]. Therefore, the faster release 
rates of encapsulated ingredients were obtained with PLGA at a ratio of 50/50 (lactic/glycolic 
acid) [63], [64].  
The adjustable wide range of degradation times as well as the possibility of modifying the 
surface by conjugation to the carboxyl groups, offer the ability to encapsulate hydrophobic 
and hydrophilic drugs (e.g. BU and CYA). Plus, proteins as well as RNA and DNA can be 
attached on PLGA based DDS [61]. During the past two decades PLGA was extensively 
studied for the production of nano- and microparticulate DDS for several areas of the human 
body e.g. blood system, skin [65], lung [66] and intestine [67], [68]. 
Targeting strategies 
With the polymeric NPs and MPs different targeting strategies can be addressed aiming for 
an improved therapy of IBD by active or passive targeting and pH- or time-dependent release 
strategies. 
For an active targeting with specific targeting moieties on the particle surface a suitable target 
cell type, which can alter the inflammatory status in IBD alone, has been not identified so far. 
In addition, a specific and accessible enough surface receptor needs still to be found. 
Nevertheless, first active targeting strategies have been tested for targeting the epithelial cells 
and immune-related cells, which are present due to the inflammation and involved in the 
pathogenesis of IBD [69]–[71].  
Passive targeting strategies by oral or rectal application of NPs and MPs were successfully 
tested and revealed the advantages of the DDS for the therapy of IBD. On the one hand NPs 
and MPs have been used in order to deliver the encapsulated drugs near to the cells, 
supporting a faster up-take in the inflamed mucosa and for saving the drug from degradation 
[72], [73]. A higher expression of p-glycoprotein and CYP3A enzymes in inflamed tissues can 
increase the degradation of drugs and lead to treatment failure [74].  
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On the other hand NPs and MPs are able to remain in the ulcerated areas of the colon for 
prolonged periods of time, due to the destroyed intestinal barrier, whereby they can release 
the encapsulated drug controlled in situ [67], [75]–[78]. Furthermore, NPs can be entrapped in 
the mucus layer of the lumen [75]. Due to the inflammation the mucus production increases, 
which leads to a thicker mucus layer, particularly in the ulcerated areas [72], [79], [80]. By 
comparing 0.1 µm, 1 µm and 10 µm polystyrene NPs in a model of experimental colitis 
(trinitrobenzenesulfonic acid (TNBS) Lewis rat model) Lamprecht et al. could show a size 
depended accumulation in the intestinal mucus and inflamed tissues. The accumulation of 
0.1 µm NPs was higher, due to the attachment to the increased mucus layer, the easier 
penetration into this mucus layer and deposition in ulcerated areas [75], [78].  
In order to control the release and avoid high systemic concentrations, mesalazine was 
covalently bound to poly (ε-caprolactone) NPs. After oral administration the particles showed 
a comparable efficacy to mesalazine solution in a TNBS colitis mice model [81]. These 
particles were improved by grafting silica NPs with mesalazine, which offer the possibility of a 
triggered release after 8 h by enzymatic cleavage [81], [82]. The silica NPs accumulated 
sixfold higher in inflamed tissues in the TNBS colitis model compared to healthy control [82]. 
Apart from the concept of time-dependent release from particulate formulations, also NPs and 
MPs with a pH-dependent release were prepared. Both concepts aimed to overcome the 
issue of the residence time of coated tablets and pellets by size reduction. BU loaded pH-
sensitive NPs, consisting of a matrix of PLGA and Eudragit®S 100, also showed an 
accumulation in inflamed tissues in a TNBS rat model [83]. In a recent study BU loaded 
PLGA NPs were coated with the pH-sensitive Eudragit®S 100 and the efficacy was confirmed 
in different acute and chronic colitis mouse models [67]. 
Studies with chitosan-calcium-alginate MPs for a colon specific oral delivery of mesalazine 
revealed in a TNBS colitis model an advantage of negatively charged DDS [84]. This effect 
was explained with the high concentration of positively charged proteins in inflamed tissues, 
in particular high amounts of eosinophil cationic protein, which could be determined in the 
colorectal perfusion fluid of IBD patients [85], [86]. Jubeh et al. underlined these findings by 
investigating a charge dependent deposition of liposomes after rectal administration. The 
study revealed a twice as strong adherence of anionic liposomes to the inflamed mucosa in 
comparison to neutral or cationic liposomes [86], [87].  
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In summary, these studies substantiate the potential of NPs and MPs for an improved therapy 
of IBD. A size-dependent accumulation can be proposed and at the moment NPs seems to 
be favorable in rodent colitis models [75], [81]. However, a recent study revealed a higher 
accumulation efficiency for MPs in human patients compared to NPs prepared with the same 
material [76]. This effect has to be further investigated. In addition, a species mechanism was 
suggested by Leonard et al., which could help to explain this effect, due to the different 
dimensions. For example the length of small intestine was determined to be <50 cm for mice 
compared to humans with 3-4 m [88].  
Unfortunately, only a few nanoformulations, mainly nanocrystals, have entered the 
pharmaceutical market until now. It can be presumed that the absence of information 
concerning production parameters is hindering the scale-up and the more widespread 
production in particular of matrix based NPs and MPs as DDS in the pharmaceutical industry 
[89]. 
 
1.5. Selected production techniques for the fabrication of PLGA based drug delivery 
systems 
The choice of the appropriate preparation technique for a particulate DDS, NPs or MPs, is 
based on nature, lipophilicity and stability of the drug, on the nature of polymer and the route 
of administration, as well as the period of administration [90], [91]. In general, the methods 
can be divided in three main groups: (a) chemical methods with in situ polymerizations of 
macromolecules, (b) physico-chemical methods using preformed polymers [91], and 
(c) mechanical methods using e.g. spray drying for the formation of the particulate DDS [92]. 
Nanoprecipitation method 
The nanoprecipitation method with all their modifications is one of the most used physico-
chemical methods for producing DDS [93]–[95]. In general, the nanoprecipitation method is 
known to be more controllable, reproducible and less time consuming due to fewer 
preparation steps [89].  
For the preparation of DDS by the nanoprecipitation method a polymer is dissolved in a 
solvent, mostly an organic solution (e.g. acetone), which has to be miscible with a so called 
non-solvent for the polymer, mostly an aqueous solution [96]. An exemplary set-up is 
depicted in Figure 1.2.  
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The drop wise addition of the organic phase into the stirred aqueous phase results in the 
spontaneous formation of an emulsion. The diffusion of the organic solvent into the outer 
aqueous phase starts the polymer precipitation [94]. In detail, the formation of particles 
involves complex interfacial hydrodynamic phenomena and can either be explained by 
interfacial turbulence [58] or the Gibbs–Marangoni effect [97]. 
 
Figure 1.2. Set-up of the nanoprecipitation method. 
In general, the aqueous phase is characterized by a high surface tension while the organic 
phase features a low surface tension. The differences in surface tension cause interfacial 
turbulences, which form eddies of solvent at the interface and generate interfacial convective 
flows [94]. Thus, the organic phase diffuses into the aqueous phase taking polymer chains 
with it. These chains are still in solution and precipitate forming particles due to further 
diffusion of organic solvent [94]. The nanoprecipitation method is limited to low polymer 
concentrations, which varies with the used polymer material. As consequence, with the 
nanoprecipitation method one achieves less DDS per volume in comparison to other physico-
chemical methods [98]. 
Nano spray drying method 
The spray drying technique is used routinely as method to convert liquid formulations into a 
dry powder as storable product. The process works for drug dispersions and dispersed 
nanoparticulate DDS [99]. Furthermore, the spray drying technique can also be used as 
mechanical method for formulating DDS in one step without extra washing or drying steps 
(single step process) for different areas of application [92].  
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A novel nano spray drying system (Figure 1.3), the Büchi Nano Spray Dryer B-90 (Büchi B-
90), was recently developed especially for producing spray dried products in the submicron 
size range and attaining high formulation yields up to 90%, realized by a vibrating mesh to 
transport the feeding solution into the drying gas flow [100], [101]. 
This system (Figure 1.3) differs from a classical spray dryer in three main functions. In 
contrast to a nozzle for atomization of the feeding solution, the Büchi B-90 uses a stainless 
steel membrane with defined pores (4 µm, 5.5 µm or 7 µm; provided by the manufacturer), 
which vibrates at a fixed ultrasonic frequency by a piezoelectric actuator. This vibrating mesh 
in the spray head of the Büchi B-90 is responsible for the formation of small droplets of 
feeding solution and, therefore, the production of particles in the low micron to submicron size 
range. Secondly, the heating system is formed of an electrically heated porous metal foam. 
This foam allows an optimal heating and a laminar flow of the drying gas which again 
provides for a quick evaporation of the sprayed solvents preventing droplet coalescence. The 
extremely small particles require an alternative mechanism for particle collection other than 
the classical cyclone collector, which is less suitable and efficient for the collection of particles 
<5 µm, especially for particles smaller than 2 to 3 µm [102]. An electrostatic particle 
precipitator consisting of a grounded and a collecting electrode allows the particle collection 
in the Büchi B-90 as third difference to classical spray dryer. 
a 
 
b 
 
Figure 1.3. (a) Schematic set-up and (b) Figure of the Büchi B-90 (adapted from Arpagaus et al. [103]). 
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Compressed air or indoor air is used for spraying of aqueous solutions. Additionally, a mixture 
of nitrogen and a small amount of carbon dioxide, which is needed for the particle collection, 
is required for a safety spraying out of organic solutions. The Büchi B-90 can be connected to 
a cooling unit, the Inert-Loop B-295, which separates the organic solvent from the drying gas. 
By today, only a few studies have been published using this system which is available since 
the year 2009. First studies concentrated on the drying of pharmaceutical excipients 
(e.g. lactose, chitosan, mannitol, trehalose), proteins [103]–[106] and dry lipid nano-
emulsions [92]. Furthermore, the Büchi B-90 has been used for the production of calpain 
inhibitor nanocrystals [107] and furosemide nanocrystals [92]. Recent studies also focused on 
the preparation of particles using polymeric wall materials (arabic gum, whey protein, 
polyvinyl alcohol, modified starch and maltodextrin) and proteins [108], [105] and the 
encapsulation of model drugs in biodegradable polymers [100], [109]. Spray drying by using 
the Büchi B-90 was also applied to improve the solubility of pure BU [110]. The solubility was 
also improved by encapsulating CYA and dexamethasone in PLGA [100]. First studies were 
carried out focusing on the encapsulation of proteins [105] and model drugs in biodegradable 
polymers [100], [109], e.g. nimodipine in PLGA MPs for post hemorrhagic cerebral 
vasospasm [111]. Apart from the pharmaceutical field, the Büchi B-90 was also used in order 
to produce lithium carbonate hollow spheres for a novel lithium battery approach [112]. 
 
1.6. In vitro three-dimensional cell culture model as an advancement in efficacy studies 
of particulate drug delivery systems 
For conventional ADME (absorption, distribution, metabolism and excretion) and permeation 
studies enteric cell lines, in detail Caco-2, HT29 or T84 cell lines, are widely used as in vitro 
models of the healthy intestinal mucosa [113]. These models consist of one cell type only 
and, therefore, cannot mimic the complex interactions with other cells in the diseased 
intestine, in particular for IBD of immune cells [114]. As an improvement co- and triple 
cultures were developed with the major focus on transport studies consisting of enterocytes 
and immune cells, e.g. macrophages [115], [116]. However, these studies addressed the 
situation in a healthy intestine. The combination of enteric and immunocompetent cells can 
be used in order to establish an inflammable intestinal model for IBD as demonstrated by 
Tanoue et al., who co-cultured Caco-2 and RAW264.7 cells, a macrophage cell line [117].  
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A recently developed three-dimensional cell culture model (triple culture model) of the 
inflamed intestinal mucosa by Leonard et al. [88], which was improved by Susewind et al. 
[118] using cell lines, demonstrated to be an optimal tool for screening of potential 
nanomedicines, including particulate DDS as well as liposomes, for IBD [119]. This model 
(Figure 1.4) consists of Caco-2, a human intestinal epithelial cell line, THP-1, which can be 
stimulated to macrophages, and MUTZ-3, a dendritic-like cell line.  
 
Figure 1.4 Set-up of triple culture on Transwell® inserts (adapted from Draheim and Susewind et al., chapter 12 
[120]). The triple culture model consists of macrophages and dendritic cells embedded in collagen. The Caco-2 
cells, as intestinal epithelial cell line, are seeded on top of the collagen layer forming a tight monolayer [119]. 
Image is not drawn to scale. 
 
Through inflammation, the model can mimic the pathophysiological changes of the inflamed 
intestinal mucosa in chronic IBD patients. They are characterized by reorganization of tight 
junctions, thus, reduced barrier properties and increased immune cell activity with the release 
of pro-inflammatory markers [119]. The inflammation of the triple culture model is induced by 
IL-1ß and afterwards significantly enhanced by the MUTZ-3 and THP-1 cells [119]. The 
usage of macrophages and dendritic cells integrates the complexity of the pathogenesis in 
IBD, as both are involved in the inflammatory reactions. 
The application of DDS on the apical compartment, which mimics the intestinal lumen, allows 
testing the anti-inflammatory efficacy via measurement of IL-8 levels and the epithelial barrier 
integrity by the measurement of the transepithelial electrical resistance (TEER). IL-8 is a pro-
inflammatory cytokine that is inducing chemotaxis and activation of granulocytes. Moreover, 
IL-8 is involved in the initiation and progression of UC and CD in human patients [121]. 
Additionally, the triple culture model can be used to determine particle deposition within the 
model [119].  
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The model shows an improved reproducibility and acts comparable to the before developed 
model with the primary cell lines. Therefore, it demonstrated its capability of acting as a tool 
to screen for potential DDS in vitro before entering the in vivo studies [118], [119]. 
 
1.7. The chemically induced dextran sodium sulfate model of colitis for in vivo studies  
For pre-clinical and efficacy studies of new therapeutic strategies for IBD rats and mice 
models of colitis are widely used. Although not presenting the complexity of the human 
disease, the rodent models were validated to study pathophysiological mechanisms and 
efficacy of new therapeutic strategies, both dosage forms and drugs [122], [123]. According to 
Wirtz et al. the models can be separated into models, which have (a) defects in epithelial 
integrity/permeability, (b) defects in innate immune cells, and (c) defects in cells of the 
adaptive immune system [123]. The defects can be induced chemically, by immune cell 
transfer or by gene targeting. 
Among the chemically induced models of colitis, the dextran sodium sulfate (DSS) model has 
been extensively characterized. Nowadays, it is widely used to study epithelial repair 
mechanisms as well as the contribution of innate immune mechanisms [123], [124]. In recent 
studies, the model has been frequently applied to evaluate the efficacy of novel anti-
inflammatory drugs [12], [122], [124]–[127], and drug delivery strategies [67], [71], [72], [77] 
for an improved therapy of IBD. This model shares many of the macroscopic, histological and 
immune characteristics of human IBD. In particular, it demonstrates clinical and histological 
similarity to human UC and is characterized by the following clinical parameters: bloody 
diarrhea, shortening of the colorectum, gastrointestinal inflammation with histopathological 
changes like villus atrophy, loss of crypt, ulcerations and infiltrations with granulocytes [123], 
[125], [128], [129].  
DSS is directly toxic to the gut epithelial cells of the basal crypts and affects the integrity of 
the mucosal barrier [123]. The increased permeability of the intestinal barrier and 
hyperosmolarity in the lumen due to the DSS cause the bloody diarrhea [130]. Furthermore, 
an enhanced mucosal production of inflammation related cytokines, from epithelial cells and 
immune competent cells, leads to an increased immune cell infiltration [130]. The DSS model 
was evaluated to have an increased production of cytokines in the colonic mucosa: TNF-ɑ, 
IL-1β, IL-6, IL-10, IL-12 and IFN-γ [130], [131]. 
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The DSS model can be used to assess an acute or chronic inflammation by adding DSS into 
the drinking water of the mice or rats. The administration of DSS over a time-period of seven 
days induces the acute colitis with increased mucosal levels of macrophage-derived 
cytokines, e.g. TNF-ɑ and IL-6. When the DSS is applied for several cycles, e.g. according to 
Wirtz et al. for seven days followed by 14 days of water, it results in chronic colitis [128]. The 
chronic model can be modified by a single initial dose of the genotoxic colon carcinogen 
azoxymethane. Azoxymethane induces an inflammation-associated colorectal cancer, 
relevant for UC treatment (chapter 1.1) [6], [132]. The chronic DSS-induced colitis is 
characterized by focal epithelial regeneration due to the destabilized intestinal repair 
mechanism and a TH1 and TH2 cytokine profile with increased mucosal IFN-γ and IL-4 levels 
[133].  
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1.8. Aim of this work  
New therapeutic strategies for inflammatory bowel disease are needed as the conventional 
medical treatment requires a lifelong application and is associated with adverse effects. 
Passive targeting approaches via nano- and microparticles seem to be favorable due to the 
ability of the particles to stick to the intestinal mucus and accumulate in the ulcerated areas of 
the intestinal mucosa. Thereby, the encapsulated drug can be released and applied in a 
controlled way to the inflamed mucosa may reducing systemic side effects. As of now only a 
few nanoformulations have entered the pharmaceutical market, because detailed knowledge 
regarding the formulation processes is lacking.  
Therefore, the aims of this work were: 
• to develop a small particulate polymeric drug delivery system of the biodegradable and 
biocompatible PLGA for oral/rectal administration for an improved therapy of inflammatory 
bowel disease with the perspective of pre-clinical efficacy studies, 
• to identify process parameters of two manufacturing processes for preparing nano- and 
microparticulate PLGA drug delivery systems and to optimize both concerning 
reproducibility and controllability applying a design of experiments, 
• to encapsulate two potential drugs for the treatment of inflammatory bowel disease, 
cyclosporine A and budesonide, in the nano- and microparticulate PLGA drug delivery 
systems and to characterize the loaded drug delivery systems, 
• to evaluate the safety of the drug delivery systems in cytotoxicity and immunotoxicity 
studies, 
• to evaluate the anti-inflammatory efficacy of the drug delivery systems on an in vitro three-
dimensional cell culture model of the inflamed intestinal mucosa to select and assess the 
most suitable particles for in vivo studies in a dextran sodium sulfate colitis model. 
 
The work in this thesis was performed in the context of the ERA-Net EuroNanoMed project 
Delivering Nanopharmaceuticals through Biological Barriers (Grant number: 13N11845), 
acronym ‘BIBA’, with a focus on the transfer of the preparation of nano- and microparticulate 
drug delivery systems to lager production scales in a future perspective. Therefore, 
established excipients and scaleable, robust methods for the preparation of the drug delivery 
systems were selected. 
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The work in this thesis has been divided into the following chapters exploring the aims of the 
thesis in detail: 
Chapter 2:  A design of experiment study of nanoprecipitation and nano spray drying as 
  processes to prepare PLGA nano- and microparticles with defined sizes and 
  size distributions  
Chapter 3:  Advanced formulations of cyclosporine A and budesonide for the therapy of 
  inflammatory bowel disease 
Chapter 4:  Structural analysis and modification of spray dried microparticles   
Chapter 5:  In vitro efficacy testing of PLGA particles on cell culture model of the inflamed  
  intestinal mucosa 
Chapter 6:  Investigation of cytotoxicity and immunotoxicity 
Chapter 7:  Evaluation of cyclosporine A loaded PLGA based drug delivery systems for  
  inflammatory bowel disease in DSS Balb/C mice model 
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2. A design of experiment study of nanoprecipitation and nano spray drying as 
processes to prepare PLGA nano- and microparticles with defined sizes and 
size distributions  
 
 
 
 
 
 
 
 
Parts of this chapter have been published in:  
Christina Draheim*, Francois de Crécy*, Steffi Hansen, Eva-Maria Collnot, Claus-Michael Lehr,  
A Design of Experiment Study of Nanoprecipitation and Nano Spray Drying as Processes to Prepare 
PLGA Nano- and Microparticles with Defined Sizes and Size Distributions, Pharmaceutical Research, 
in press. doi: 10.1007/s11095-015-1647-9 
Reproduced with permission form Springer. © 2015 
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2.1. Introduction 
In the production of nano- and microparticulate DDS it is highly important to understand which 
parameters have an influence on the process and, thus, on the formation of the DDS, or 
process yield. Size and size distribution are both critical properties, which may affect drug 
release and bioavailability [59]. With the knowledge of process parameters and limitations, 
critical quality attributes and sources of variability, reproducibility and controllability of the 
process and consistent quality of the DDS can be achieved [134]. This knowledge can further 
be utilized specifically to optimize and adapt the DDS e.g. in size for different application 
purposes. This is important for research and development of nano- and microscaled DDS and 
makes the production process more efficient by reducing the number of experiments and 
material, which is a benefit for expensive active ingredients and excipients.  
Furthermore, it facilitates the scale-up process in a future perspective. The complex transfer 
of nano- and microscaled DDS to a larger production scale is often hindering the 
advancement of a promising formulation from early development to production stage and can 
be a bottleneck for entrance of particle-based DDS into the pharmaceutical market [89].  
In this context quality by design by applying a design of experiments (DOE) approach to the 
nanoprecipitation method (NPR) and nano spray drying technique (NSD), both were 
introduced in chapter 1.5, was pursued in this chapter for the preparation of PLGA based 
particulate DDS. The NPR represents one of the most frequently used physico-chemical 
method for producing DDS [93]. In contrast, the NSD is less examined and uses as 
advantage a vibrating mesh instead of a nozzle in order to atomize the feeding solution 
(chapter 1.5). PLGA is approved in the medical field, e.g. for surgical sutures (chapter 1.4) 
[59], [60]. The fastest degradation of PLGA is reached with a 50/50 ratio of lactic and glycolic 
acids (wt/wt). In this ratio PLGA is amorphous and, therefore, optimal for DDS as it 
decomposes within two months [61], [62].  
Quality by design in the pharmaceutical field means the systematic development of 
pharmaceutical products on the basis of sound scientific principles to ensure pre-defined 
product quality [134]–[136]. Quality by design studies have increasingly been used in the field 
of nano- and microparticulate DDS throughout the last years focusing mainly on the 
optimization of DDS loaded with active ingredients. 
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Especially for complex processes, such as processes for production of nanomedicines, DOE 
methods are excellent quality by design tool for identifying (a) critical process parameters, (b) 
to understand and (c) to optimize process conditions and, therefore, the final formulation in 
the field of nano- and microparticulate DDS [105], [135]–[141]. 
Some recently published studies focused mainly on the optimization of drug loaded DDS. In 
these studies e.g. the optimization of size [105], [108], [141]–[143] and of drug loading for 
PLGA NPs [65], [141]–[144], Eudragit®E NPs [135] and liposomes [140] were investigated. 
Furthermore, DOE studies have been applied to investigate colloidal stability of lipid NPs 
[145] or the influence of the stabilizer on size and zeta potential of PLGA NPs. Moreover, also 
the modification of the drug release from established DDS was investigated by a DOE [143], 
[146]. All these studies describe the optimization in preparation of DDS in a laboratory 
context. Only Park et al. [135] and Verma et al. [136] underlined the importance to 
characterize process parameters and limitations, as well as critical quality attributes to 
achieve high quality products and to facilitate the entrance to further studies [135]. Bürki et al. 
and Lee et al. were the first to apply a DOE, full factorial design and Taguchi method, 
respectively, focusing on spray drying of a protein using β-galactosidase [108] and bovine 
serum albumin [105]. A recent study used a 23 factorial design to develop inhalable 
capreomycin powders [147]. 
To investigate both methods systematically a fractional factorial design was used based on a 
response surface approach with an IV (Integrated Variance)-optimal design. A DOE could 
help to understand in detail the influence of parameters on an investigated process. 
Compared to classical experiments a DOE has many advantages. For example, a DOE offers 
the opportunity to vary several factors at the same time and, thus, to evaluate their main 
effects as well as interactions of factors. In general, interactions of third and fourth order are 
negligible [148]. Multiple types of factors can be accommodated such as continuous, 
categorical and discrete factors. Furthermore, experimental limitations, due to safety reasons, 
can be taken into consideration in the design of the DOE, which is not possible in a classical 
experimental design [146]. Hence, it appears an adequate tool for the development of DDS. 
The DOE can also be used in order to characterize new methods without knowing any 
limitations of the system. Moreover, it can be applied to adapt a method or process for a new 
application approach [149].  
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In this chapter for both methods, NPR and NSD, the two major goals of the DOE was to (a) 
identify parameters controlling the respective process, and (b) identify limitations of the 
process with regard to fabricable batch sizes for a fixed set of (optimized) process 
parameters. The different batch sizes should be produced without changing the general 
apparatus set-up, which is relevant e.g. in the context of early formulation development, 
characterization and pre-clinical development, in particular in the field of nano- and 
microscaled DDS. The complexity of the process techniques can cause problems by 
changing the apparatus [89]. Therefore, a set-up which can be used to produce first test 
batches up to batches for pre-clinical studies would be a benefit. 
Our main focus for the NPR was to prepare PLGA based NPs with a size of 150-200 nm and 
a narrow size distribution characterized by a polydispersity index (PDI) <0.150. For the NSD 
the DOE should show controllability, limitations and robustness of the process for the 
examined variables size, size distribution and yield larger than 50%. The goal for the NSD 
was to produce PLGA particles as small as possible and with narrow size distributions for 
creating a novel PLGA based DDS in a single step.  
Additionally, after determining the influencing factors for NPR and NSD, limitations of both 
processes by exploring maximal and minimal batch size were investigated. This is an 
indicator for the robustness of the process. 
 
2.2. Materials 
Poly (lactic-co-glycolic acid) (PLGA; Resomer RG 503 H (lactic/glycolic acid, 50/50, wt/wt; 
MW 40,300 Da; inherent viscosity 0.41 dl/g) was bought from Evonik Industries AG 
(Darmstadt, Germany). Poloxamer 407 and polysorbate 80 were purchased form Caesar & 
Loretz GmbH (Hilden, Germany) and sorbitan monostearate (Span60) was purchased from 
FAGRON GmbH & Co. KG (Barsbüttel, Germany). Purified water was of Milli-Q quality and 
prepared by a Millipore Milli-Q Synthesis system (Merck KGaA, Darmstadt, Germany). 
All solvents were high-performance liquid chromatography grade and all chemicals met the 
quality requirements of the European Pharmacopoeia 6.0–7.3. 
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2.3. Methods 
2.3.1. Preparation of nanoparticles by nanoprecipitation  
The NPs were produced by NPR as in principle described elsewhere in chapter 1.5. PLGA 
was weighed accurately and dissolved in the organic phase (acetone; acetone/ethanol, 
16/3, v/v). The solution was injected with a Hamilton® glass syringe (1005 TTL 5 ml, 
chromatography service GmbH, Germany) into purified water containing a stabilizer, 
polysorbate 80 (0.145%, wt/v) or poloxamer 407 (1%, wt/v), forming the aqueous phase. The 
ratio of organic to aqueous phase was kept constant at 5 ml/10 ml in all experiments. 
Likewise, in all experiments of the DOE the size of the magnetic stirrer (15 mm x 4.5 mm, 
VWR, Germany), the inner diameter of the glass beaker (borosilicate glass beaker 3.3, 50 ml, 
VWR, Germany) and the stirring speed (500 rpm) during the injection were kept constant. 
To accurately control the injection speed a high accuracy HARVARD® Ultra PHD pump (Hugo 
Sachs Elektronik, Germany) with a microprocessor controlled, small step angle motor that 
drives the pusher block was used. The HARVARD® Ultra PHD pump operates at constant 
pressure and constant flow with a flow accuracy of ± 0.25% and flow reproducibility 
of ± 0.05%. The Hamilton® glass syringe was installed in the HARVARD® Ultra PHD pump in 
vertical direction to place the needle into the aqueous phase. After diffusion of organic 
solvent, which was verified organoleptic and by the measurement of the volume, into the 
outer phase (aqueous phase), the stirring speed was reduced to 400 rpm and the organic 
solvent was evaporated by stirring overnight.  
 
2.3.2. Preparation of PLGA particles by nano spray drying  
A Büchi Nano Spray Dryer B-90 (Büchi B-90; Büchi Labortechnik GmbH, Essen, Germany) 
was used for the NSD with a total drying chamber height of 150 cm (long set-up) as provided 
by the manufacturer (Figure 1.3b). To allow a safe use of organic solvent the spray drying 
apparatus was operated in the closed mode set-up with inert gas mixture (N2 and CO2 at 
0.8 bar) (chapter 1.5). The feeding solution was circulated in the spray head and atomized by 
pushing it through a 4 µm spray mesh, which vibrates at 60 kHz and transports the feeding 
solution into the drying chamber. As in-process parameter the out-let temperature and the 
drying gas flow, which was fixed at 115 l/min, were monitored. The out-let temperature was 
found to be between 29-36°C, which is below glass-transition temperature (Tg) of the PLGA 
(~45°C, determined by differential scanning calorimetry).  
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The spray dried particles were collected by an electrostatic particle precipitator, generated by 
a high voltage between a grounded and a collecting electrode. 
For preparation of the feeding solution PLGA together with Span60 or poloxamer 407 as 
stabilizer were accurately weighed and dissolved or suspended in the organic solvent 
(acetone, ethyl acetate or dichloromethane (DCM)). Afterwards the feeding solution was 
sprayed under ice-cooling of the supplied dispersion to prevent heating of the circulating 
solution. The particles were collected by a plastic scratcher and the amount was accurately 
weighed. 
 
2.3.3.  Design of experiments  
Design Expert Software® (version 08, StatEase Minneapolis, USA) was used to perform a 
design of experiment study. The design (model) was based on an IV (I = integrated; 
V = variance)-optimal design for surface response. Response surface designs using optimal 
designs provide lower average prediction variance over the region of experimentation. The 
design was chosen to minimize the integral of prediction variance over the region of 
experimentation, thereby compromising between the minimum number of experiments and 
maximum information on the investigated effects [148]. 
The selection of the experimental points for each factor was performed by the software and 
resulted in a table of experiments. The experiments (runs, R) were organized in a random 
order to minimize the effect of any drift. The results were evaluated by analysis of variance 
(ANOVA) and a regression analysis. 
The coefficient of determination (R2) measures the accuracy of the model and is defined as 
the proportion of the total variance of the experimental points explained by the model. The 
predicted coefficient of determination (predicted_R2) was used to measure the reliability and 
robustness of the model and is defined in equation 1 (eq. 1). 
																	predicted_R = 1 − (
residual	cross	validated	variance
total	variance
) 
 
 (eq. 1) 
In equation 1 the residual cross-validated variance is defined by ∑ (	 −  ), where 
	equals the experimental response and  equals the predicted response using a model 
based on n-1 other experimental points. 
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The ANOVA was performed with the Design Expert Software® to reveal the influence of 
factors on total variance, expressed as effect. The influence between two factors is 
expressed as interaction. The results were expressed as % of total variance. 
 
2.3.4.  Factors varied for the nanoprecipitation method in the design of experiments 
The investigated process parameters for the NPR were assigned as factors (Table 2.1). For 
the NPR two continuous factors (polymer concentration and injection speed), one discrete 
factor (inner diameter of needle) and two two-level categorical factors (nature of the stabilizer 
and nature of the solvent) were evaluated. The investigated ranges are summarized in 
Table 2.1. All factors received a coding for analysing in the DOE. The selection of 
experimental points leads to the construction of initial 34 experiments including repetitions of 
five experiments. The investigated responses were size and size distribution. The objective 
was to produce particles controllable in size, expected to be between 100 and 200 nm, and 
narrow size distribution (PDI <0.150). The maximum polymer concentration was fixed at 2% 
(wt/v) based on values commonly reported in the literature [150]. 
Table 2.1. Factors varied for NPR and the investigated ranges. The factors were separated in continuous, discrete 
and level categorical factors and coded (A-E) for the DOE. 
coding factor investigated range 
A 
continuous 
polymer concentration 0.1–2% 
B injection speed 0.25–10 ml/min 
C discrete inner diameter of needle 0.41/0.60 mm 
D 
level categorical 
stabilizer 
polysorbate 80 
poloxamer 407 
E organic solvent 
acetone 
acetone/ethanol (16/3, v/v) 
 
2.3.5.  Factors varied for the nano spray drying in the design of experiments 
The investigated factors for the NSD and ranges are presented in Table 2.2. For the NSD 
four continuous factors (temperature, polymer concentration, stabilizer concentration and 
spray rate) and three level categorical factors (nature of organic solvent, pumping rate and 
nature of stabilizer) were considered. The pumping rate was adjusted to low (level 1) or high 
(level 2) according to the specification of the manufacturer.  
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Table 2.2. Factors varied for NSD and the investigated ranges. The factors were separated in continuous and level 
categorical factors and coded (A-E) for the DOE. 
coding factor investigated range 
A 
continuous 
temperature 50–90°C 
B polymer concentration 0.1–5.0% 
C stabilizer concentration 0.05–2.00% 
D spray rate 70–100% 
E 
level categorical 
organic solvent 
acetone 
ethyl acetate 
dichloromethane 
F pumping rate 
low (level 1) 
high (level 2) 
G stabilizer 
poloxamer 407 
Span60 
The selection of the experimental points led to the construction of initial 56 experiments 
including repetitions of four experiments. All factors received a coding for analysing in the 
DOE. 
The examined response variables were size, size distribution and yield with the objectives to 
produce PLGA particles as small as possible, down to the submicron size range, with narrow 
size distributions. Furthermore, the yield should be above 50%. 
 
2.3.6. Determination of particle size and size distribution and yield 
Particles produced by NPR 
Hydrodynamic diameter and polydispersity index (PDI) of NPs were measured by dynamic 
light scattering (Zetasizer® Nano ZS, Malvern Instruments, UK) in purified water at 25°C and 
a fixed angle of 173°. The measurements were carried out for each batch in triplicate and the 
mean value and standard deviation (S.D.) was calculated. 
Particles produced by NSD 
The spray dried particles were characterized by laser diffraction using a Mastersizer® 2000 
equipped with a Mastersizer®2000 µP dispersion module (Malvern Instruments, Herrenberg, 
Germany) due to their size. The particles were re-dispersed in purified water. Each batch was 
measured in triplicate and the mean value and standard deviation (S.D.) were calculated.  
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The volume median size (d 0.5) as well as the percentile values d 0.1 and d 0.9 were 
calculated by the Mastersizer® unit. D 0.1 and d 0.9 describe, that 10% or 90% of the 
particles are smaller than the measured diameter for the corresponding value, respectively. 
The size distribution (width) is defined in equation 2 (eq. 2). A narrow size distribution is 
indicated by a small width.  
 
                                                  !"ℎ = 	
$	%.'
$	%.
 
 
 (eq. 2) 
 
In this work an acceptable width ranges was defined from 1, where d 0.5 is equal to d 0.1 and 
d 0.9, to 50. For example, for a typical particle with d 0.5 of 1 µm a width of 50 would result by 
a d 0.1 of 0.2 µm and a d 0.9 of 10 µm. 
The yield for the NSD is defined in equation 3 (eq. 3). The value for the starting material was 
corrected for the dead volume of the tubes feeding the spray head (Figure 1.3). Therefore, 
the supplied dispersion (chapter 2.3.2) was weighed before and after the spray drying 
process. By subtracting both values the actually spray dried starting material could be 
determined. 
 
																 ()! = 	
"*+,-.	$,/$	+,0$123
"*3-,34	5-3/,-6
∗ 100% 
 
 (eq. 3) 
2.3.7. Investigation of morphology by scanning electron microscopy  
The morphology of spray dried particles and particles produced by NPR were investigated by 
scanning electron microscopy (SEM). The morphology of the particles can be different due to 
the preparation technique or selected preparation conditions, in particular for spray drying 
[109], [151]. For the sample preparation of spray dried particles a small amount of powder 
was spread on adhesive tape. Surplus of powder was removed by stripping the adhesive tape 
twice with a second piece of adhesive tape. The remaining powder was deposited onto a 
double sided adhesive carbon tape, which was afterwards glued onto an aluminium stub.  
The particles produced by NPR were re-dispersed in purified water. One drop of the 
suspension was pipetted onto a silica waver that was glued with double sided adhesive 
carbon tape onto the aluminium stub.  
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The samples were sputtered with gold using a Quorum Q150 RES (Quorum Technologies, 
UK) and examined using a Zeiss Evo HD 15 (Carl Zeiss AG, Germany) at 5 kV. 
 
2.3.8. Investigation of robustness for the nanoprecipitation method 
To investigate the practical limitations of the developed process, and therefore the robustness 
of the used set-up, the minimum possible batch size and the maximum possible batch size for 
preparing PLGA NPs with a target size of 150 nm ± 10 nm without changing the experimental 
set-up was determined. For this purpose the parameter in Table 2.3 were used as revealed in 
the optimization. The particles were produced in general as described in chapter 2.3.1. 
Minimum/maximum batch size is defined for this experiment as the volume of organic solvent 
used for the NPR. Therefore, the volume was used as starting point for changing 
experimental parameters. Thus, batches were prepared in triplicate using 5 ml, 2.5 ml, 
1.250 ml and 0.625 ml to minimize batch size, 20.0 ml, 40.0 ml and 50.0 ml for the maximum 
batch size. 
The lower limit for the volume was fixed at 0.625 ml as lowest possible volume to allow 
handling without changing the technical set-up. 
Table 2.3. Parameters for the NPR used to determine maximum/minimum possible batch size without changing 
the set-up and producing NPs with a size of 150 nm ± 10 nm calculated from the DOE.  
factor coding parameter 
polymer concentration A 1.3% 
inner diameter of needle B 0.6 mm 
injection speed C 1.531 ml/min 
stabilizer D poloxamer 407 (1%, wt/v) 
organic solvent E acetone/ethanol (16/3, v/v) 
 
50.0 ml was set as the maximum (corresponding to 650 mg PLGA weight of polymer used for 
preparing one batch), which is a reasonably large batch size commonly required during 
formulation development, batch characterization or pre-clinical development. 
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2.3.9. Investigation of robustness for the nano spray drying 
To investigate the practical limitations of the NSD system the possible minimum batch size 
and the maximum possible batch size without changing the general experimental set-up were 
determined. Minimum/maximum batch size is defined for this experiment as the used volume 
of organic solvent and not related to the polymer concentration or actual yield. For these 
experiments the volume was again defined as starting point for changing experimental 
parameter. The total amount (wt) of PLGA and Span60 was hence calculated with respect to 
the used volume for each individual experiment. Several possible solutions were found which 
predict the composition of an optimal formulation based on the before defined criteria. The 
calculation was abridged as 100 solutions had been obtained. From these solutions one 
formulation was selected for investigating the limitation in batch size giving mean particles 
size ~2.8 µm with a narrow width (0.9). The spray dried particles were produced as described 
in chapter 2.3.2 using the parameter in Table 2.4. 
As the spray dried products always have a wider size distribution compared to particles 
produced with the NPR the mean particle size should be between 2-5 µm. Based on the dead 
volume which is defined as the volume remaining in the spray head and in the feeding tubes, 
which was experimentally determined to be 2.9 ml, 5 ml was fixed as minimum batch size. To 
find the maximum batch size 10.0 ml, 20.0 ml, 40.0 ml and 50.0 ml batches were sprayed in 
triplicate. Additionally, also the yield was determined. 
Table 2.4. Parameters for the NSD used to determine maximum/minimum possible batch size without changing 
the set-up. 
factor coding parameter 
temperature A 71°C 
polymer concentration B 1.1% 
stabilizer concentration C 1.6% 
spray rate D 82% 
organic solvent E acetone 
pumping rate F high (level 2) 
stabilizer G Span60 
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2.4. Results 
2.4.1. NPR - Results of the DOE: Influence on size and size distribution 
Using the NPR method NPs in a size range of 50-177 nm were produced with a PDI of 0.013 
to 0.294, by combination of the parameters as summarized in Table 2.5. Within the range of 
investigated factors, only NPs with average sizes above 110 nm met the quality criterion of 
PDI <0.150. Smaller NPs with average sizes down to 50 nm could be prepared, but only with 
slightly broader size distributions (PDI up to 0.294).  
Table 2.5. Process factors and response for NPR. The investigated process parameters were assigned as factors 
and coded (A-E) for analysing in the design of experiments. For the NPR two continuous factors: (A) polymer 
concentration and (C) injection speed; one discrete factor: (B) inner diameter of needle; and further two level 
categorical factors: (D) nature of the stabilizer and (E) nature of the solvent, were evaluated. The investigated 
responses were size and size distribution, both measured by dynamic light scattering. 
 
process factors 
response 
coding A B C D E 
run  
polymer 
concentration 
[%] 
inner 
diameter 
needle 
[mm] 
injection 
speed 
[ml/min] 
nature of 
stabilizer solvent  
sizea 
[nm] 
size 
distributiona 
(PDI) 
 
1 0.803 0.60 8.341172 poloxamer 407 acetone/ethanol 132.5 ± 1.0 0.041 ± 0.009 
2 2.001 0.41 0.250000 poloxamer 407 acetone/ethanol 177.0 ± 0.7 0.013 ± 0.016 
3 0.670 0.60 6.587500 polysorbate 80 acetone 119.2 ± 0.4 0.072 ± 0.022 
4 0.869 0.41 10.000000 poloxamer 407 acetone/ethanol 131.7 ± 1.8 0.044 ± 0.030 
5 1.336 0.41 0.250000 polysorbate 80 acetone/ethanol 148.0 ± 1.2 0.033 ± 0.026 
6 1.050 0.41 5.125000 polysorbate 80 acetone 117.9 ± 0.9 0.073 ± 0.015 
7 2.010 0.41 0.250000 polysorbate 80 acetone 174.2 ± 0.7 0.057 ± 0.017 
8 0.764 0.60 2.200000 poloxamer 407 acetone 161.6 ± 0.8 0.025 ± 0.005 
9 2.000 0.60 0.250000 poloxamer 407 acetone 174.2 ± 0.1 0.057 ± 0.014 
10 0.102 0.60 10.000000 poloxamer 407 acetone  63.9 ± 0.1 0.132 ± 0.003 
11 0.101 0.41 6.062155 poloxamer 407 acetone/ethanol  50.9 ± 0.5 0.168 ± 0.008 
12 0.101 0.41 0.250000 polysorbate 80 acetone/ethanol  50.5 ± 0.2 0.220 ± 0.005 
13 1.231 0.41 0.250000 poloxamer 407 acetone 155.1 ± 0.8 0.069 ± 0.002 
14 0.774 0.60 2.093961 polysorbate 80 acetone/ethanol 116.8 ± 0.7 0.040 ± 0.032 
15 2.002 0.41 10.00000 polysorbate 80 acetone/ethanol 124.0 ±1.1 0.082 ± 0.006 
16 2.001 0.60 0.250000 polysorbate 80 acetone/ethanol 151.5 ± 1.8 0.028 ± 0.010 
17 0.102 0.41 6.062155 poloxamer 407 acetone/ethanol  48.4 ± 0.8 0.195 ± 0.007 
18 2.000 0.41 4.296250 poloxamer 407 acetone 155.3 ± 1.5 0.070 ± 0.017 
19 0.100 0.60 0.250000 poloxamer 407 acetone/ethanol  75.1 ± 0.5 0.122 ± 0.007 
20 0.100 0.60 10.000000 polysorbate 80 acetone/ethanol  31.6 ± 0.4 0.294 ± 0.294 
21 2.004 0.60 10.000000 polysorbate 80 acetone 139.9 ± 0.8 0.060 ± 0.015 
22 2.001 0.60 10.000000 poloxamer 407 acetone/ethanol 173.7 ± 3.4 0.024 ± 0.030 
23 2.003 0.41 10.000000 polysorbate 80 acetone/ethanol 126.4 ± 0.6 0.062 ± 0.007 
24 1.506 0.60 3.175000 poloxamer 407 acetone/ethanol 161.6 ± 0.9 0.022 ± 0.020 
25 0.102 0.41 0.250000 poloxamer 407 acetone  73.4 ± 0.4 0.107 ± 0.021 
26 1.054 0.41 3.175000 poloxamer 407 acetone/ethanol 132.3 ± 0.3 0.025 ± 0.015 
27 1.051 0.41 5.125000 polysorbate 80 acetone 111.9 ± 0.4 0.089 ± 0.006 
28 1.544 0.60 6.983995 polysorbate 80 acetone/ethanol 131.4 ± 0.8 0.067 ± 0.009 
29 0.621 0.41 7.318750 poloxamer 407 acetone 136.0 ± 1.8 0.054 ± 0.015 
30 0.766 0.600 2.200000 poloxamer 407 acetone 157.2 ± 0.7 0.058 ± 0.001 
31 2.001 0.41 10.000000 poloxamer 407 acetone 176.6 ± 1.9 0.037 ± 0.009 
32 0.103 0.41 10.000000 polysorbate 80 acetone  45.5 ± 0.1 0.231 ± 0.005 
33 0.869 0.41 10.000000 poloxamer 407 acetone/ethanol 137.7 ± 0.9 0.067 ± 0.006 
34 0.103 0.60 0.250000 polysorbate 80 acetone 70.2 ± 0.8 0.148 ± 0.004 
a
 mean ± range 
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None of the experiments failed completely and in none of the experiments aggregates were 
visible after evaporation of the organic solvent. Depending on the polymer concentration the 
NP suspensions were opalescent (polymer concentration <0.6%) to milky (polymer 
concentration >0.6%) in appearance.  
SEM images were taken to visualize the NPs and to investigate the morphology. The batches 
visualized in Figure 2.1 differ in particles density due to the different initial PLGA amounts 
used for the preparation of different batches for the purpose of a DOE.  
a 
 
b 
 
c 
 
d 
 
Figure 2.1. Representative SEM images of (a) R 2, (b) R 10, (c) R 20 and (d) particles produced with optimized 
parameters (chapter 2.4.2) were taken to investigate and to compare the morphology. The SEM images differ in 
particles density due to the different initial PLGA amounts. (a) NPs are round and spherical in shape with a narrow 
size distribution. Monodispersity is not further improved prepared compared to a batch prepared with optimal 
parameters in (d). Runs, which generated smaller particles, show a wider size distribution with irregular shaped 
NPs () in (c) and (d). 
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The SEM image of R 2 (Figure 2.1a) confirms the size measurement and shows that the NPs 
are round and spherical in shape with a narrow size distribution. The robustness of the NPR 
with regard to size distribution is also highlighted when comparing R 2 to a batch prepared 
using calculated optimal parameters (Figure 2.1d), as monodispersity is not further improved. 
SEM images of R 10 (Figure 2.1b) and R 20 (Figure 2.1c) show that in contrast to R 2 the 
NPs are smaller with a wider size distribution (arrow points towards small PLGA NPs). Also 
irregular shaped NPs are visible. 
The statistical properties for the whole experiment were calculated: the coefficient of 
determination is R2=0.973 and predicted_R2=0.950 for size, R2=0.971 and 
predicted_R2=0.928 for size distribution. This demonstrates that the model of the DOE 
reached high accuracy, good reliability and robustness for both size and size distribution. 
These values confirm a high controllability of the NPR.  
The analysis of variance (ANOVA) of the DOE showed that the polymer concentration is the 
main factor influencing size and size distribution. The results are summarized in Table 2.6 for 
size and in Table 2.7 for size distribution. Factors have a significant contribution on the 
response as the p-value ≤0.05. The ANOVA by partial sum of squares type III demonstrated 
that 79.5% of total variance was based on the square root of polymer concentration 
(Table 2.6). The two other noticeable and significant effects were injection speed and nature 
of stabilizer contributing 2.4% and 7.3% to total variance. Effects equal to or less than 1.5% 
were contributed by the organic solvent (1.5%), the inner diameter (0.8%) and the interaction 
between injection speed and organic solvent (0.7%). Other interactions between the factors 
showed no effect and therefore were not listed in Table 2.6.  
Table 2.6. Contribution of process parameters and second order interactions affecting size in the NPR. p ≤0.05 is 
considered significant. 
factor coding total variance [%] p-value 
square root of polymer conc. A 79.48 <0.0001 
inner diameter of needle B 0.83 0.0104 
injection speed C 2.36 <0.0001 
stabilizer D 7.25 <0.0001 
organic solvent E 1.50 0.001 
interaction  
injection speed x stabilizer CxD 0.70 0.0173 
polymer concentration A² 4.2 <0.0001 
square of injection speed C² 0.96 0.0062 
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Table 2.7. Contribution of process parameters and second order interactions affecting size distribution in the NPR. 
p ≤0.05 is considered significant. 
factor coding total variance [%] p-value 
square root of polymer conc. A 58.00 <0.0001 
inner diameter of needle B 1.04 0.0117 
injection speed C 4.27 <0.0001 
stabilizer D 10.43 <0.0001 
organic solvent E 0.67 0.0369 
interaction 
   
square root polymer conc. x injection 
speed 
AxC 2.24 0.0006 
square root polymer conc. x stabilizer AxD 2.95 0.0001 
square root polymer conc. x organic 
solvent 
AxE 4.64 <0.0001 
injection speed x stabilizer CxD 1.37 0.0045 
injection speed x organic solvent CxE 1.28 0.0058 
stabilizer x organic solvent DxE 0.49 0.0713 
polymer conc. A² 9.78 <0.0001 
 
For the size distribution the ANOVA is shown in Table 2.7. All factors showed a significant 
effect. 58% of total variance was due to the square root of polymer concentration, additional 
9.8% due to the polymer concentration. The two other noticeable and significant effects were 
stabilizer (10.4%) and injection speed (4.3%). An effect <1.5% was determined for organic 
solvent (0.67%) and the inner diameter (1.04%). All investigated interactions showed an 
influence with <3.0% of total variance except the interaction between polymer concentration 
and organic solvent (4.6%). Additionally the other interactions showed no effect and were not 
listed in Table 2.7.  
 
2.4.2. NPR - Optimization based on the DOE 
From the screening data we proposed polynomial models using the Design Expert Software® 
to fit the experimental data for size and size distribution on factors A-E and combinations 
thereof. For both size and size distribution all five factors had a statistically significant 
influence. These fitting should offer the possibility to calculate the respective factors (A-E) for 
producing NPs with a special size or size distribution.  
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As the size and size distribution were separate response we get separate equations. Our 
focus was set on a specific particle size. The results of the fitting are expressed for size and 
size distribution in equation 4 (eq. 4) and equation 5 (eq. 5), respectively. These equations 
are significant and reliable, as can be seen from the good values of R2 and predicted_R2. 
: ;( = 120.79 + (50.74 ∗ B) + (3.96 ∗ E) − (8.2 ∗ G) − (11.81 ∗ H) − (5.37 ∗ I) − 
           
4.58 ∗ G ∗ H − 23.2 ∗ B + 11.73 ∗ G                 (eq. 4) 
 
: ;( ! :"J KL" MN =   0.066 − 0.068 ∗ B − 6.98O ∗ E + 0.018 ∗ G + 0.023 ∗ H ∗ 5.76O ∗ I − 
          
0.015 ∗ B ∗ G − 0.015 ∗ B ∗ H − 0.019 ∗ B ∗ I + 0.01 ∗ G ∗ H + 
          9.78O ∗ G ∗ I + 4.87O ∗ H ∗ I + 0.049 ∗ B              (eq. 5) 
 
The equations 4 and 5 are expressed in terms of a coded factor, being a dimensionless 
number varying between -1 and +1 for continuous or discrete factors, and using the traditional 
coding for categorical factors. 
Based on these equations and as an example two equations were calculated for the different 
stabilizer using the mixture of ethanol/acetone (3/16, v/v) as organic solvent as expressed in 
equation 6 (eq.6) for poloxamer 407 and equation 7 (eq. 7) for polysorbate 80. 
: ;(+060P-5/,,-2/30/:/3S-06 = −14.35 + T224.59 ∗ √BV + 41.73 ∗ E − 5.80 ∗ G − 76.41 ∗ B + 
         0.49 ∗ G                  (eq. 6) 
 
: ;(+06.*0,W-3/ X%,-2/30/:/3S-06 =  −28.35 + T224.59 ∗ √B V + 41.73 ∗ E − 7.68 ∗ G − 
               
76.41 ∗ B + 0.49 ∗ G                 (eq. 7) 
 
The equations 6 and 7 are expressed in term of (dimensional) actual factors (instead of 
coded factors). With the equation 6 and 7 process parameters and conditions (factors A, B, C 
and E) can be proposed in the investigated range of the DOE. The accuracy (trueness and 
precision) of these equations was therefore tested for the preparation of NPs with a size of 
150 nm ± 10 nm. For calculating the optimal parameters a limitation in injection speed 
(>1ml/min) was set to allow reduced and feasible production times. The predicted factors 
were calculated and summarized in Table 2.8. 
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Table 2.8. Predicted factors for producing NPs with a size of 150 nm ± 10 nm calculated from the results of the 
DOE for polysorbate 80 and poloxamer 407.  
factor coding polysorbate 80 poloxamer 407 
polymer concentration A 1.2% 1.1% 
inner diameter of needle B 0.6 mm 0.6 mm 
injection speed C 1.531 ml/min 4.55 ml/min 
organic solvent E acetone/ethanol (16/3, v/v) acetone/ethanol (16/3, v/v) 
 
To confirm the predicted factors particles were prepared with the parameter settings shown in 
Table 2.8 as calculated from equations 6 and 7. Thus, NPs with a size of 133.3 ± 2.7 nm for 
polysorbate 80 and 135.4 ± 2.2 nm for poloxamer 407 were prepared (n=4). The mean size 
was smaller than predicted by ca. 17 nm (polysorbate 80), and 15 nm (poloxamer 407), 
respectively. This was lower than the acceptable lower size limit of 140 nm. For both types of 
stabilizers we had learned from the DOE that the polymer concentration is the main 
influencing factor on particle size. Therefore, particles were also prepared with slightly higher 
polymer concentrations for both stabilizer and the results were presented in Figure 2.2a and 
Figure 2.2b.  
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Figure 2.2. Confirmation of predicted factors calculated from the results of the DOE. NPs were produced with 
different polymer concentrations using (a) polysorbate 80 and (b) poloxamer 407 as stabilizer under conditions 
summarized Table 2.8. Size and size distribution were measured by dynamic light scattering. The values are 
presented as the mean ± S.D. (n=4), --- 150 nm ± 10 nm. 
 
Figure 2.2a shows that PLGA concentrations of 1.35-1.55% (compared to 1.2% assigned by 
the DOE, Table 2.8) generated NPs between 147.2-155.2 nm with a PDI <0.058 using 
polysorbate 80 as stabilizer, when leaving all other parameters as assigned by the DOE.  
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PLGA concentrations between 1.20-1.40% (compared to 1.1% assigned by the DOE, 
Table 2.8) result in particles with sizes between 147.1-155.7 nm and a PDI <0.040 using 
poloxamer 407 as stabilizer, when leaving all other parameters as assigned by the DOE. 
 
2.4.3. NPR - Investigation of robustness 
To investigate the practical limitations of the developed process, and therefore the robustness 
of the used set-up, the minimum possible batch size and the maximum possible batch size for 
preparing PLGA NPs with 150 nm ± 10 nm without changing the experimental set-up was 
determined.  
The measured NP sizes and size distributions were summarized for the minimum and 
maximum batch size in Figure 2.3. All batches had a size of 150 ± 10 nm with a narrow size 
distribution, PDI <0.042. Therefore, the NPR is very robust an can be used to produce 
batches with minimum 0.625 ml and at least up to 50.0 ml of organic solvent without changing 
the experimental set-up. 
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Figure 2.3. Investigation of (a) minimum and (b) maximum batch size (robustness) for the NPR by determining 
size and size distribution from batches produced with different volumes. The PLGA concentration (1.3%, v/wt) was 
kept constant for all experiments and poloxamer 407 was selected as stabilizer. Size and size distribution were 
measured by dynamic light scattering. The values are presented as the mean ± S.D. (n=3). 
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2.4.4. NSD - Results of the DOE on size and size distribution 
All response values of size, size distribution and yield were presented in Table 2.9. With the 
spray drying technique stable re-dispersable microparticles (MPs) could be prepared with the 
lowest mean size (d 0.5) of 2-163 µm. The smallest mean size was found in R 15 and R 4 
with 2.34 µm and 2.38 µm, respectively, both produced with Span60 as stabilizer. The 
maximum mean size was found in R 21 with 163.3 µm, produced with poloxamer 407 as 
stabilizer.  
With Span60 smaller particle mean sizes (d 0.5 values), in comparison to particles prepared 
with poloxamer 407, were prepared, so that particle mean sizes of <8 µm were achieved in 
20 runs. For poloxamer 407 only one batch had a mean size of <8 µm. Furthermore, particles 
prepared with poloxamer 407 and a low polymer concentration (0.1% PLGA, wt/v) had a 
mean size of <100 µm. Note that the goal was to produce particles as small in mean size as 
possible. In the used set-up and with PLGA as polymer we achieved particles in the low 
micrometer size range. 
The evaluation of the DOE shows that the size of the MPs is most affected by the stabilizer 
(Table 2.10). The ANOVA by partial sum of squares type II demonstrates that 38.91% of total 
variance is based on the stabilizer. The two other noticeable and significant effects are 
polymer concentration (4.39%) and stabilizer concentration (6.74%). A very weak influence 
was determined for the organic solvent with 1.62% of influence, which is not significant. 
Factors showing no influence were not listed in Table 2.10. The ANOVA also showed that 
second order interactions have a strong influence on the size of the spray dried particles, but 
only polymer concentration/stabilizer contributing 21.08% and stabilizer 
concentration/stabilizer contribution 5.11% were determined to be significant interactions. The 
remaining second order interactions showed no effect and were therefore not listed in Table 
2.10. Nevertheless, the value of the coefficient of determination R2=0.899 and 
predicted_R2=0.790 demonstrated that the model is less accurate, robust and reliable 
compared to the NPR. 
The factors most strongly influencing the size distribution, represented as width, were the 
polymer concentration (15.33%) and the organic solvent (19.27%) as described in Table 2.11. 
The other factors are determined to be significant, but had only weak influence <1%. For the 
interactions between polymer concentration and organic solvent an influence of 6.62% was 
determined. The remaining second order interactions showed no effect and were not listed in 
Table 2.11.  
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Table 2.9. Process factors and response for the NSD.  
Run Process factors   Response  
coding A B C D E F G    
 T 
[°
C] 
PC 
[%] 
SC 
[%] 
spra
y 
rate  
organic 
solvent 
pumping 
rate  
stabilizer awidth ad 0.5 [µm] yield 
[%] 
1 80 0.1 0.67 100 acetone 1x Span60 124.9 ± 2.0 5.9 ± 0.3 23.49 
2 54 2.2 0.92 100 DCM 2x Span60 10.8 ± 0.3 4.6 ± 0.2 15.32 
3 70 5.0 1.51 70 DCM 2x poloxamer 407 8.2 ± 0.6 41.2 ± 4.2 7.91 
4 74 0.7 1.18 72 acetone 2x Span60 32.3 ± 2.0 2.4 ± 0.1 62.81 
5 80 0.1 0.05 90 acetone 2x poloxamer 407 -* -* -* 
6 62 0.1 0.05 70 DCM 1x poloxamer 407 - - - 
7 90 5.0 2.00 70 ethyl acetate 1x poloxamer 407 3.9 ± 0.2 26.9 ± 0.5 6.52 
8 80 0.1 0.05 100 ethyl acetate 2x Span60 3.8 ± 0.1 8.6 ± 0.1 41.21 
9 70 2.9 0.05 100 DCM 1x poloxamer 407 9.5 ± 0.6 10.6 ± 0.5 13.17 
10 87 0.4 0.76 89 ethyl acetate 2x Span60 -+ -+ -+ 
11 85 5.0 1.81 85 ethyl acetate 2x poloxamer 407 -+ -+ -+ 
12 86 2.7 0.71 71 ethyl acetate 2x poloxamer 407 -+ -+ -+ 
13 70 4.6 0.05 100 acetone 2x Span60 4.6 ± 0.2 4.0 ± 0.1 25.48 
14 70 0.1 2.00 99 acetone 2x Span60 112.0 ± 7.6 3.7 ± 1.8 58.26 
15 58 2.6 0.05 81 DCM 2x Span60 3.1 ± 0.1 2.3 ± 0.0 17.85 
16 90 0.1 2.00 70 ethyl acetate 2x poloxamer 407 -* -* -* 
17 70 0.3 2.00 84 DCM 1x Span60 9.6 ± 0.7 2.8 ± 0.0 31.60 
18 70 0.1 0.05 100 acetone 1x poloxamer 407 -* -* -* 
19 83 0.1 2.00 70 ethyl acetate 1x Span60 17.0 ± 2.0 2.4 ± 0.1 13.81 
20 80 5.0 2.00 70 acetone 2x Span60 2.6 ± 0.2 2.8 ± 0.1 43.63 
21 50 0.1 2.00 70 DCM 2x poloxamer 407 95.3 ± 22.8 163.3 ± 23.0 10.10 
22 50 0.1 2.00 100 DCM 1x Span60 22.4 ± 4.0 53.3 ± 4.5 10.73 
23 62 0.1 1.24 100 DCM 2x poloxamer 407 4.6 ± 0.7 111.2 ± 2.1 11.69 
24 50 5.0 0.93 70 DCM 1x Span60 12.1 ± 0.6 10.2 ± 0.7 13.34 
25 70 5.0 2.00 100 acetone 1x Span60 23.2 ± 2.0 4.3 ± 0.6 48.68 
26 80 5.0 2.00 100 acetone 2x poloxamer 407 6.3 ± 1.0 31.2 ± 1.1 12.44 
27 70 0.1 0.15 70 acetone 2x poloxamer 407 -* -* -* 
28 80 2.7 2.00 100 ethyl acetate 2x poloxamer 407 -* -* -* 
29 76 1.8 2.00 100 acetone 1x Span60 -+ -+ -+ 
30 74 5.0 0.34 89 acetone 1x poloxamer 407 7.2 ± 1.1 17.8 ± 0.5 21.98 
31 50 5.0 0.05 93 DCM 2x poloxamer 407 14.7 ± 0.1 10.6 ± 0.7 20.10 
32 62 0.1 0.05 70 DCM 1x poloxamer 407 -* -* -* 
33 80 0.6 2.00 70 acetone 1x poloxamer 407 -* -* -* 
34 70 0.1 0.05 70 acetone 1x Span60 43.4 ± 4.5 5.9 ± 0.3 46.03 
35 85 3.5 1.12 89 ethyl acetate 1x Span60 113.7 ± 15.4 16.8 ± 6.3 2.82 
36 80 3.0 1.69 76 ethyl acetate 2x Span60 16.2 ± 1.7 2.1 ± 0.1 12.44 
37 88 5.0 0.05 100 ethyl acetate 2x poloxamer 407 10.9 ± 0.1 14.4 ± 0.2 18.07 
38 80 5.0 0.05 100 ethyl acetate 1x Span60 205.3 ± 21.9 15.4 ± 0.6 4.19 
39 90 0.1 2.00 100 ethyl acetate 1x poloxamer 407 -+ -+ -+ 
40 50 5.0 2.00 100 DCM 2x Span60 20.3 ± 0.2 36.3 ± 0.7 5.69 
41 80 5.0 1.04 100 acetone 1x Span60 22.6 2.0 3.1 ± 0.1 38.46 
42 50 5.0 0.05 93 DCM 2x poloxamer 407 24.2 ± 6.5 4.9 ± 0.4 12.49 
43 80 0.1 1.07 84 ethyl acetate 1x poloxamer 407 -* -* -* 
44 70 0.1 0.64 70 DCM 2x Span60 30.0 ± 0.2 7.6 ± 0.9 29.16 
45 74 3.8 2.00 72 acetone 1x Span60 4.4 ± 0.7 2.8 ± 0.1 54.14 
46 70 5.0 2.00 70 acetone 2x poloxamer 407 15.8 ± 1.1 49.3 ± 5.4 18.00 
47 90 2.1 0.05 70 ethyl acetate 1x Span60 61.3 ± 1.5 2.5 ± 0.3 24.39 
48 50 0.1 2.00 70 DCM 2x poloxamer 407 8.2 ± 2.3 105.4 ± 3.2 13.42 
49 80 5.0 0.05 70 acetone 1x poloxamer 407 50.2 ± 4.0 13.2 ± 8.4 16.71 
50 70 5.0 0.05 100 DCM 2x Span60 8.8 ± 0.4 17.7 ± 0.4 14.18 
51 90 3.0 1.71 100 ethyl acetate 2x Span60 7.9 ± 0.2 5.0 ± 0.0 31.16 
52 80 5.0 0.05 70 ethyl acetate 2x Span60 11.9 ± 1.7 4.5 ± 0.4 4.70 
53 55 5.0 2.00 100 DCM 1x poloxamer 407 -+ -+ -+ 
54 70 4.6 0.73 80 DCM 1x Span60 25.0 ± 6.2 10.3 ± 0.2 8.58 
55 80 3.4 0.06 70 ethyl acetate 1x poloxamer 407 -+ -+ -+ 
56 70 4.6 0.05 100 acetone 2x Span60 6.2 ± 0.1 4.9 ± 0.1 37.25 
(a mean ± range); T = inlet temperature, PC = polymer concentration, SC = stabilizer concentration; 
 - experiment failed due to membrane blocking (+) or polymer film (*) formation 
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Table 2.10. Contribution of process parameters and second order interactions affecting size in the NSD. p ≤0.05 is 
considered significant. 
factor coding total variance [%] p-value 
polymer concentration B 4.39 0.0074 
stabilizer concentration C 6.74 0.0013 
organic solvent E 1.62 0.2335 
stabilizer G 38.91 <0.0001 
interaction 
   
polymer concentration x 
stabilizer 
BxG 21.08 <0.0001 
stabilizer concentration x 
organic solvent 
CxE 6.23 0.0071 
stabilizer concentration x 
stabilizer 
CxG 5.11 0.0042 
 
Table 2.11. Contribution of process parameters and second order interactions affecting size distribution (width) in 
the NSD. p ≤ 0.05 is considered significant. 
factor coding total variance [%] p-value 
temperature A 0.11 <0.0001 
polymer concentration B 15.33 <0.0001 
stabilizer concentration C 0.04 <0.0001 
spray rate D 0.20 <0.0001 
organic solvent E 19.27 <0.0001 
pumping rate F 0.45 <0.0001 
stabilizer G 0.30 <0.0001 
interaction 
   
polymer concentration x 
organic solvent 
BxE 6.62 <0.0001 
 
From the ANOVA it is obvious that the formation of particles with NSD is influenced by 
various factors with the individual factors carrying little weight to the total variance. This is 
true for the particle size as well as for the width. 
The shape of the prepared MPs was investigated by SEM imaging. As the aim was to 
prepare particles as small as possible one of the batches with the lowest mean sizes (R 4) 
was investigated, showing that the particles were round and regular shaped (Figure 2.4a).  
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This batch was produced with a medium amount (1.18%, wt/v; according to the range defined 
in the DOE) of Span60 as stabilizer and compared to the optimized batch with high stabilizer 
concentration (1.6%, wt/v) of Span60 in Figure 2.4 d, which was used for determining 
minimum and maximum batch size (robustness). There was no visible change in the 
morphology or size distribution.  
a 
 
b 
 
c 
 
d 
 
Figure 2.4. Representative SEM images of (a) R 4, (b) R 49, (c) R 56 and (d) optimal formulation used for 
robustness experiments. (a) Investigation of one of the batches with the lowest mean sizes, which contains 
medium amount (1.18%, wt/v) of Span60, showing that the particles were round and regular shaped. Compared to 
the optimal batch with high stabilizer concentration (1.6%, wt/v) of Span60 in (d) no visible change in the 
morphology or size distribution could be determined. In (b) particles with lower amount (0.05%, wt/v) of 
poloxamer 407 and in (c) particles produced with a small amount (0.05%, wt/v) of Span60 were visualized showing 
a fraction of the particles in the submicron range <1 µm and a broad overall size distribution. 
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In Figure 2.4c particles (R 56) with lower amount (0.05%, wt/v) of Span60 were visualized 
showing that a fraction of the particles were indeed in the submicron range <1 µm, however 
the overall size distribution was relative broad with an average size of 4.9 µm. The same 
effect is also obvious for particles produced with a small amount (0.05%, wt/v) of 
poloxamer 407 as stabilizer (Figure 2.4b). 
 
2.4.5. NSD - Results of the DOE on yield 
Yields were obtained in the range of 1.16% (R 6) to 62.81% (R 4) and listed in Table 2.9. In 
general the highest yields were achieved with Span60 as stabilizer (R 4=62.81%, 
R 14=58.26%, R 45=54.14%). For seven out of 56 runs the yield was greater than 40%. 
Furthermore, a yield greater 30% was determined for runs with mean sizes <9 µm (R 4, R 9, 
R 14, R 17, R 20, R 25, R 34, R 41, R 45, R 51, R 56). 
The evaluation of the DOE showed that the organic solvent is the main factor influencing the 
yield, being responsible for 30.1% of total variance (Table 2.12). The two other noticeable 
and significant effects were stabilizer and polymer concentration contributing 13.1% and 8.3% 
to total variance. 
The effect of temperature, stabilizer concentration, spray rate and pumping rate were 
investigated to be very weak with <0.1% and not significant. Interestingly, the interactions of 
temperature/organic solvent and stabilizer/ organic solvent showed an effect of 10.19% and 
7.04%, respectively. Also other interactions were tested and had an influence of 3.1-4.2%, 
which was significant, except the interaction polymer concentration/stabilizer. The remaining 
second order interactions showed no effect and were not listed in Table 2.12.  
The statistical properties for the whole experiment were R2=0.899 and predicted_R2=0.666. 
Therefore, the model is less accurate, must be considered with caution for robustness and 
reliability. 
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Table 2.12. Contribution of process parameters and second order interactions affecting yield in the NSD. p ≤0.05 
is considered significant. 
factor coding total variance [%] p-value 
temperature A 0 0.9956 
polymer concentration B 8.33 0.0002 
stabilizer concentration C 0.19 0.5078 
spray rate D 0.44 0.3118 
organic solvent E 30.09 <0.0001 
pumping rate F 0.95 0.1418 
stabilizer G 13.14 <0.0001 
interaction 
   
temperature x stabilizer 
concentration 
AxC 4.02 0.0047 
temperature x organic solvent AxE 10.19 0.0002 
polymer concentration x 
pumping rat 
BxF 4.16 0.0041 
polymer concentration x 
stabilizer 
BxG 1.65 0.0572 
stabilizer concentration x spray 
rate 
CxD 3.25 0.0099 
stabilizer concentration x 
organic solvent 
CxE 7.04 0.0017 
stabilizer concentration x 
stabilizer 
CxG 4.01 0.0048 
organic solvent x pumping rate ExF 3.11 0.038 
 
2.4.6. NSD – Optimization 
As described above by the results of the DOE size and size distribution of particles as well as 
the yield using NSD is influenced by various factors and therefore more difficult to control. 
Based on the experimental data we proposed polynomial models using the Design Expert 
Software® to fit the data for size and size distribution on factors A-G. The goal was to 
calculate values for the factors (A-G) to reach the smallest possible size and size distribution 
with maximum yield (optimal formulation). Several possible solutions were found which 
predict the composition of an optimal formulation based on the before defined criteria.  
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The calculation was abridged as 100 solutions had been obtained. For determining the 
robustness (chapter 2.4.6) one formulation of these solutions was selected for investigating 
the limitation in batch size giving mean particles size ~2.8 µm with a narrow width of 0.9. 
 
2.4.7. NSD – Investigation of robustness 
All results of size, size distribution and yield were presented in Figure 2.5a and Figure 2.5b. 
Figure 2.5a shows a slight increase in size from 10.0 to 20.0 ml and in parallel also the width 
increases. From 40.0 to 50.0 ml the mean size doubles, but the width kept constant. The 
minimum yield was determined for 5 ml with 60%. For other volumes the yield ranges from 
71.1% to 84.8%. From 5.0 ml to 40.0 ml the yield increased, whereas with 50.0 ml the yield 
decreased slightly. The results show that between 5.0 ml-40.0 ml particles with a mean size 
of 2.6 µm to 4.3 µm with a mean width of 0.91 to 2.50 and yield >60% could be produced. 
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Figure 2.5. Investigation of maximum and minimum batch size (robustness) for the NSD by determining (a) mean 
size and size distribution (width) and (b) yield from batches produced with different volumes. The concentration of 
PLGA and Span60 was kept constant. Mean size and size distribution (width) were measured by laser light 
diffraction. The values are presented as the mean ± S.D. (n=3). 
 
2.5. Discussion 
The absence of information regarding the influence of parameters on the production of NP-
based DDS is hindering the scale-up and the more widespread production of such systems in 
the pharmaceutical industry [89]. To enter in the pharmaceutical production and thereafter the 
pharmaceutical market a transfer from bench top to pharmaceutical production (scale-up) has 
to be achieved.  
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It is known that process limitations can become significant in a larger production process, 
which were not apparent before. At the moment, only one albumin based nanoparticulate 
DDS (Abraxane®) is approved by the FDA and European Medicines Agency (EMA) and a 
second, which is a polyalkylcyanoacrylate based nanoparticulate DDS (Livatag®, doxorubicin 
Transdrug™), is currently in phase III clinical trial [152].  
To evaluate the influence of process parameters, a DOE was applied on the NPR and NSD. 
Choosing the optimal design of the DOE a full factorial design requires a large number of 
experiments. Therefore, fractional factorial designs e.g. response surface designs are 
appropriate for series varying several factors. Furthermore, a fractional factorial design can 
reduce costs and material due to the reduced number of experiments [146].  
NPR is one of the most frequently used physico-chemical methods [93] for producing NPs as 
DDS [94], [95]. Compared e.g. to emulsion-diffusion-evaporation methods it is less time 
consuming, more reproducible and controllable due to less production steps [89] and was, 
therefore, investigated. Previously performed DOE studies using the NPR studies were 
mostly focusing on drug loading [65]. So far no study was carried out using a DOE as a tool 
to screen the production process for parameters influencing size and size distribution. The 
second method was the spray drying technique selected to formulate DDS in one step 
without extra washing or drying steps (single step process) [92]. For the NSD a system, the 
Büchi B-90 was used specially designed to produce and to collect spay dried products with a 
particle size in the submicron size range [100], which was introduced in chapter 1.5. As of 
now only a few studies have been done with this spray dryer, mainly investigating the 
preparation of particles using polymeric wall materials, the drying of pharmaceutical 
excipients [104] and drying of nano-emulsions [92]. First studies were carried out focusing on 
the encapsulation of proteins [105] and model drugs in biodegradable polymers [100], [109]. 
A recent study used a 23 factorial design to develop inhalable capreomycin powders [147]. 
 
2.5.1. Outcome of the design of experiments for the NPR 
To use the DOE as a tool in order to understand process parameters was successful for the 
NPR. The results of the DOE revealed that the size is mostly influenced by the polymer 
concentration (79.5%), which is thus easy to control. This is in accordance with a meta-
analysis performed by Mora-Huertas et al. on published and experimental data showing that 
the size of submicron particle size can be changed by the polymer concentration, regardless 
of the nature of polymer, nature of stabilizer or the operating conditions [94]. 
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In the performed experiments in this chapter stable NPs in the range of 110-180 nm were 
achieved (Table 2.5) with polymer concentrations of 1%-2% (wt/v). None of the experiments 
failed completely and in none of the experiments aggregates were visible after evaporation of 
the organic solvent.  
Increasing polymer concentrations lead to the formation of larger particles, which is in 
agreement with the observations of Thioune et al. [153], preparing hydroxypropyl 
methylcellulose phthalate NPs, and Galindo-Rodriguez et al. [97], preparing 
polymethacrylic acid copolymer NPs. Moreover, in the present study high polymer 
concentrations of 2% invariably lead to the largest particle sizes (>170 nm) with narrow size 
distributions (PDI <0.070) independent of inner needle diameter, injection speed, stabilizer or 
organic solvent (Table 2.5). At high polymer concentrations the theoretical concentration of 
polymer chains is higher and a more even distribution of polymer chains among all solvent 
droplets results in particles with the same size. Low concentrations increase the probability to 
have less or different concentrations of polymer chains in the droplets. Below a critical 
polymer concentration hence a wider size distribution results [97]. For the investigated set-up 
the critical polymer concentration could be proposed to be at ~0.1% (wt/v) (lowest polymer 
concentrations) or below, which resulted in a dramatic increase in the PDI (0.132–0.294).  
In the present study the stirring speed was set to 500 rpm in order to improve distribution of 
the organic phase into the aqueous phase and largely prevent unstirred layers. Unstirred 
layers hinder diffusion, which lead to a time-dependent particle growth as the droplets of the 
organic solvents will not be split evenly at fast injection speeds [94]. A high stirring speed 
reduces the influence of injection speed, demonstrated in the results of the DOE in Table 2.6, 
of organic to aqueous phase ratios and of stirring speed, both were fixed in the DOE, on the 
complex fluid dynamics and, therefore, particle formation [94], [154]. Furthermore, in the 
present study the stabilizer concentrations were fixed. In the NPR the stabilizer is in general 
needed to avoid aggregation during particles formation and known to have independent of the 
concentration an influence on particle mean sizes, which was also demonstrated by the DOE 
(Table 2.6) with 7.3% of total variance [94]. It was reported that poloxamer 407 generates 
larger particles in comparison to polysorbate 80 [94]. A tendency could be seen in the 
optimization of the NPR as both stabilizers need different parameter to generate 150 nm 
particles.  
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Indeed, that the influence on size and size distribution was dominated by the polymer 
concentration might appear relatively obvious. However, the DOE allowed defining a 
mathematical and statistical reliable correlation, expressed in equations 6 and 7. Using these 
equations, the process can be easily adapted to generate other particles sizes, between 110-
180 nm with narrow size distributions, within the constraints of the dataset used for the 
development of the equations. We demonstrated furthermore that the used system based on 
these equations was robust and accurate within a range between some minimally needed 
and maximally possible volume-based batch size. The maximal batch size using 50 ml of 
organic solvent allows fabricating particles based on 650 mg PLGA, which is likely suffice for 
first pre-clinical studies. Very small batch sizes (0.625 ml) allow preparing particles for first 
physico-chemical characterization studies. Therefore, the used set-up can be adapted in the 
particle quantity for different experimental purposes.  
 
2.5.2. Outcome of the design of experiments for the NSD on size and size distribution 
For the NSD the DOE was designed to investigate controllability, limitations and robustness 
regarding particle size, size distribution and yield of this so far less characterized system [92]. 
Therefore, seven factors were screened, which were expected to have an influence on the 
outcome of the spray drying process. Combining rather a high number of factors is also a limit 
for a DOE, but necessary to thoroughly screen an unknown system. A reduced number of 
factors allows investigating more values in the defined ranges, but would not necessarily 
reduce the number of initial experiments. By reducing the factors of a totally unknown 
process effects could be missed. Furthermore, the outcome could be so weak, that the other 
factors had to be investigated in a second DOE, further increasing the number of 
experiments. The results show clearly that NSD is influenced by various factors and, hence, 
more difficult to control than the NPR.  
The aim was to produce the smallest possible size using PLGA and within the technical 
constraints of the Büchi B-90 with a spraying tower of 150 cm in length. The results show that 
the smallest particles, which were prepared, were MPs with an average size of ~2 µm. This 
can be explained by the formation of the particles, which is governed in a first step by 
interplay of polymer concentration in the droplet, pore size of the vibrating membrane used 
for evaporating the spraying solution and the frequency of vibration. The frequency defines 
the volume of the droplet, which is injected in the drying gas flow. Further the droplet 
diameter is mostly influenced by the pore size of the membrane.  
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The smallest membrane pore size, which is currently available, has a pore size of 4 µm and 
generates droplets ~8 µm [103]. It would be interesting to see the effect on the droplet size 
using a pore size ~1 µm, while changing the frequency of vibration (at the moment fixed at 
60 kHz by the manufacturer). However, a smaller pore size will increase spraying times. In a 
second step the droplets are dried in the gas flow forming the particles depending on surface 
tension and density. Therefore, the feeding material, as well as density and viscosity of the 
feeding solution, containing in the present study the polymer and the stabilizer, influence the 
transport through the membrane and the successful particle formation.  
In comparison to NPR some experiments failed completely (Table 2.9), in particular if 
poloxamer 407 was used as stabilizer or if ethyl acetate was used as organic solvent. 
Especially high viscosity and density of the feeding solution can block the vibrating 
membrane and droplet coalescence can lead to the formation of a polymer film on the 
collecting electrode. 
Polymer and stabilizer in this study were revealed to have an effect on the particles size 
(Table 2.10). The identified interaction between polymer concentration/stabilizer underlines 
this aspect (Table 2.10). This is not unexpected as recent studies had also shown that the 
polymer concentration influences the particle size [92], [105], [155] or that the particle size is 
depending on the wall material [92]. Moreover, Beck-Broichsitter et al. determined that the 
concentration of the feeding solution and also the molecular weight (MW) of PLGA with 
different lactic/glycolic ratios can influence the size [109]. As in the present study the 
stabilizer is part of the DDS, the different MW of poloxamer 407 (MW 12,785 g/mol) and 
Span60 (MW 430 g/mol) could, therefore, influence the particles size as demonstrated by the 
results in Table 2.9. In general, smaller mean sizes were achieved with Span60 and, 
furthermore, the mean size increased strongly by increasing the concentration of 
poloxamer 407 (Table 2.9).  
For the size distribution a significant effect of the polymer concentration and of the organic 
solvent, and of the interaction of these two factors, was determined (Table 2.11). This reflects 
that intuitively quicker drying of the spray droplets in a gas flow would avoid droplet 
coalescence. The generated particles had a smooth surfaced as visualized in SEM images in 
Figure 2.4. More hollow particles were normally obtained with fast drying processes [109], 
[151]. 
Due to the complexity interplay of influencing factors on the NSD no single mathematical 
solution for an optimal formulation could be expressed.  
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Nevertheless, a selected formulation was robust and accurate to a volume-based evaluation 
of the minimum (5.0 ml) and the maximally possible (40.0 ml) batch size. Both the maximally 
possible and the minimum batch size were limited by technical constrains and characterized 
by a smaller range compared to the NPR. 
Yields achieved with the Büchi B-90 ranged between 43-95% as reported in the literature 
[100], [156], depending e.g. on spray dried material and spray rates [92], [108]. The yields we 
obtained were in the range of 1.16% to 62.81%. We found in our DOE that yield was mostly 
influenced by organic solvent, stabilizer and polymer concentration and the interaction 
between stabilizer/organic solvent (Table 2.12). But in contrast to Bürki et al., no effect of the 
spray rates were determined [108]. The spray rate in the NSD can only be adjusted indirectly 
by the relative volume flow, which passes through the membrane. This volume flow is 
influenced by the viscosity of the feeding solution as well as of the pore size of the spray cap 
and the inlet temperature of the spray head. Thus, the spray rate can indirectly be influenced 
by the choice of organic solvent, polymer concentration and stabilizer, which is obvious in the 
DOE, as the different combinations of organic solvent, polymer concentration and stabilizer 
resulted in different viscosities of the feeding solution. Therefore, no direct influence on the 
spray rate could be determined. 
In the Büchi B-90 an electrostatic precipitator is used for the particle collection, which has in 
general an efficacy of 90-99% depending on the sprayed material, mass and the used gas 
[157]. A low precipitation efficiency of submicron particles in electrostatic particle precipitator 
is due to the difficulty in charging the spray dried material, which is depending on the 
electrical resistivity [157]. Low charge results in low particle mobility and low collection 
efficiency due to fast discharging [158]. In the present study an effect of the interaction 
temperature/organic solvent on yield was observed, which may indicate that inefficient dried 
particles have a different ability to be charged than full dried particles. Due to the solvent 
residues in the sprayed particles a change in the electrical resistivity could be assumed. 
Electrostatic precipitators are normally constructed with a system to remove the deposited 
particles from the collector electrode (e.g. a mechanical rapping device), before the saturation 
is reached. In the Büchi B-90 no such auto-cleaning system is installed and a saturation of 
the collector electrode was observed, which limits the robustness of the method when 
spraying large batch sizes. The yield decreased from 84.8% to 74.0%, when using 40 ml and 
50 ml initial volume, yielding an effective amount of particles 1080 mg and 1350 mg, 
respectively (Figure 2.5).  
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2.5.3. Design of experiments as tool in the development of nano- and microparticulate 
 drug delivery systems 
It is obvious that a DOE generates an objective view on an unknown or poorly characterized 
process. However, the gain of information of a DOE could be little or enormous compared to 
the investment of practical work. However, the combination of parameters in the DOE can 
save time and indicate limitations. The main challenge is to precisely ask the questions, 
which should be answered by the DOE. A DOE is useless/inefficiently answering yes-no 
questions, such as e.g.: Can my drug be encapsulated in NPs at all? Instead, a DOE will 
answer the following questions: Do different stabilizers have an effect on the encapsulation 
efficiency? Does a given stabilizer has a different effect when combined with another 
solvent?, etc. Depending on the influence of the factors in question, the DOE would reveal a 
statistical correlation. 
Before starting the DOE it is important to perform some preliminary studies to decrease the 
range of investigated factors and, hence, to increase the accuracy of the DOE model. For 
example it will not make sense to use an amount of polymer which is insoluble in the organic 
phase or at so high contents that an injection is impossible due to the increased viscosity. 
Such limitations can be taken into account in the DOE. A DOE could be a benefit and save 
time for frequently used processes, e. g. production processes of solid dosage forms, mixing 
processes, coating processes, improving quality, accuracy and reliability for the respective 
process in development as well as in research. 
 
2.6. Conclusion 
The DOE approach as performed in this study revealed that the particle size and its 
distribution in the NPR are dominantly controlled by the polymer concentration. Hence, the 
DOE allowed for the NPR to define a mathematical model and statistically reliable correlation, 
which can be used for the optimization of the process and prediction of optimal formulation. 
It was possible to distinguish between important and unimportant factors based on the 
unambiguous statistical criteria. Thus, the major advantage of the DOE is to provide a 
statistically sound basis for discarding unimportant parameters and focusing on the essential 
ones. The model built by the DOE for the NPR for producing particles with a size of 
150 ± 10 nm was accurate, robust and reliable, so that the predicted optimized parameters 
were in excellent agreement with experimental data.  
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In case of NSD, the DOE revealed that the formation of particles is more complex as being 
influenced by various process parameters and, therefore, more difficult to control. The use of 
the DOE approach allowed discerning the interaction of factors and helped in explaining the 
indirect influence of factors on the process. We could demonstrate that each of the seven 
investigated process parameters in the DOE were of significant influence and necessary to 
be thoroughly addressed. With NSD, the smallest possible particle sizes were in the lower 
micrometer size range and several possible solutions were found which predict the 
composition of an optimal formulation based on the DOE. Both NPR and NSD were robust 
and accurate to a volume-based evaluation of the minimally necessary and the maximally 
possible batch size using optimized set-ups.  
We conclude that DOE can help to optimize well known processes and, furthermore, to 
understand and optimize innovative manufacturing processes, which is urgently needed for 
the quality by design preparation of nano- and micronsized DDS.  
Parameters used for the following experiments 
Based on the results of this chapter the following parameters for the preparation of NPs were 
selected as listed in Table 2.3. Briefly, 1.3% PLGA, poloxamer 407 and mixture of 
acetone/ethanol as organic solvent were used. For the NSD parameters were selected as 
listed in Table 2.4. Briefly, 1.1% PLGA (wt/v), 1.6% Span60 (wt/v) and acetone as organic 
solvent were selected. 
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3. Advanced formulations of cyclosporine A and budesonide for the therapy of 
inflammatory bowel disease 
 
 
 
 
 
 
 
 
 
Parts of this chapter will be included in a manuscript for submission to a peer-reviewed journal: 
Christina Draheim*, Julia Susewind*, Alexis Guillot, Brigitta Loretz, Steffi Hansen, Eva-Maria Collnot, 
Markus Limberger, Claus-Michael Lehr, PLGA based nano- and microsized particles for inflammatory 
bowel disease therapy: evaluation of size-dependent accumulation and anti-inflammatory effect in an in 
vitro triple culture model 
*These authors contributed equally to this work. 
 
 
 
The author of the thesis made the following contributions to the chapter: Conceived, designed and 
performed experiments. Analysed and interpreted the data. Wrote the manuscript. 
The X-ray powder diffraction (XRD) analysis was kindly performed and designed by Sebastian Slawik 
at the Material Engineering Center Saarland (MECS). The author thanks the MECS for the support. 
  
                                                           Advanced formulations of cyclosporine A and budesonide 
 
54 
3.1. Introduction 
The therapy of IBD is at the moment limited to reduce the symptoms and to increase life 
quality, mainly based on a medical treatment [17]. The daily administration of high doses of 
immunosuppressive or anti-inflammatory drugs is hence required for the treatment of IBD, 
leading to severe adverse effects. The application of pellets or tablets, targeting the upper 
parts of the intestine, is often inefficient in IBD mainly due to enhanced elimination of these 
dosage forms by diarrhea [43]. Therefore, patients would benefit from a DDS that delivers the 
used drugs directly to the inflamed areas of the intestine. Such a more local treatment would 
reduce high systemic concentrations and, furthermore, allow a dose reduction compared to a 
systemic application reducing side effects.  
In IBD a reorganization of the epithelium within ulcerated areas occur due to the inflammation 
and depending on the level of severity [43], [159]. The ulcerations have been revealed to be 
an accessible target for particulate DDS in a suitable size range [71], [73], [76]. Particles can 
accumulate in the inflamed areas of the intestine and remain there for prolonged times, 
releasing the encapsulated active pharmaceutical ingredient (API) in a controlled manner. 
Several recent studies show the efficacy of this passive targeting approach and were 
introduced in chapter 1.4. A size-dependent accumulation was identified: NPs seems to be 
favorable in rodent colitis models (chapter 1.4) [75], [81]. At the same time a recent study 
demonstrated a higher accumulation efficiency for MPs, compared to NPs of the same 
material, in human patient [76]. However, this effect has to be further investigated. 
The emergence and more widespread production of particulate DDS in the pharmaceutical 
industry is hindered by the absence of information regarding the influence of process 
parameters [89]. The identification of critical process parameters is important in the early 
stage of DDS development in order to achieve particles of consistent quality. Thus, for the 
preparation of PLGA particles a DOE was applied on NPR and NSD to understand the control 
of size and size distribution (chapter 2). The NPR was optimized for producing NPs with a 
size of 150 ± 10 nm. With the NSD MPs can be fabricated in a single step with a size of ~2-
4 µm. Both methods were robust and accurate across the volume-based batch size range of 
0.625-50.0 ml for the NPR and 5-40 ml for the NSD. This is important in the development 
process, where in the beginning a limited amount of material is available and later the batch 
size needs to be scalable for larger test series. 
In this chapter the immunosuppressive drug CYA and the anti-inflammatory drug BU were 
encapsulated into the in chapter 2 optimized NPs and MPs.  
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The two lipophilic drugs were selected due to their potential in IBD therapy and different 
pharmacological and physico-chemical properties (chapter 1.2), which can influence the 
encapsulation efficiencies (EE) and the release from the DDS. PLGA can be used to 
encapsulate hydrophobic drugs, e.g. CYA and BU, and is present in an amorphous state 
when used at a ratio of 50/50 (lactic/glycolic acids, wt/wt). This leads to a relatively faster 
decomposition within two month, an optimal degradation time for an orally applied DDS. 
CYA, a calcineurin inhibitor, is applied to UC patients suffering from steroid-refractory disease 
or from fulminant colitis, often also in co-medication with azathioprine and methotrexate for 
maintenance therapy [17], [29], [160]. BU, a corticosteroid, is a first-line drug for the treatment 
of inflamed ileum and ascending colon in CD [17], [37]. In contrast to other corticosteroids, 
BU undergoes an extensive first-pass metabolism, thereby, the systemic bioavailability is 
reduced to 10-15% after oral administration [39], [40]. Nevertheless, both APIs lead to several 
serious side effects [161], which should be decreased by using a suitable DDS. 
Additionally, in this chapter NPs were transferred to a storable form by freeze drying and this 
process was further optimized. Afterwards the optimal loading of both drugs was determined 
by encapsulating increasing amounts of CYA or BU in NPs and MPs. The particles were 
characterized in size and size distribution. In a second step optimal loaded NPs and MPs 
were analysed by X-ray powder diffraction, to determine the crystalline content of BU and 
CYA in NPs and MPs, and in vitro release profiles were performed. 
The direct comparison of NPs and MPs aimed to improve the understanding of inflammation 
targeting. The physico-chemical and biopharmaceutical properties (e.g. size, EE and release) 
were characterized to determine in the following in vitro (chapter 5) and in vivo experiments 
(chapter 7) their impact on the success of IBD therapy.  
 
3.2. Materials 
Excipients for NP and MP preparation and active ingredients were used as described in 
chapter 2.2. Budesonide (BU) and tween®80 were purchased from Caesar & Loretz GmbH 
(Hilden, Germany). Cyclosporine A (CYA, Fluka), sucrose and D-(+)-trehalose dehydrate 
were purchased from Sigma Aldrich (Schnelldorf, Germany). Polyvinyl alcohol (PVA, 
Mowiol®4-88) was purchased from Merck (Merck KGaA, Darmstadt, Germany). Purified water 
was of Milli-Q quality and prepared by a Millipore Milli-Q Synthesis system (Merck KGaA, 
Darmstadt, Germany). 
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All solvents were high-performance liquid chromatography grade and all chemicals met the 
quality requirements of the European Pharmacopoeia 6.0–7.3. 
 
3.3. Methods  
3.3.1. Optimization of the freeze drying process of nanoparticles 
Preparation of nanoparticles 
The NPs were prepared by nanoprecipitation (NPR) as introduced in chapter 1.5 and 
described in chapter 2.3.8. Briefly, PLGA (1.3%, wt/v) were weighed accurately and dissolved 
in a mixture of acetone/ethanol (organic phase, 16/3, v/v). The solution was injected with a 
Hamilton® glass syringe using a 0.6 mm in diameter needle (1005 TTL 5 ml, chromatography 
service, GmbH, Germany) at 500 rpm and a flow of 4.55 ml/min into purified water containing 
1% poloxamer 407 (wt/v) as stabilizer, forming the aqueous phase. The ratio organic 
phase/aqueous phase was kept at a ratio of 1/2. The poloxamer 407 was separated from the 
NPs by dialysis (Spectra/Por® dialysis membrane, molecular weight cut-off (MWCO) 300 kDa, 
Carl Roth GmbH & Co. KG, Germany) overnight against purified water. After washing of the 
NP suspension the volume was readjusted with purified water to the initial volume. 
Freeze drying of nanoparticles 
The drug free washed NPs were freeze dried separately in the presence of 2.6% trehalose, 
1.3% mannitol and 1.3% sucrose in a first step. Hence, the ratio PLGA/sugar is 1/1 (wt/wt) or 
1/2 (wt/wt) for trehalose. As the results turned out an unsuccessful re-constitution also 
mixtures of trehalose at a ratio of 1/1 in combination with polyvinyl alcohol (PVA) were tested. 
PVA was added as solution (2%, wt/v, pH 7.0) at different concentrations referring to the 
volume of the NP suspension (0.01%, 0.05%, 0.1%, 0.3%, 0.6%, 1.0%; wt/v). NPs were 
freeze dried without any cryoprotective agent as a control. Before freeze drying the samples 
were frozen at -80°C for 12 h. Afterwards the samples were immediately placed into the 
freeze drying chamber (Christ alpha 2-4 LSC, Germany). The first drying step was performed 
at 15°C and 0.08 mbar for 72 h. Secondly, the temperature was increased to 20°C and the 
pressure increased to 0.20 mbar for 2 h. The freeze dried cake was characterized according 
to following criteria according to Chacón et al. [162]: (a) volume contraction of cake in high, 
(b) volume contraction of cake in diameter. Sample reconstitution was performed by addition 
of purified water to restore the starting volume before freeze drying and mild manual shaking.  
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The particle size and size distribution was measured by dynamic light scattering 
(chapter 3.3.4). The experiments were performed at least in triplicate. Also the macroscopic 
appearance of NP suspension after reconstitution was evaluated according to the following 
criteria: (c) absence of aggregates, (d) few small sized aggregates, and (e) large aggregates 
[162].  
After optimization of both processes freeze drying and drug loading (chapter 3.4.2) stability 
studies under storage conditions (4°C, in closed vials) were performed. Freeze dried samples 
of unloaded NPs were analysed for size and size distribution after three and six month. 
Loaded NPs were analysed only after six month. 
 
3.3.2. Preparation of API loaded nanoparticles by nanoprecipitation  
The NPs were prepared by NPR as introduced in chapter 1.5 and described in chapter 3.3.1. 
To determine the optimal loading of the NPs, increasing amounts of both APIs were 
separately encapsulated in the same amount of PLGA (65 mg, equal to 1.3% in 5 ml organic 
phase). The used ratios API/PLGA (wt/wt) were 0.5/10, 1/10, 2/10, 3/10, 4/10 and 5/10 both 
dissolved in the organic phase. The ratio of 1/10 was defined as standard loading. The 
encapsulation of BU was stopped at a ratio of 4/10 due to the resulting EE (chapter 3.4.2.). 
The volume of organic solvent was kept at 5 ml and the ratio organic phase/aqueous phase 
was kept at a ratio of 1/2 (5 ml/10 ml). After preparation the particles were washed 
(chapter 3.3.2.1), freeze dried using trehalose at a ratio of 1/1 (trehalose/PLGA, wt/wt) 
combined with 0.3% (wt/v) PVA according to the results in chapter 3.4.1 and the EE was 
determined (chapter 3.3.6). Experiments were performed at least in triplicate. 
 
3.3.2.1. Purification 
To separate the free BU content and the stabilizer (poloxamer 407) from the solution the NP 
suspension was washed four times with purified water by tangential flow filtration using a 
Minimate™ TFF capsule (MWCO 300 kDa, Pall, Germany). The filtration was carried out by 
adding four times the initial volume of the aqueous phase.  
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The free CYA content was separated from the NPs by dialysis (Spectra/Por® dialysis 
membrane, MWCO 300 kDa, Carl Roth GmbH & Co. KG, Germany) over two days against 
purified water. The dialysis allows also separating the stabilizer. 
Different systems were used for the purification as the BU was attaching to the dialysis 
membrane. 
After washing of the NP suspension the volume was readjusted with purified water to the 
initial volume. This is important to maintain the same concentration for the following freeze 
drying step. 
 
3.3.3. Preparation of API loaded microparticles by nano spray drying 
The MPs were prepared by NSD as introduced in chapter 1.5 and described in chapter 2.3.2 
and chapter 2.3.9. Briefly, the Büchi B-90 was operated in the closed mode set-up with inert 
gas (N2 and CO2 at 0.8 bar). As in-process parameters the out-let temperature and the drying 
gas flow, which was fixed at 115 l/min, were monitored. The out-let temperature was 
determined to be 28-38°C, which should be below the Tg of the used PLGA (~45°C, 
determined by differential scanning calorimetry). For preparation of the feeding solution 1.1% 
PLGA (wt/v), 1.6% Span60 (wt/v) as stabilizer and the API, BU or CYA, were accurately 
weighted and dissolved in acetone. To determine the optimal loading of the MPs increasing 
amounts of both APIs were separately encapsulated in the same amount of PLGA (110 mg, 
equal to 1.1% in 10 ml organic phase). The used ratios API/PLGA (wt/wt) were 0.5/10, 1/10, 
1/15, 2/10, 3/10, 4/10 and 5/10. The ratio of 1/10 was defined as standard loading. The 
encapsulation of BU was stopped at a ratio of 4/10 due to the resulting aggregation of the BU 
loaded MPs at high ratios (chapter 3.4.2). The volume of acetone was kept for all 
experiments at 10 ml. The feeding solution was sprayed using the 4 µm mesh under ice-
cooling of the supplied dispersion to prevent heating of the circulating solution. The particles 
were collected by an electrostatic particle precipitator, removed by a plastic scratcher from 
the collector electrode and the EE was determined (chapter 3.3.6). Experiments were 
performed at least in triplicate. The MPs are already a dry powder and, thus, do not need an 
additional washing and freeze drying step. 
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3.3.4. Determination of particles size, size distribution and zeta potential 
Particles produced by NPR 
Hydrodynamic diameter and polydispersity index (PDI) of NPs were measured by dynamic 
light scattering (Zetasizer® Nano ZS, Malvern Instruments, UK) as described in chapter 2.3.6. 
The zeta potential was measured in purified water using the Zetasizer® Nano ZS. The 
measurements were carried out for each batch in triplicate and the mean value and standard 
deviation (S.D.) were calculated. 
Particles produced by NSD 
The spray dried MPs were characterized by laser diffraction using a Mastersizer® 2000 
(Malvern Instruments, Herrenberg, Germany) as described in chapter 2.3.6. The particles 
were re-dispersed in purified water containing 0.01% PVA under manual shaking for 10 s. All 
batches were measured each in triplicate and the mean value and standard deviation (S.D.) 
were calculated. The volume mean diameter (d 0.5) as well as the percentile values d 0.1 and 
d 0.9 were further calculated by the Mastersizer® software. D 0.1 and d 0.9 describe, that 
10% or 90% of the particles are smaller than the measured diameter for the corresponding 
value, respectively. The size distribution (width) is defined in equation 8 (eq. 8). A narrow size 
distribution is indicated by a small width 
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3.3.5. Investigation of morphology by scanning electron microscopy 
The SEM imaging was performed as described in chapter 2.3.8. 
 
3.3.6. Determination of encapsulation efficiency and optimal loading 
High-performance liquid chromatography (HPLC) was used for the quantification of both APIs 
using the following methods. HPLC quantification was performed with a Dionex system 
(Thermo Fisher GmbH, Idstein, Germany) consisting of a Dionex ISO-3100A pump, a Dionex 
WPS-3000 TSL autosampler, a Dionex VWD-3400 variable wavelength detector, a Dionex 
TCC-3000 column compartment and a Dionex SRD-3200 solvent rack. The system ran on 
Chromeleon software version 6.80 SP2. 
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A reversed phase column, LiChrosphere® RP18 column (5 µm x 125 mm x4 mm; Merck 
KGaA, Germany), and an isocratic elution were used. All standards were dissolved in a 
mixture of acetonitrile/phosphate buffer pH 3.0 (1/1, v/v). The mobile phase consisted for BU 
of a mixture of acetonitrile/phosphate buffer pH 3.0 (2/3, v/v). The oven temperature was set 
to 30°C. An injection volume of 80 µl and a flow of 1.9 ml/min were used. The retention time 
was 4.0 ± 0.1 min detecting BU with UV at 242 nm. The method was linear (r2 >0.999) 
between 2.0 µg/ml-100.0 µg/ml with a calculated lower limit of quantification (LOQ) of 
2.0 µg/ml. For CYA a mixture of phosphate buffer pH 3.0/methanol (1/9, v/v) was used as 
mobile phase. The oven temperature was set to 50°C. An injection volume of 30 µl and a flow 
of 1.0 ml/min were used. The retention time was 2.1 ± 0.1 min detecting CYA with UV at 
205 nm. The method was linear (r2 >0.999) between 10.0 µg/ml-100.0 µg/ml with a calculated 
LOQ of 6.0 µg/ml.  
The EE was determined by a direct method using the final formulation after freeze drying for 
NPs and after spray drying for MPs. Likewise, a known amount of API loaded NPs or MPs 
was dissolved in a mixture of acetonitrile/phosphate buffer pH 3 (1/1, v/v) and treated 
2x15 min in an ultrasonic bath to disintegrate the PLGA particles. The solution was cooled 
down to room temperature and filtered through a disposable syringe filter with 0.45 µm pore 
size (CHROMAFIL GF/PET 45/25). The clear filtrate was collected and analysed by HPLC to 
determine the API content. Experiments were at least performed in triplicate. 
															II =
Z	(B[\	(N]^_:L)^"(!)
Z	(B[\ N " ^))
∗ 100% 
 
eq. 9 
 
The EE describes the percentage of encapsulated API referring to the initial mass of API and 
is defined by equation 9 (eq. 9). In this equation m (APIinitial) refers to the weight (m) of API put 
into the formulation and m (APIencapsulated) refers to the amount of API measured after re-
dispersion and disintegration. 
The mass of encapsulated API was used to determine the actual loading. The actual loading 
is expressed in equation 10 (eq. 10) and describes the actual loading as ratio of weight (m) 
encapsulated API in mg to 100 mg of PLGA. The actual loading displays the loading capacity. 
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The theoretical loading can be calculated form the initial amount of API referring to 100 mg of 
PLGA as expressed in equation 11 (eq. 11). 
																^]"L^)	)M^! N` =
Z	(B[\/2-+*16-3/$)
Z	([abB3-6)
∗ 100 
 
eq. 10 
 
															"ℎ(MJ(" ]^)	)M^! N` =
Z	(B[\3-6)
Z	([abB3-6)
∗ 100 
 
eq. 11 
 
The actual loading and theoretical loading were correlated in one graph for NPs or MPs, and 
both APIs, respectively (Figure 3.2). This representation can be used to determine the 
optimal theoretical loading, which is reached, if by increasing initial API mass the actual 
loading is not increasing proportional.  
Optimal loaded NPs and MPs were further analysed by X-ray powder diffraction 
(chapter 3.3.7) and in vitro release profiles (chapter 3.3.8) were performed. 
 
3.3.7. X-ray powder diffraction  
The X-ray powder diffraction (XRD) analysis was used to determine the crystalline content of 
BU and CYA in optimal loaded NPs and MPs (ratio of 1/4, CYA/PLGA, wt/wt, for NPs and 
MPs; 1/10 and 2/10, BU/PLGA, wt/wt, for NPs and MPs, respectively). First, samples of pure 
materials (PLGA, Span60 and trehalose) and pure APIs were scanned by XRD to identify the 
signals from pure material in the formulations as listed in Table 3.1. Further drug free and 
optimal loaded particles (chapter 3.4.2) both NPs and MPs were investigated as well as 
physical mixtures of drug free particles mixed with API at concentrations referring to optimal 
loading. All samples were analysed in dry powder state. A PANalytical X’Pert Pro MPD was 
used with Cu anode at 40 kV and 40 mA. Samples were scanned across an angular range 
from 5 to 145 2θ with a step size of 0.013°2θ. The powders were analysed in a nickel or 
monocrystalline silicon sample holder for small batch sizes, which was used for the APIs. 
Characteristic high intensity peaks were used in order to determine qualitatively the API 
contents in the particles. 
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Table 3.1. Samples analysed by XRD. 
sample nanoparticles microparticles 
API CYA 
API BU 
cryoprotective/ stabilizer trehalose Span60 
 drug free drug free 
 CYA loaded CYA loaded 
 BU loaded BU loaded 
physical mixture drug free NPs + CYA drug free MPs + CYA 
physical mixture drug free NPs + BU drug free MPs + BU 
 
3.3.8. In vitro drug release studies 
The release profiles of the optimal loaded NPs and MPs (chapter 3.4.2; ratio of 1/4, 
CYA/PLGA, wt/wt, for NPs and MPs; 1/10 and 2/10, BU/PLGA, wt/wt, for NPs and MPs, 
respectively) were investigated in phosphate buffered saline (PBS, 10mMNaCl) pH 6.8, to 
mimic the conditions in the proximal colon [50], at room temperature in triplicate. To increase 
the solubility of CYA 0.05% tween®80 (wt/v) was added to the PBS.  
Sink conditions and determination of saturation concentration 
The release was performed under sink conditions, which were defined as 30% of the 
saturation concentration according to the United States Pharmacopeia (USP, 2003). The 
saturation concentration was determined to be 42.3 ± 0.8 µg/ml for CYA and 21.7 ± 0.6 µg/ml 
for BU. The experiments were performed in triplicate. Likewise, BU and CYA as powder were 
added to 3 ml PBS pH 6.8, containing 0.05% tween®80 (wt/v) for CYA, in a snap vial until a 
visible pellet was formed. The PBS was stirred for 24 h at room temperature. Afterward the 
supernatant was separated from the pellet by centrifugation for BU (Hettich Rotina 420 R, 
Hettich Holding GmbH & Co. oHG, Germany; at 15000x g at 20°C for 15 min). For CYA a 
floating during centrifugation was observed and the separation was performed by filtration 
through a 450 µm disposable filter (CHROMAFIL GF/PET 45/25). The 1 ml of the clear 
solution was used to quantify the respective API content using the HPLC methods described 
in chapter 3.4.2. 
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In vitro release profiles 
Briefly, API loaded NPs or MPs were suspended in 30 ml of the release medium. The release 
experiments were performed in a stock bottle closed with Parafilm®M (BRAND GMBH + CO 
KG, Germany) to avoid evaporation. The suspension was stirred at 400 rpm. At pre-
determined time points 1.5 ml suspension was removed and centrifuged (Hettich Rotina 
420 R, Hettich Holding GmbH & Co. oHG, Germany) at 24400x g at 20°C for 15 min. 1 ml of 
the supernatant was drawn as sample and analysed by HPLC as described in chapter 3.3.6. 
1 ml fresh medium was added to the rest of the supernatant to re-disperse the pellet before 
adding to the release medium. The release was cumulatively calculated and normalized to 
the actual drug content of the particles, which can be determined from the EE. The following 
values were defined for classifying the release of the different formulations: 
• Fast release: >80% API is released t=4 h, 
• Intermediate release: 50-60% API is released t=48 h, 
• Slow release: <10% API is released t=4 h and <30% t= 48 h. 
 
3.4. Results 
3.4.1. Optimization of freeze drying process of nanoparticles 
All results of the macroscopic characterization of the freeze dried samples were summarized 
in Table 3.2. All freeze dried samples were white and fluffy in appearance. Although no 
volume contraction was visible for NPs without cryoprotectant (control) an incomplete re-
constitution with large aggregates was observed. For trehalose/PVA mixtures and mannitol 
also no contraction was determined. Mannitol, sucrose and trehalose did not enable a 
complete reconstitution as macroscopic aggregates were visible. For all these samples, as 
well as the mixtures of trehalose with 0.05% (wt/v) and 0.01% (wt/v) PVA, although no 
aggregates were visible, mean sizes >1 µm and size distributions PDI >0.48 were 
determined. The results for mixtures of trehalose/PVA turned out to be the most promising 
approach. Moreover, trehalose was described in literature as preferred cryoprotectant agent 
for DDS due to less hygroscopicity and formation of flexible formation hydrogen bonds 
between the NPs [163]–[165]. Therefore, trehalose was combined with other concentrations 
of PVA and compared to NPs before freeze drying in Figure 3.1a. 
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Table 3.2. Macroscopic characterization of freeze dried samples using mannitol, sucrose or trehalose, also in 
different combinations with PVA (0.01%, 0.05%, 0.1%, 0.3%, 0.6%, 1.0%; wt/v), as cryoprotective agent. Samples 
were compared to NPs freeze dried without cryoprotective agent (control). 
cryoprotective agent 
freeze dried cake 
re-constitution 
(a) volume 
contraction in 
diameter 
(b) volume contraction 
in height 
without (control) - - large aggregates 
mannitol - - large aggregates 
sucrose - + few small sized aggregates 
trehalose + + large aggregates 
trehalose + 1.0%  PVA - - absence of aggregates 
trehalose + 0.6% PVA - - absence of aggregates 
trehalose + 0.3% PVA - - absence of aggregates 
trehalose + 0.1% PVA - - absence of aggregates 
trehalose + 0.05% PVA - - absence of aggregates 
trehalose + 0.01% PVA - - absence of aggregates 
+ contraction visible, - no contraction visible 
Using 0.1% PVA the size increased dramatically indicating an incomplete re-constitution. For 
concentrations of 1%, 0.6% and 0.3% PVA, a perfect re-constitution was achieved as the 
measured particle sizes were slightly higher compared to the particles before freeze drying. It 
was also obvious, that higher PVA concentrations lead to slightly higher particle sizes. Based 
on these results, for further experiments trehalose at a ratio of 1/1 (trehalose/PLGA, wt/wt) 
combined with 0.3% PVA will be used for freeze drying of NPs. 
SEM images of the NPs after freeze drying in Figure 3.1b show the stability of the particles 
during freeze drying. No change of the morphology was observed and the particles were 
round and spherical as before freeze drying (Figure 3.5). “Bridges” are visible between the 
particles as well as an embedding of the particles due to the trehalose and PVA between the 
particles. The bridges consisting of the trehalose and PVA result during the drying. 
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Figure 3.1. (a) Characterization of freeze dried samples in size and size distribution by dynamic light scattering. 
Different combinations of trehalose and PVA (0.1%, 0.3%, 0.6%, 1.0%, wt/v) were used and compared to NPs 
before freeze drying. The values are presented as mean ± S.D. (n=3). (b) SEM image of freeze dried batch using 
trehalose (1/1, PLGA/trehalose) and 0.3% PVA demonstrating the stability of NPs during freeze drying. 
 
3.4.2. Determination of encapsulation efficiency and optimal loading 
Particulate DDS should be loaded with the highest possible API content as the DDS itself 
should only act as transporter or reservoir for the respective API. In general, the loading of 
APIs into DDS is a function of lipophilicity of the API and the polymer used to prepare the 
DDS [61]. Both API have different physico-chemical properties, therefore, the results have to 
be considered separately. The EEs were determined and presented in Table 3.3 for CYA and 
Table 3.4 for BU. The loading values are presented in Figure 3.2a for CYA and in Figure 3.2b 
for BU. In general, at 100% EE the actual loading would be equal to the theoretical loading 
(Figure 3.2 line of identity). The optimal theoretical loading is reached if by increasing initial 
material the actual loading is not increasing proportional.  
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Table 3.3. EE of CYA loaded NPs and MPs. The values are presented as mean ± S.D. (n≥3). 
ratio formulation  
CYA-NP CYA-MP 
0.5/10 53.3 ± 3.8 87.9 ± 3.3 
1/10 11.6 ± 3.6 92.0 ± 0.8 
2/10 11.0 ± 0.6 90.9 ± 3.2 
3/10 46.2 ± 9.2 90.1 ± 1.5 
4/10 67.2 ± 7.5 89.2 ± 3.8 
5/10 65.4 ± 8.7 89.0 ± 0.8 
 
Table 3.4. EE of BU loaded NPs and MPs. The values are presented as mean ± S.D. (n≥3). 
ratio formulation 
BU-NP BU-MP 
0.5/10 26.5 ±  2.5 91.6 ± 0.2 
1/10 36.5 ±  4.3 91.4 ± 6.3 
2/10 29.7 ±  9.9 98.3 ± 5.4 
3/10 39.1 ± 10.3 92.9 ± 6.6 
4/10 34.1 ±  7.6 94.8 ± 2.6 
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Figure 3.2. Actual and theoretical loading of (a) CYA loaded NPs ( ) and MPs ( ) and of (b) BU loaded NPs ( ) 
and MPs ( ). The values are presented as mean ± S.D. (n≥3;  line of identity). 
 
EEs between 11% and 67% were determined for encapsulating CYA in NPs (Table 3.3). A 
high EE (53%) was measured for a ratio of 0.5/10 (CYA/PLGA, wt/wt).  
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As the spray dried MPs were produced in one step, nearly 100% of the encapsulated CYA 
was detected for all ratios (Table 3.3), which was to be expected. After spray drying the MPs 
are available as dry powder, which do not require a washing step. Losses could arise due to 
adsorption of initial API on equipment surfaces such as beaker, tubes etc. Since a slight 
decrease in the actual loading and in the EE was observed at ratios >4/10 (CYA/PLGA, wt/wt) 
the optimal loading was fixed at this ratio. The optimal loading results in an actual loading of 
26.8 mg CYA/100 mg PLGA and an EE of 67.2 ± 7.5%. Keeping the same ratio of 4/10 
(CYA/PLGA, wt/wt) between NPs and MPs allows a better comparison for following 
experiments. For the CYA loaded MPs the optimal loading (4/10, CYA/PLGA, wt/wt) results in 
35.7 mg CYA/100 mg PLGA and an EE of 89.2% ± 3.8%.  
For the BU encapsulation in NPs EE values <40% (Table 3.4) were determined for all tested 
ratios. For ratios >1/10 (BU/PLGA, wt/wt) a high intra batch variation was observed in the EE 
(S.D.>9.9, n=3), which was less for the ratio of 4/10. Hence, the optimal loading was fixed at 
1/10, which was defined as standard loading, resulting in 3.7 mg BU/100 mg PLGA with an 
EE of 36.5% ± 4.3%. SEM images of the BU loaded MPs show aggregates at ratios >2/10 in 
(Figure 3.3). Aiming for a loading as high as possible the optimal loading was fixed at 2/10 
resulting in 19.3 mg BU/100 mg PLGA with an EE of 98.3% ± 5.4%. 
For the NPs the final formulation contains also trehalose (100 mg/100 mg PLGA, 
chapter 3.4.1) as cryoprotective agent and PVA (46 mg/100 mg PLGA) to allow a better re-
dispersion. Calculating the final API content based on the EE of the final formulation CYA 
loaded NPs contain ~94 µg CYA per 1 mg of final formulation and BU loaded NPs ~14 µg/mg. 
For the MPs the final formulation contains also the stabilizer Span60 (160 mg/100 mg PLGA, 
chapter 3.3.3). Therefore, the CYA loaded MPs contain ~144 µg/mg and the BU loaded MPs 
~74 µg/mg. 
 
                                                           Advanced formulations of cyclosporine A and budesonide 
 
68 
Figure 3.3. Representative SEM images of BU loaded MPs at different ratios: (a) 0.5/10, (b) 2/10, (c) 3/10 and  
(d) 4/10 (BU/PLGA, wt/wt). Aggregates (marked with an ) are significant visible for ratios >2/10. 
 
3.4.3. Size and size distribution of loaded nanoparticles and microparticles 
The size and size distribution of CYA and BU loaded NPs (CYA-NP, BU-NP) and MPs (CYA-
MP, BU-MP) with optimal loading are summarized in Figure 3.4 and compared to drug free 
NPs (blank). The size and size distribution of loaded particles after storage are, furthermore, 
presented in Figure 3.4. Batches were visualized by SEM imaging as presented in Figure 3.5. 
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Figure 3.4. (a) Size and size distribution measured by dynamic light scattering of drug free (blank) and loaded NPs 
(BU-NP, CYA-NP), and (b) characterization in size and size distribution of freeze dried samples after storage.  
(c) Size and size distribution of drug free (blank) and loaded MPs (BU-MP, CYA-MP), measured by laser light 
diffraction. The values are presented as mean ± S.D. (n=3). 
 
By encapsulation of CYA and BU in NPs no significant increase or decrease in size or size 
distribution was observed (Figure 3.4a). Only for the CYA-NPs a slight increase in the size 
distribution was determined. Nevertheless, all particles had a size of 150 ± 10 nm with a 
narrow size distribution (PDI <0.150). After freeze drying the size increased ~23 nm for the 
drug free NPs, ~13 nm for BU loaded and ~14 nm for the CYA-NPs for all batches due to the 
cryoprotective agent PVA. A negative zeta potential was determined, as expected before for 
PLGA NPs: -27.8 ± 0.61 mV for the drug free, -18.9 ± 0.51 mV for CYA-NPs and  
-25.0 ± 3.91 mV for BU-NPs. After storage of NPs in Figure 3.4 b no change in size or size 
distribution was determined for drug free NPs and BU-NPs. Only for CYA-NPs a slight 
increase in size (~10 nm) and size distribution was observed.  
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Figure 3.5. Representative SEM images of (a) blank NPs and (b) blank MPs, (c) CYA-NPs and (d) CYA-MPs, and 
(e) BU-NPs and (f) BU-MPs. 
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The size of the MPs was in the low micron size range (Figure 3.4c). In comparison to drug 
free MPs a slight increase in the mean size was determined by encapsulating BU, whereas 
no change in size was observed by loading the MPs with CYA. Furthermore, no change in 
size distribution was determined. 
The SEM images (Figure 3.5) confirm the narrow size distribution for the NPs. Furthermore, 
they show that all particles are round and spherical in shape. The surface of the MPs is rough 
possibly due to the Span60 in the composition. 
 
3.4.4. X-ray powder diffraction 
The XRD analysis was used to determine the crystalline content of BU and CYA in the 
particles. The results are presented in Figure 3.6. Initially, the XRD diffractograms for PLGA, 
Span60, trehalose and the pure APIs were recorded for identifying characteristic intensity 
peaks. The used PLGA (50/50, lactic/glycolic acids, wt/wt) is showing a typical signal for 
amorphous substances (Figure 3.6a/b). Characteristic peaks with high intensity could be 
identified for trehalose at 23.78° (Figure 3.6a) and for Span60 at 21.38° (Figure 3.6b). For 
CYA two single peaks at 6.71° and 7.69°, furthermore, a double-peak at 9.05°/9.27° could be 
used for the identification (Figure 3.6c/d). BU showed two characteristic double peaks at 
15.37°/16.00° and 22.76°/23.21° (Figure 3.6e/f). All characteristic peaks were marked with a 
coloured rectangle (blue=trehalose, yellow=Span60, green=CYA, red=BU). In Figure 3.6c a 
signal from crystalline CYA was detected at 6.71° and 7.69°. For CYA-MPs in Figure 3.6d no 
crystalline CYA was detected due to the absence of intensity of characteristic peaks. For both 
BU-NPs (Figure 3.6e) and BU-MPs (Figure 3.6f) no characteristic peak of BU was detected.  
In Figure 3.7 physical mixtures of drug free particles and API were also scanned to verify, if 
the respective API content could be qualitatively detected, and compared to the scans of pure 
material, drug free and loaded particles as presented in Figure 3.6. Figure 3.7a and 
Figure 3.7b show that crystalline CYA could be clearly detected within both NPs and MPs. 
For physical mixture of BU with drug free particles characteristic peaks of BU could be 
detected for BU-MPs, but not for BU-NPs (Figure 3.7c/d). In comparison to the BU-MPs, 
which contain ~74 µg BU/mg in the final formulation, contain the CYA-NPs and CYA-MPs 
~94 µg CYA/mg and ~144 µg CYA/mg, respectively. BU-NPs contain ~14 µg BU/mg 
indicating that the BU content in the NPs is under the lower limit of detection for the XRD 
method.  
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Figure 3.6. XRD scans of (a) pure PLGA, trehalose and drug free NPs (blank NP) and (b) pure PLGA, Span60 and 
drug free MPs (blank MP), (c) CYA-NPs and (d) CYA-MPs, (e) BU-NPs and (f) BU-MPs. All scans are shown in 
combination with API and respective drug free particles. Results are presented in 5000 intensity step-size. The 
coloured rectangles mark the characteristic peaks (blue=trehalose, yellow=Span60, green=CYA, red=BU). 
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Figure 3.7. XRD scans of physical mixtures (“spiking”) of drug free particles with API. CYA, drug free (blank) 
particles and CYA loaded particles are presented in comparison with spiked (a) NPs and (b) MPs. BU, drug free 
(blank) particles and BU loaded particles are presented in comparison with spiked (c) NPs and (d) MPs. Results 
are presented in 5000 intensity step-size. The coloured rectangles mark the characteristic peaks (green=CYA, 
red=BU). 
 
3.4.5. In vitro drug release studies 
The results of the release profile in PBS pH 6.8 are summarized in Figure 3.8. Interestingly, 
the NPs and MPs show for both API different release behaviours. The CYA-NPs show a low 
release with a slow burst release with 14.03 ± 2.4% after 1 h, followed by a very slow 
sustained release (32.7%, t=48 h). The CYA-MP show fast to intermediate release with a high 
release within 24 h (91.3%; 15.9% after 1 h), that is faster but continuous for the first 6 h and 
then the release is slowing down and heading to a plateau of approx. 91% (t=48 h). In 
general, a burst release followed by a sustained release is typical for PLGA particles [61].  
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Figure 3.8. In vitro release profile of (a) CYA-NPs ( ) and CYA-MPs ( ) in comparison to (b) BU-NPs ( ) and  
BU-MPs ( ).The values are presented as mean ± S.D. (n=3).  
 
The BU-NPs show a fast, but uncontrolled, strong burst release within 30 min (80.6%; 89.6%, 
t=48 h). This could indicate that, although the particles were washed, BU is attached to the 
surface of the particles or located at the outer edge of the polymeric particles. In contrast, the 
BU-MPs show an intermediate release with a slow and sustained release reaching a plateau 
of after 8-10 h (63.7%, t=48 h). 48% of the encapsulated BU is released in 1 h. 
 
3.5. Discussion 
Particulate DDS can improve the therapy options in IBD as they can passively accumulate in 
inflamed intestinal areas of the intestine [75]. Thus, they can form a depot and reduce 
systemic adverse effects by reduced systemic bioavailability of the encapsulated API. So far 
NPs seem to be favorable in rodent colitis models [75], [78], whereas MPs show in a recent 
study a better deposition efficacy in human patients [76]. An enhanced accumulation of MPs 
in the ulcerated lesions was demonstrated. In contrast NPs were only found in traces of the 
mucosa in patients with CD and UC [76]. Hence, both NPs prepared by NPR and MPs 
prepared by NSD were selected to encapsulate the two model drugs CYA and BU. These 
lipophilic drugs are ideal candidates for the encapsulation in PLGA and both drugs showed 
efficacy in the treatment of IBD [17], [29], [37], [39], [40], [160]. 
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The NPs are in suspension after the preparation and must be transferred in a storable form. 
Thus, the freeze drying technique was selected.  
For this process the suitable cryoprotectant to prevent particles aggregation and to ensure a 
maximum stabilization of NPs during freeze drying must be evaluated and its concentration 
optimized. Sugars are used due to their ability to isolate individual particles (isolation 
hypothesis) in suspension preventing aggregation during freezing [164]. It has to be taken 
into account that also the NP concentration influences the freeze drying process. Due to 
stabilization of the cryoprotectant a complete re-dispersion without change in particle size 
should be achieved.  
In recent publications PLGA based NPs were successfully freeze dried with sucrose and 
glucose at a concentration of 20% (wt/v) [166]. A complete re-dispersion of poly(lactide acid-
co-ethylene oxide) NPs after freeze drying could be obtained when trehalose was added to 
the NP suspension at a ratio of 1/1 (trehalose/PLGA, wt/wt) [163]. In the present study 
trehalose was revealed to be the optimal cryoprotectant reaching a complete re-dispersion 
only in a mixture with PVA. This can be explained by the ability of the PVA to attach on the 
NPs polymer surface by hydrophobic bonding [167]. This effect can be seen by the slightly 
increased size after freeze drying (Figure 3.1). Furthermore, it can be proposed that free 
PVA, which is not attached to the surface of the NPs, can act as stabilizer. The PVA avoids 
aggregation during freeze drying as it forms a glassy state at low temperatures [167]. 
Moreover, PVA forms hydrogen bonds from between the polymer and water molecules 
contributing a better re-dispersion [168].  
In this thesis in a first step the DDS were developed (chapter 2) with regard to reproducibility 
and controllability of the fabrication processes and, therefore, quality of the DDS. Only the 
polymer was pre-selected due to its biodegradability and biocompatibility and with regard to 
the used drugs, CYA and BU, which is important for the encapsulation ability apart from the 
preparation method [90]. In contrast, studies often follow the approach to develop a DDS for a 
special API. Therefore, it was possible that the encapsulation in NPs or MPs failed for one or 
both APIs.  
After encapsulation of the selected APIs, in our hands for CYA optimized loadings with high 
EEs could be determined for both carrier NPs (>67%) and MPs (>89%). In general, high EEs 
for CYA were also reported before, EE>96% for MPs [63] and EE>72% for NPs [64] for 
particles prepared by emulsion-diffusion-evaporation method.  
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The emulsion-diffusion-evaporation method contains a meta stable system - the emulsion 
itself - and was therefore not selected as preparation method.  
In this work PLGA based CYA-NPs prepared by NPR for oral delivery by Chacón et al. 
showed EEs of 47.9% to 84.7% depending on the size (46 nm to 146 nm, respectively) and, 
hence, on the surface area of particles [162]. Interestingly, in the present study the EE could 
be increased without changing the size of the particles (Figure 3.2).  
Barichello et al. determined with a loading of 0.33/10 an 87.3% EE of for CYA loaded NPs 
prepared by NPR [169], which was also determined for our lowest loading. This can be 
explained by the low solubility of CYA in aqueous media (~ 4µg/ml [162]) and distribution in 
the hydrophobic PLGA matrix due to the lipophilicity of CYA (Table 1.1). Therefore, a smaller 
amount of CYA could be more easily distributed in the carrier matrix. BU was successfully 
encapsulated into MPs (EE>91%), but for BU-NPs EE values <40% (Table 3.4) were 
determined for all tested ratios with a high intra batch variation. 
The value of in vitro release tests is still under discussion due to limited power to predict the 
in vivo situation. Nevertheless, in vitro release tests demonstrate a useful research tool to 
estimate release kinetics and to compare between various samples and batches. The in vitro 
test might help to unravel the release mechanism, although the test conditions may not reflect 
the in vivo conditions and, thus, the release kinetics cannot directly transferred. In general, 
the release of APIs from DDS is driven by three main mechanisms: (a) swelling/ erosion, (b) 
diffusion, and (c) degradation [170]. PLGA based DDS show a biphasic release profile 
including a burst release followed by a sustained release [61]. Furthermore, the API is 
released as a function of solubility/lipophilicity and penetration of water into the polymer 
matrix [61]. In the present study, the release profiles from both carriers for each drug are 
different. In particular, the diffusion will be influenced by the lipophilicity of the BU and CYA 
(chapter 1, Table 1.1; BU: log Poctanol/water 3.2, CYA: log Poctanol/water 2.92) in the present work. 
For CYA-NPs and CYA-MPs an improvement in the release compared to the recent studies 
in the context of the passive targeting approach was achieved [63], [64]. In addition, the CYA 
loaded MPs demonstrated the best controlled release profile (91.3 ± 4.4% after 24 h), which 
could be classified as fast to intermediate release. Recently published studies demonstrated 
that the encapsulation of CYA in PLGA MPs leads to a release of weeks ending in 60% after 
50 days [63]. Also for CYA loaded NPs a release over three weeks and more was reported 
[63].  
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In the present study the release from the MPs might be supported by the stabilizer and, 
furthermore, by the crystallization processes during MPs formation by spray drying, which 
may produce micro voids in the MPs and support water penetration [171]. This would also 
explain the faster release of CYA from the MPs in comparison to the release from CYA-NPs. 
Additionally, the results of the XRD studies (Figure 3.6) revealed that the CYA is in an 
amorphous state in the MPs and, therefore, molecularly dispersed [100], [172].  
In contrast, the CYA-NPs (loading 4/10, CYA/PLGA, wt/wt) show a weak crystalline signal 
indicating that partially crystalline structures of CYA are located in the NPs. At higher drug 
loading (30%, wt/wt) a crystallization of APIs was reported explaining the crystalline content 
in the CYA-NPs [173]. Therefore, a reduced burst behaviour and a slow sustained release 
(Figure 3.8) occur as the release rate is controlled by the solubilisation of crystals.  
The in vitro release profile of BU-NPs revealed a dramatic burst with 80% in 30 min for NPs in 
comparison to 40% for MPs, which indicates that the BU is more adsorbed at the surface or 
encapsulated at the outer edge of the NPs [61]. In previous studies BU loaded PLGA NPs so 
far showed a strong burst behaviour [67], which can be reduced depending on the method 
and used stabilizer [174]. A pH-dependent coating or blending of PLGA particles with 
methacrylate copolymers (Eudragit®S) can trigger the release depending on the pH [67], [83]. 
Nevertheless, also a relatively fast release (60% in 6 h [67] and 40% in 6 h [83]) was 
observed after reaching the pH to solubilize the methacrylate copolymer. In the present study 
~40% of BU remains in the MPs after 48 h (Figure 3.8). For the BU-MPs it seems that some 
BU is encapsulated in the inner core of the particle. The rest is released by swelling of the 
particles and diffusion processes and, furthermore, degradation of the stabilizer, as the 
Span60 is dispersable in aqueous media [175]. Also the BU encapsulated in MPs was 
investigated to be in the amorphous state, which was also reported before for spray drying of 
BU [110], [176].  
As the accumulation of particles is size-dependent and NPs are supposed to accumulate at a 
higher content, building a depot in the inflamed regions [75], a faster release of the 
encapsulated API in the MPs in comparison to NPs could be a benefit for the application as 
the MPs could be cleared faster from the lumen by the main symptom of IBD: diarrhea. 
Moreover, the DDS will stay in the inflamed areas only for a certain time-period due to e.g. 
the regeneration of epithelium. Alf Lamprecht et al. determined an accumulation of 
14.5 ± 6.3% for 100 nm polystyrene NPs, which decreased after four, six and eight days to 
9.1 ± 2.8%, 3.4 ± 2.2% and 1.9 ± 1.1%, respectively [75].  
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Therefore, the NPs should ideally have an intermediate to slow release, as presented by the 
CYA-NPs, to avoid high systemic concentrations and to release the drug in the inflamed 
areas. A too fast release would results in high systemic concentrations and, thus, side effects 
of the applied drug. 
 
3.6. Conclusion 
CYA had been successfully encapsulated into NPs and MPs leading to different release 
profiles, both promising for the passive targeting approach. Therefore, both CYA loaded DDS 
are most promising carrier with regard to the investigated physico-chemical and 
biopharmaceutical properties in this chapter, in detail higher encapsulation efficiencies and 
more controlled release. 
BU was successfully encapsulated into MPs although ~40% of the BU remains in the DDS 
after 48 h. BU encapsulated in NPs leads to a high burst release as the BU supposed to be 
adsorbed at the particle surface. The high burst release could lead to high systemic 
concentrations when applied in vivo. 
The difference in release can be explained by the amorphous or crystalline status of the API 
in the respective particles and the lipophilicity of the drugs. 
In a next step the ability of the particles to accumulate size-dependently and their anti-
inflammatory efficacy had been tested on a three-dimensional cell culture model in chapter 5.  
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4. Structural analysis and modification of spray dried microparticles  
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4.1. Introduction 
As reported in chapter 2 and chapter 3 a ratio of 1.1/1.6 (PLGA/Span60, wt/wt) is needed for 
a well dispersable spray dried formulation in the target size range. Thus, Span60 is a 
quantitative and qualitative significant part of the matrix system and this leads to the question 
of the location or spatial distribution of the Span60 in the DDS. Therefore, a small angle x-ray 
scattering (SAXS) study was performed to determine if the Span60 is homogeneously 
distributed throughout the particles, organized in cluster or only located at the surface of the 
MPs. In general, SAXS can be used to investigate the morphology, size and internal structure 
of particulate samples using a suitable set-up and with a limit of particle sizes <100 nm for 
screening the whole particle [177], [178]. The beam, which can go through the material, 
interacts with the electrons of the sample and is scattered. The detected scattering pattern is 
characteristic of the investigated structures. The intensity of the scattered radiation is 
measured in dependence of the scattering angle [93], [179].  
In chapter 2 and chapter 3 the optimization of MPs with regard to size, size distribution and 
yield, and loading was discussed, respectively. In this part of the work one further attempt 
was to modulate the release from MPs, in particular for BU, with regard to a depot effect with 
controlled release (matrix controlled diffusion) over relevant time-period, when particles 
accumulate at the place of inflammation. According to the structure, the use of 
polyethylene glycol (PEG) should enable a more controlled and complete release of the 
encapsulated drug. The proposed mechanism is the swelling of PEG components in aqueous 
solutions, which create pores [61], [180], [181]. This effect was demonstrated for PEG-PLGA-
block co-polymers and, moreover, for PEG blend PLGA particles (PEG-PLGA particles) [180], 
[181]. Furthermore, PEG can increase the hydrophilicity of DDS improving the swelling 
properties in aqueous media and supporting, therefore, the release [182]. 
Additionally, a lower molecular weight PLGA polymer was used to assess the effect of 
polymer length on the particle size. The aim was to further decrease the size of spray dried 
particles. 
 
4.2. Materials 
Excipients for NP and MP preparation and active ingredients were used as described in 
chapter 2.2 and chapter 3.2.  
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Resomer® Condensate RG, (lactic/glycolic (50/50, wt/wt); MW 2149 Da) was bought from 
Evonik (Darmstadt, Germany). Polyethylene glycol 1000 (PEG-1000, MW 1000 Da) was 
purchased from Sigma Aldrich (Schnelldorf, Germany). Purified water was of Milli-Q quality 
and prepared by a Millipore Milli-Q Synthesis system (Merck KGaA, Darmstadt, Germany).  
All solvents were high-performance liquid chromatography grade and all chemicals met the 
quality requirements of the European Pharmacopoeia 6.0–7.3. 
 
4.3. Methods 
4.3.1. SAXS analysis 
SAXS measurements were performed with a Kratky-type instrument (SAXSess from Anton 
Paar, Austria). The scattered intensities were recorded with a cooled (-40°C) CCD camera 
(PI-SCX, Princeton Instruments, USA) in the line collimation geometry and integrated into the 
one-dimensional scattering function I (q) using SAXSQuant 1D software (Anton-Paar, 
Austria). Drug free MPs, as solid powder and in dispersion, pure PLGA and Span60 were 
measured to verify the signals. Aqueous solution (purified water) of the drug free MPs (blank 
MPs) with concentrations in the range of 1.0 to 2.0 g/l were poured into vacuum-tight thin 
quartz capillaries at room temperature and placed in a TCS 120 temperature-controlled 
sample holder. The temperature was held constant at 20°C. Background contributions from 
capillary and solvent scattering were subtracted from the sample scattering. The scattering 
vector q, defined as q = 4π/λ sin θ where θ is the scattering angle and λ the wavelength of 
the radiation, varied in the 0.1 to 6.0 nm-1 range. A 100 nm window was, therefore, 
investigated. 
 
4.3.2. Modification of spray dried microparticles 
4.3.2.1. Modification of in vitro release  
For the modification of spray dried MPs PEG blend PLGA particles [181] were prepared. For 
this purpose PEG-1000 (MW 1000 Da, Sigma Aldrich, Germany) at a concentration of 5%, 
10% and 20% (wt/wt) referring to the used amount of PLGA was used. To prepare the 
feeding solution 1.1% PLGA (wt/v) and 1.6% Span60 (wt/v) together with BU (loading 1/10, 
BU/PLGA, wt/wt; standard loading) were dissolved in acetone and stirred at least for 1 h. 
Afterwards PEG-1000 was added and the solution was stirred until everything was dissolved.  
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The feeding solution was sprayed as described in chapter 3.3.3. The experiment was 
performed at least in triplicate. The particles were compared to particles without PEG using 
the standard loading (1/10, BU/PLGA, wt/wt; standard loading). The morphology was 
investigated before and after incubation for 24 h in purified water at room temperature as 
described before by Cleek et al. by SEM imaging as described in chapter 2.3.7 [181]. 
All spray dried MPs, non-modified and modified, were characterized as described in 
chapter 3. All release studies were performed as described in chapter 3.3.8. The release was 
performed at least in triplicate and stopped after 24 h due to the resulting profile (Figure 4.2). 
The size and size distribution was measured by laser light diffraction as described in 
chapter 3.3.4. The EE of loaded MPs was determined as described in chapter 3.3.6.  
 
4.3.2.2. Modification of size by spraying of low molecular weight PLGA 
Particles were prepared with low molecular weight PLGA (Resomer® Condensate RG, 
MW 2149 Da) as described before in chapter 3.3.3 and compared to MPs produced with 
PLGA with a MW of 40,300 Da.  
The size and size distribution were measured by laser light diffraction as described in 
chapter 3.3.4. The morphology was investigated by SEM imaging as described in 
chapter 2.3.7. 
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4.4. Results 
4.4.1. SAXS analysis 
 
 
Figure 4.1. SAXS analysis of PLGA (blue line), Span60 (sorbitan monostearate, black line), drug free (blank) MPs 
as powder (red line) and blank MPs in dispersion (green line). The graph shows the scattered intensities referring 
to scattering vector q in nm-1. 
The SAXS intensities of sorbitan monostearate (Span60), PLGA and drug free MPs (size: 
2.58 ± 0.13 µm, width: 0.92 ± 0.06), in dispersion and as powder are presented in Figure 4.1 
as a function of the scattering vector. Both ingredients of the MPs give a representative 
signal. The signal of PLGA (blue line) shows a pattern which is typical for an amorphous 
substance [183]. That is the expected result for a spray dried polymer, as no crystalline signal 
was detected, and is in agreement with the XRD studies (chapter 3, Figure 3.6). The Span60 
(black line) shows a typical peak at 1 q (nm-1) [183]. The MPs measured in solid state (red 
line) show a shift of the Span60 signal towards higher q (nm-1) values. No shift could be 
detected when particles were measured in dispersion (green line). The shift of the signal 
indicates that the Span60 is under tensions in the particles. The contact with the aqueous 
solution leads to a relaxation and, therefore, the peak of Span60 (green line) shows the same 
scattering vector as the pure Span60. 
 
4.4.2. Modification of spray dried microparticles 
Spray drying of PLGA particles with 5-20 % (w/w) of PEG-1000 for blending leads to PEG-
PLGA particles with a size 3.1-3.5 µm for 5% and 10% of PEG, which is increased to 6.4 µm 
for 20% PEG. The spray dried MPs form a white, free flowing powder. 
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All results for size, size distribution, EE and yield were summarized in Table 4.1. High yields 
ranging between 72.1% and 78.5%, and also an expected high EE >95% could be achieved 
for a loading of 1/10 (BU/PLGA, wt/wt). The in vitro release profile of modified MPs is 
presented in Figure 4.2 and leads for all concentrations of PEG to a strong burst effect 
ranging from 67.9% (20% PEG) to 74.8% (5% PEG) released BU after 1 h. Overall, the 
cumulative amount of released BU within 24 h remains in the same range than for PLGA MPs 
without PEG modification at the loading of BU (1/10, BU/PLGA, wt/wt). Furthermore, ~25-
32% remain in the PEG-PLGA MPs after 24 h, which is the same amount as for MPs without 
PEG. No improvement could be achieved with the modification. 
Table 4.1. Size, size distribution, EE and yield of PEG-PLGA particles (n=4). Different PEG concentrations were 
used in the particles ranging from 5-20% referring to the used amount of PLGA. Data are presented as 
mean ± S.D. (n=3). 
formulation PEG content size [µm] 
size 
distribution 
[width] 
EE [%] yield [%] 
I 5% 3.1 ± 0.15 3.6 ± 0.80 96.84 ± 0.10 75.6 ± 4.5 
II 10% 3.5 ± 0.59 5.3 ± 6.05 97.24 ± 0.16 72.1 ± 8.4 
III 20% 6.4 ± 5.33 3.6 ± 2.21 95.57 ± 0.54 78.5 ± 6.7 
 
PEG-PLGA particles were incubated 24 h in purified water to investigate a swelling behaviour 
according to Cleek et al. and visualized by SEM imaging [181]. SEM images of PEG-PLGA 
particles before incubation (Figure 4.3a) are spherical in shape, and have an uneven and 
rough surface. All other PEG concentrations show equal morphology in the SEM images. The 
surface seems to be wax like due to the PEG and Span60 (chapter 3, Figure 3.5). SEM 
images of PEG-PLGA particles incubated 24 h with purified water (Figure 4.3b) show no pore 
development. This might be due to the size of the particles with ~3-6 µm compared to the 
particles produced by Cleek et al. with ~64-92 µm. Due to the dispersibility of Span60 in water 
and the solubility of PEG punctual erosions (Figure 4.3b, marked with an ) on the surface 
could be assumed. These erosions were only visible after incubation.  
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Figure 4.2. In vitro release profile of BU-MPs containing PEG at different concentrations (n=4) in comparison to 
BU-MPs without PEG (n=3). The loading was for all formulations 1/10 (BU/PLGA, wt/wt, standard loading). The 
values are presented as mean ± S.D.  
 
a 
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Figure 4.3. Representative SEM images of PEG-PLGA particles (containing 10% PEG). (a) PEG-PLGA MPs 
before incubation in purified water and (b) after incubation over 24 h in purified water according to Cleek et al. 
[181]. In (b) punctual erosions are visible and marked with a white arrow (). 
 
To modify the size of the MPs with the aim to reach a reduction in size, the used PLGA 
(MW 40,300 Da) was exchanged to low molecular weight PLGA (MW 2149 Da). The spray 
drying process was successful and a white and free flowable powder could be collected. The 
results of size and size distribution as well as a visualization of particles are presented in 
Figure 4.4. No change in size was determined compared to the in chapter 2 optimized 
particles (Figure 4.4a). The particles are smooth and spherical in shape (Figure 4.4b). 
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Figure 4.4. (a) Size ( ) and size distribution (●) of MPs produced with low molecular weight (n=2, mean ± range) 
and optimized MPs (n=3, mean ± S.D.). (b) Representative SEM image of MPs prepared with low molecular 
weight PLGA. 
 
4.5. Discussion 
The results from the SAXS measurement revealed a peak shift for the Span60 and, therefore, 
a tension in the particles could be concluded (Figure 4.1). With used SAXS method only a 
100 nm window could be screened. To screen the complete particle a particle accelerator 
would be necessary, which makes the analysis of the whole particles very costly. However, 
the measurement supports the structural analysis. In a aqueous dispersion the MPs swell, 
due to the PLGA matrix (chapter 3.5) [170] or/and Span60 disperses [175] leading to a 
relaxation of the particles. From the results of the SAXS analysis it could be proposed that the 
Span60 is organized in clusters and not homogeneously distributed all over the particle due 
to the investigated tension and, therefore, peak shift. A homogeneous distribution would not 
lead to tensions in the MPs.  
Spraying PLGA in combination with PEG and Span60 leads to no improvement of the total 
released amount of BU within 24 h as the profiles are comparable to the profile from MPs 
prepared without PEG. Furthermore, a strong burst release could be determined and ~25-
32% remained in the particles after 24 h. A strong burst release was observed before for PEG 
blended PLGA MPs [181]. In general, the three basic mechanisms (a) swelling/ erosion, (b) 
diffusion, and (c) degradation are responsible for releasing the encapsulated API in polymeric 
DDS (chapter 3) [170]. PLGA based DDS show in general a biphasic release profile including 
a burst release followed by a sustained release [61].  
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The burst release is driven by API which is attached on the surface and, therefore, relatively 
fast in contact with the medium. Moreover, DDS prepared by spray drying have a more 
porous quality, compared to DDS prepared by classical physico-chemical methods 
(e.g. NPR) [182]. By modifying the MPs with PEG a matrix system based on PLGA, Span60 
and PEG was fabricated. Due to the hydrophilicity of the PEG it can be suggested that in the 
fabricated MPs the PEG is not homogenously distributed, but more clustered in the PEG-
PLGA particles as also reported by Mu et al. [182]. This would also explain the punctual 
erosions in Figure 4.3. Furthermore, Cleek et al. explained that in a blending the release 
might be influenced by polymer chain entanglements between PLGA and PEG [181]. In the 
present study it can be assumed that the strong burst release of the encapsulated BU is also 
supported by the PEG. PEG is water soluble and will be re-dispersed in the release medium, 
forcing surface and bulk erosion/swelling. The supposed porous structure promote the 
release due to enhanced water penetration [181]. As the degradation of the used PLGA takes 
two to three month, the release of BU from the particles is due to drug diffusion and 
solubility/dispersibility of PEG and, furthermore, Span60 as discussed in chapter 3 [175]. 
Cleek et al. demonstrated that the initial burst effect could dependent on the PLGA/PEG 
blend ratio, which was not observed in the present study [181].  
Additionally, the interaction between API and DDS, and the loading could influence the 
release [184]. Polakovic et al. demonstrated by mathematically modelled release profiles, that 
a slower release from high loaded PLGA particles (30%, wt/wt) is supported by API crystals 
[173]. At low loading the release rate is diffusion controlled [173]. The XRD studies 
(chapter 3, Figure 3.6) revealed that the BU in the MPs is in an amorphous state and, 
therefore, the release rate diffusion controlled.  
The distribution of PEG in a block-co-polymer is more homogenously compared to a 
blending. In a recent study a successful modification in release was demonstrated compared 
to particles produced only by PLGA, although the release was faster using the block-co-
polymer [180].  
MPs prepared with PLGA with a molecular weight of 2149 Da show no reduction in mean size 
(mean size ~ 4 µm) compared to MPs sprayed with PLGA of 40,300 Da. Reported before by 
Schafroth et al. a slight size reduction could be detected from 2.23 µm to 0.95 µm for spray 
dried CYA loaded PLGA MPs by using PLGA with 15,000 Da instead of 40,000 Da [100]. 
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In chapter 2 the DOE revealed that the size is mostly affected by the stabilizer (for nature of 
stabilizer 38.91% of total variance, for concentration 6.74%) and depending on the interaction 
between polymer concentration/stabilizer (21.08%) shown in Table 2.10 in the present work. 
In the present experiments the polymer concentration was not changed. Therefore, it could 
be assumed that spraying low molecular weight PLGA will not influence the particle size, but 
may change the particle matrix. Hence, the influence of the Span60 (stabilizer) as component 
of the particles was also visible in these experiments.  
 
4.6. Conclusion 
SAXS analysis underlined the hypothesis that the stabilizer Span60 is organized not only at 
the particle surface but also in clusters in the MPs. 
By blending the PLGA MPs with PEG no improvement in the release could be achieved for 
the present application approach. The use of PEG did not help to reduce the burst effect or to 
achieve a higher percentage in release of the encapsulated BU. 25-32% of the encapsulated 
BU remained in the particles. 
No change in size was determined by spraying PLGA with lower molecular weight due to the 
strong influence of the used stabilizer on size in this study. 
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5. In vitro efficacy testing of PLGA particles on cell culture model of the 
inflamed intestinal mucosa  
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5.1. Introduction 
Enteric cell lines, e.g. Caco-2, HT29 or T84, are accepted models of the normal, healthy 
intestinal mucosa [113], but cannot mimic the complex interactions with immune cells in the 
diseased intestine of IBD patients [114]. To test the anti-inflammatory efficacy and size-
dependent accumulation of the nano- and microparticulate DDS, which development was 
reported in chapter 2 and optimization in loading in chapter 3, a three-dimensional cell culture 
model (triple culture model) of the inflamed intestinal mucosa was used. The triple culture 
model consists of three cell lines: Caco-2, THP-1, which can be stimulated via phorbol 
myristate acetate to macrophages, and MUTZ-3 a dendritic-like cells [118]. The usage of 
macrophages and dendritic cells as key players in inflammatory reactions is crucial for the 
inflammation stimulation and address the complexity of the pathogenesis in IBD.  
The inflammation of the model is induced by addition of the pro-inflammatory cytokine IL-1ß. 
This cytokine was shown to lead to pathophysiological changes, which are in accordance with 
observed inflammation in the intestinal barrier in IBD patients e.g. IL-8 release, reorganization 
of tight junctions, and reduced epithelial barrier integrity [88]. These changes were also 
observed in the triple culture model using cell lines [118]. Therefore, the model can be used 
to evaluate effects of particulate DDS by monitoring decreasing TEER values, indicating 
reduced epithelial barrier integrity, and increased IL-8 release. 
In this chapter CYA-NPs and CYA-MPs and, furthermore, BU-NPs and BU-MPs, all optimal 
loaded (chapter 3), were applied in the apical compartment of the triple culture model to 
simulate the application from the luminal side (oral/rectal administration). By loading the NPs 
and MPs with the far-red fluorescent dye DID, the size-dependent accumulation at the site of 
inflammation was investigated by confocal laser scanning microscopy (CLSM).  
 
5.2. Materials  
Excipients for NP and MP preparation and active ingredients were used as described in 
chapter 2.2 and chapter 3.2. 
DMEM, RPMI1640 and αMEM cell culture medium were purchased from Gibco (Carlsbad, 
CA, USA). Fetal bovine serum (FBS), phosphate buffered saline (PBS), 
Penicillin/Streptomycin (Pen/Strep), non-essential amino acids (NEAA) and sodium pyruvate 
were obtained from PAA (Pasching, Austria).  
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Trypsin, ethylenediaminetetraacetic acid (EDTA) and phorbol myristate acetate (PMA) were 
purchased by Sigma (Steinheim, Germany). T75 flasks and 6 well cell culture plates were 
obtained from Corning Incorporated (Acton, MA, USA). IL-1ß was obtained from Promokine 
(Heidelberg, Germany). Purified water was of Milli-Q quality and prepared by a Millipore Milli-
Q Synthesis system (Merck KGaA, Darmstadt, Germany). 
All solvents were high-performance liquid chromatography grade and all chemicals met the 
quality requirements of the European Pharmacopoeia 6.0–7.3. 
 
5.3. Methods  
5.3.1. Preparation and characterization of API loaded nanoparticles and microparticles 
The BU and CYA loaded NPs and MPs were prepared with an optimal loading as described 
in chapter 3.3.2 and chapter 3.3.3, respectively. Hence, for CYA a loading of 4/10 
(CYA/PLGA, wt/wt) for both NPs (CYA-NP) and MPs (CYA-MP) was used. For BU a loading 
of 1/10 (BU/PLGA, wt/wt) was used for the NPs (BU-NP) and of 2/10 for the MPs (BU-MP). 
Hydrodynamic diameter, polydispersity index (PDI) and zeta potential (ZP) of NPs were 
measured by laser light scattering as described in chapter 2.3.6 and chapter 3.3.4. The size 
and size distribution (width) of MPs were measured by laser light diffraction as described in 
chapter 3.3.4. The encapsulation efficiency (EE) was determined as described in 
chapter 3.3.6.  
 
5.3.2. Preparation of DID loaded particles 
The DID (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate, Invitrogen, Life 
Technologies GmbH, Darmstadt, Germany; excitation maximum: 644 nm, emission 
maximum: 665 nm) loaded NPs (DID-NPs) and MPs (DID-MPs) were prepared as described 
in chapter 3.3.2 and chapter 3.3.3, respectively, for imaging the particles on the triple culture.  
Nanoparticles 
Briefly, for the DID-NPs the lipophilic DID was encapsulated following the described protocol 
in chapter 3.3.2. A DID stock solution (25 mg/ml, in ethanol) was directly added (10 µl stock 
solution per 10 mg of PLGA) in the mixture of acetone/ethanol (16/3, v/v). 
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The DID-NPs could be separated from the stabilizer poloxamer 407 by a fast dialysis over-
night (Spectra/Por® dialysis membrane, MWCO 300 kDa, Carl Roth GmbH & Co. KG, 
Germany) against purified water.  
Microparticles 
For imaging the particles on the triple culture model the lipophilic DID was encapsulated in 
the MPs following the described protocol in chapter 3.3.3. A DID stock solution (25 mg/ml, in 
ethanol) was directly added (10 µl stock solution per 10 mg of PLGA) to the feeding solution.  
 
5.3.3. Characterization of DID loaded particles 
5.3.3.1. Determination of size, size distribution and zeta potential 
The DID-NPs were characterized in size and size distribution re-dispersed in purified water by 
NP tracking analysis using a NanoSight® LM10 HS system (NTA, NanoSight Limited, UK). 
The measurements were carried out for each batch in triplicate. The mean diameter (d 0.5) 
as well as the percentile values d 0.1 and d 0.9 were further calculated by the NanoSight® 
software. The size distribution (width) is defined in eq. 8. A narrow size distribution is 
indicated by a small width. A different system had to be used for the DID loaded particles as 
the 633 nm laser in the Zetasizer® could excite the DID. The emission would interfere with the 
laser light scattering measurement and falsify the measurement. The used NTA system was 
equipped with a 532 nm laser allowing the measurement without interference. 
The ZP was measured in purified water using a Zetasizer® Nano ZS (Malvern Instruments, 
UK). 
 
5.3.3.2. Determination of encapsulation efficiency  
For determining the EE, the DID-NPs (~2-3 mg) were accurately weight and disintegrated in 
5 ml acetonitrile for 1 h at 400 rpm. Afterwards, 5 ml of purified water was added and the 
solution stirred for 10 min to get a clear solution. The solution was placed for 15 min in an 
ultrasonic bath and then cool down to room temperature.  
The spray dried DID-MPs (~3-5 mg) were disintegrated in 200 µl acetone. Afterwards, first 
5 ml of acetonitrile were added dropwise followed by 5 ml purified water.  
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The fluorescence intensity of 100 µl of each solution was measured by plate reader (Tecan 
Infinite M 200, Tecan Deutschland GmbH, Crailsheim, Germany; excitation: 630 nm, 
emission: 674 nm) in triplicate. For the standards a stock solution (25 mg DID in 2.4 ml 
ethanol) was diluted with a mixture of acetonitrile/purified water (1/1, v/v) to standards with a 
concentration between 0.16 µg/ml - 5.2 µg/ml. The method was linear (r2 >0.99) between 
0.16 µg/ml - 5.2 µg/ml with a calculated lower limit of detection (LOD) of 0.090 µg/ml and a 
LOQ of 0.091 µg/ml. All experiments were performed in triplicate.  
 
5.3.4. Cell culture 
For the set-up of the triple culture Caco-2 (a human adenocarcinoma cell line), THP-1 (a 
human monocytic cell line) and MUTZ-3 (a human monocytic cell line) cells were used.  
Caco-2 clone HTB37, passage 30-50, was obtained from ATCC (American Type Culture 
Collection, Rockville, MD). Cells were cultured in DMEM supplemented with 20% FBS, 1% 
NEAA and 1% sodium pyruvate in a T75 flask and maintained at 37°C and 5% CO2. This cell 
culture medium will be designed as Caco-2 medium. Medium was changed every second day 
and cells were sub-cultured once a week with 0.1% trypsin and 0.02% EDTA and 0.5x106 
cells were seeded in a new T75 flask.  
THP-1 cells were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen, Braunschweig, Germany) and cultured in RPMI1640 supplemented with 10% 
FBS under similar conditions as Caco-2 cells. The cell culture medium will be designed as 
THP-1 medium. To differentiate THP-1 to macrophage-like cells, THP-1 cells are incubated 
with cell culture medium that contains 5 ng/ml PMA. After 48 h cells are attached at the 
bottom of the T75 flask and can be harvested. 
MUTZ-3 cells were purchased from DSMZ. Cells were cultured in a 6-well plate with αMEM 
supplemented with 20% FBS and 20% conditioned medium from 5637 cells. The cultivation 
of MUTZ-3 cells in conditioned medium differentiates them to dendritic-like cells. 5637 cells 
are human blastoma carcinoma cells, obtained from DSMZ. 5637 cells were cultured in 
RPMI1640 supplemented with 10% FBS in a T75 flask. Medium was collected every second 
day, filtrated and used as supplement for MUTZ-3 medium.  
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5.3.5. Set-up of triple culture and experimental design of efficacy studies 
Caco-2, THP-1 and MUTZ-3 cells were used to set up a triple culture of the inflamed 
intestinal mucosa as previously developed [118], [119]. MUTZ-3 cells and differentiated THP-
1 cells were collected and embedded in a bovine collagen type I (Advanced Biomatrix, 
Tucson, Arizona, USA) layer with human AB serum (Invitrogen, Wisconsin, USA). 150 µl 
were pipetted in transwell filter inserts (Corning Incorporated, Acton, MA, USA, 0.4 µm pore 
size, 1.12 cm2 area). 104 cells were seeded per cell type per well. The cells were incubated 
for 1 h at 37°C and 5% CO2 until the collagen was solid. The Caco-2 cells were trypsinated, 
collected and 6x104 cells were seeded on top of the collagen layer.  
The experimental set-up is depicted in Figure 5.1. Triple culture was grown for 11 days with 
500 µl Caco-2 medium containing 1% Pen/Strep in the apical and THP-1 medium containing 
1% Pen/Strep in the basolateral compartment. Medium was changed every second day. On 
day 11 cells were inflamed by adding 10 ng/ml of IL-1ß into the apical compartment for 48 h. 
After two days (day 13) IL-1ß was removed and cells were treated with CYA loaded DDS for 
8 h at a concentration of 1.2 µg CYA/ml, and with BU loaded DDS for 4 h at a concentration 
of 0.4 µg BU/ml [119]. Therefore, the particles were re-suspended and diluted to the 
respective concentrations in Caco-2 medium.  
 
Figure 5.1. Experimental set-up of efficacy studies on triple culture model. 
 
The concentrations were evaluated in tolerability and effectiveness before. Due to the 
different pharmacological mechanism of CYA, CYA was expected to act slower anti-
inflammatory as BU. For that reason a longer time-period was chosen which was still 
physiologically relevant [23]. Both incubation times refer to transition times of oral 
formulations through the human intestine [23]. 
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Based on the loading, DDS were applied on the following concentrations: CYA-NPs at 
~13.5 µg/ml, CYA-MPs at ~7.6 µg/ml, BU-NPs at ~24.0 µg/ml and BU-MPs at ~5.2 µg/ml. All 
formulations were compared to a drug solution (stock solution: 1.2 µg CYA/ml, 0.4 µg BU/ml) 
and to drug free NPs or MPs at a concentration referring to the loaded particles. The drug 
solutions were prepared by dilution with Caco-2 medium from a stock solution in ethanol 
(CYA: 12 mg/ml, BU: 100 mg/ml). Afterwards, the formulations were removed, cells were 
washed with PBS and fresh cell culture medium was added. TEER values and IL-8 release 
were measured before, and 24 h, 48 h and 72 h after treatment with the drug loaded particles 
as can be seen in Figure 5.1. Each test group was performed with n=6. 
 
5.3.6. Monitoring of triple culture during efficacy studies 
To control the confluence of epithelial monolayer the TEER was measured with an electric 
voltohmmeter (EVOM, World Precision Instruments, Sarasota, USA) and chop stick 
electrodes. After inflammation TEER values decrease [185]. Recovery is indicated by an 
increase in TEER. For the experiments only triple cultures with TEER values >400 Ω*cm2 at 
day 11 were used in order to show high enough barriers properties before the inflammation. 
For the measurement of IL-8 level to determine the efficacy of the anti-inflammatory API [88], 
50 µl supernatant from apical compartment were collected before applying the particles, and 
24 h, 48 h and 72 h after application. The IL-8 amount was measured in the supernatant by 
CBA Flex set for IL-8 (BD Biosciences, Heidelberg, Germany) following protocol provided by 
the manufacturer. Measurement was performed via bead array analysis using a flow 
cytometer (FACS Calibur, BD Biosciences, Heidelberg, Germany) and the data were 
analysed by FCAP array v3.0.1 cytometric bead array analysis software.  
 
5.3.7. Stability of nanoparticles and microparticles in triple culture media 
Approximately 2 mg of drug free, CYA and BU loaded particles, NPs and MPs, were 
accurately weight and re-dispersed in 2.0 ml of Caco-2 or THP-1 medium. The particles were 
incubated for 24 h at 37°C shaking at 100 rpm in an incubator (GLF 3031, Germany). At pre-
defined time points (0, 4, 8 and 24 h) 100 µl of the Caco-2 or THP-1 medium-particle 
suspension were diluted with purified water to 2 ml. The experiments were performed in 
triplicate. Hydrodynamic diameter and polydispersity index (PDI) of NPs were measured by 
laser light scattering as described in chapter 2.3.6.  
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The size and size distribution (width) of MPs were measured by laser light diffraction as 
described in chapter 3.3.4. An increase in size and size distribution would indicate the 
formation of aggregates and, therefore, instability. 
The dilution in purified water is necessary to avoid light scattering of medium components 
e.g. proteins. The amount of particles was chosen according to the respective size 
characterization technique. 
 
5.3.8. Investigation of cytotoxicity of nano- and microparticles on cells used for the
 triple culture 
NPs and MPs should not show any toxic effects on the triple culture, hence, a cytotoxicity 
assay (LDH assay) was performed with the three different cell types (Caco-2, THP-1, Mutz-3), 
which were used in the triple culture model. The cells were seeded separately and incubated 
with different concentrations of NPs and MPs without any API for 24 h. For NPs 
concentrations between 6 mg/ml and 0.006 mg/ml were used and for MPs concentrations 
between 1.43 mg/ml and 0.00143 mg/ml. Different concentrations were due to the different 
loading of NPs and MPs. The highest concentration is e.g. equal to a concentration of 
100 µg BU/ml applying loaded particles. 
Different cell types were seeded separately in 96 well plates and grown for seven days. For 
Caco-2 cells 6x104 cells were seeded per well, for THP-1 and MUTZ-3 1x104 cells per well 
according to the triple culture set-up. Cells were incubated with different concentrations of 
NPs and MPs at 37°C and 5% CO2. After 24 h 100 µl of the supernatants were collected and 
LDH reagents were prepared after manufacturer protocol (Roche, Mannheim, Germany). 
Cells were incubated with the reagent for 3 min at room temperature and the excitation was 
measured at 492 nm. Cell culture medium and 1% Triton X (v/v) were used as negative and 
positive control, respectively. 
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5.3.9. Deposition of nano- and microparticles on the triple cell culture model 
To investigate the deposition of NPs and MPs on the inflamed triple culture model DID loaded 
particles were applied at the following concentrations referring to the concentrations of the 
loaded particles: NPs at ~13.5 µg/ml and MPs at ~7.6 µg/ml incubated for 8 h (CYA), and 
NPs at ~24.0 µg/ml and MPs at ~5.2 µg/ml incubated for 4 h (BU). The set-up of triple culture 
model and incubation of particles on the triple culture model were performed as described in 
chapter 5.3.5. The experiment was performed in triplicate 
For the investigation of particle deposition the triple cultures were stained using anti-occludin 
antibody for the tight junctions and DAPI for the nucleus. Cells were fixed with 3% 
paraformaldehyde for 30 min at room temperature and incubated with 50 mM NH4Cl for 
10 min. After removal of NH4Cl, cells were incubated at room temperature for 30 min with 1% 
BSA and 0.05% Saponin in PBS. The primary antibody (monoclonal mouse anti-occludin, 
Zymed, San Francisco, CA, USA) was diluted 1:200 in PBS and incubated with the cells at 
4°C overnight. The cells were washed with PBS and incubated with the secondary antibody 
(Alexa488 anti-mouse, LifeTechnologies, Darmstadt, Germany) for 1 h at room temperature. 
After washing with PBS, cells were incubated with DAPI (100 ng/ml) for 15 min and mounted 
with fluorescence mounting medium (DAKO Glostrup, Denmark) on object slides.  
Images were taken with a confocal laser scanning microscope (CLSM, LSM 150, Zeiss, 
Göttingen, Germany) and processed with Zen 2012 software (Zeiss, Göttingen, Germany). 
DID was detected in the red spectral region (laser excitation: 633 nm, emission: 647-695 nm), 
Alexa488 was detected in the green spectral region (laser excitation: 488 nm, emission: 506-
544 nm) and DAPI was detected in the blue spectral region (laser excitation: 405 nm, 
emission: 434-487 nm). 
 
5.3.10. Statistical analysis 
The statistical analysis was performed by one way ANOVA followed by Holm-Sidak multiple 
comparison using Sigma Plot 12.5 software (Systat Software GmbH, Erkrath, Germany). 
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5.4. Results 
5.4.1. Characterization of nano- and microparticles  
The physico-chemical characterization of NPs and MPs used for studies on the triple culture 
model were summarized in Table 5.1 for NPs and in for MPs Table 5.2, and confirmed the 
characterization in chapter 3. 
Table 5.1. Physico-chemical characterization (size, size distribution, zeta potential, EE and API content in final 
formulation) of NPs used for studies on triple culture model. The values are presented as mean ± S.D. (n=3). 
formulation size [nm] PDI 
zeta 
potential 
[mV] 
EE [%] API in final formulation [µg/mg] 
drug free NP 149.8 ± 2.2 0.020 ± 0.010 -29.2 ± 1.3 - - 
CYA-NP 142.1 ± 0.7 0.050 ± 0.037 -20.1 ± 0.7 62.4 ± 4.3 96.36 
BU-NP 137.3 ± 0.4 0.009 ± 0.010 -26.7 ± 1.5 36.0 ± 2.1 16.67 
 
size [nm] width 
zeta 
potential 
[mV] 
EE [%] API in final formulation [µg/mg] 
DID-NP 144.7 ± 7.8 0.81 ± 0.14 -21.8 ± 1.1 68.3 ± 11.9  2.57 
 
Table 5.2. Physico-chemical characterization (size, size distribution, EE and API content in final formulation) of 
MPs used for studies on triple culture model. The values are presented as mean ± S.D. (n=3). 
formulation size [µm] width EE 
API in final 
formulation 
[µg/mg] 
drug free MP 3.45 ± 0.03 1.45 ± 0.06 - - 
CYA-MP 4.14 ± 0.63 2.35 ± 0.86  96.2 ± 4.6 132.90 
BU-MP 6.45 ± 0.26 1.71 ± 0.03 101.5 ± 1.2  76.34 
DID-MP 3.95 ± 0.13 2.78 ± 0.10 103.3 ± 0.6   3.00 
  
5.4.2. Stability of nanoparticles and microparticles in triple culture media 
The anti-inflammatory efficacy of the drug free (blank) and API loaded NPs and MPs with 
optimal loading were tested in a triple culture model of the inflamed intestine. Therefore, the 
stability according to size and size distribution was tested by incubating the particles in the 
two culture media (Caco-2- and THP-1-medium), which were previously defined (chapter 
5.3.4 and 5.3.5) and are used in the triple culture model. The results for size and size 
distribution were summarized in Figure 5.2 for NPs and in Figure 5.3 for MPs.  
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Figure 5.2. Stability (according to size and size distribution) of drug free (blank) NPs, CYA-NPs and BU-NPs in 
triple culture media at different time points: (a) size and (b) size distribution of NPs incubated in Caco-2 medium 
and (c) size and (d) size distribution of NPs incubated in THP-1 medium. The size and size distribution were 
measured by dynamic light scattering. The results were presented as mean ± S.D. (n=3). 
 
All NPs were stable over 24 h. No significant changes in size or size distribution were 
determined in both cell culture media. In Caco-2 medium also no aggregation of the MPs was 
determined by increasing size or size distribution. In the THP-1 medium the size and size 
distribution increased for all MPs, drug free and loaded after 24 h. From t0h to t4h the size of 
the MPs decreased in different values, in particular in the Caco-2 medium, possibly due to the 
Span60 in the composition, which may disperses [175]. 
All formulations are stable enough for evaluation in the triple culture model as the incubation 
times are set to 4 h for BU loaded and 8 h for CYA loaded particles (chapter 5.3.5). 
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microparticles incubated in Caco-2 medium 
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microparticles incubated in THP-1 medium 
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Figure 5.3. Stability (size, size distribution, zeta potential, EE and API content in final formulation) of drug free 
(blank) MPs, CYA-MPs and BU-MPs in triple culture media at different time points: (a) size and (b) size distribution 
of MPs incubated in Caco-2 medium and (c) size and (d) size distribution of MPs incubated in THP-1 medium. The 
size and size distribution were measured by laser light diffraction. The results were presented as mean ± S.D. 
(n=3). 
 
5.4.3. Investigation of cytotoxicity of nano- and microparticles on cells used for the
 triple culture 
The results of the cytotoxicity assay on Caco-2, THP-1 and MUTZ-3 cells are summarized in 
Figure 5.4. For further experiments it was important that the tested concentrations of the DDS 
were in a non-toxic range. NPs show 40% toxicity at the highest tested concentration 
(~6 mg/ml) for THP-1 and MUTZ-3 cells (Figure 5.4a). MPs do not show any toxic effect on 
the three cell types in the tested concentrations (Figure 5.4b). In general, Caco-2 cells are 
more robust than the monocytic cell lines.  
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For both NPs and MPs no toxicity in the used concentrations for the triple culture experiments 
was determined. On the triple culture model, depending on the loading, CYA-MPs were 
applied at concentrations of ~7.6 µg/ml, CYA-NPs at ~13.5 µg/ml, BU-NPs at ~24.0 µg/ml 
and BU-MPs at ~5.2 µg/ml.  
a 
 
b 
 
Figure 5.4. Results of cytotoxicity assay (LDH assay) for (a) NPs and (b) MPs incubated with  
Caco-2 ( ), THP-1 ( ) and MUTZ-3 ( ) cells at different concentrations. The results were presented as 
mean ± S.D. (n=3). 
 
5.4.4. Efficacy studies of budesonide loaded nano- and microparticles on triple
 culture 
The results of the TEER measurement following BU-NPs and BU-MPs incubation were 
summarized in Figure 5.5 and results for determined IL-8 values in Figure 5.6. The results 
were compared to an uninflamed and an inflamed triple culture as controls, furthermore, to 
free BU solution and drug free (blank) NPs and MPs.  
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Figure 5.5. TEER measurement during triple culture experiments: (a) inflamed control ( ), uninflamed control ( ) 
and free BU solution ( ); (b) blank NP ( ), BU-NP ( ) and free BU solution ( ); (c) blank MP ( ), BU-MP ( ) and 
free BU solution ( ). Treatment according to Figure 5.1: Inflammation started at day 11 by addition of IL-1ß, which 
was removed at day 13. Treatment was started on day 13. The results were presented as mean ± S.D. (n=6).  
 
The treatment with BU solution and BU loaded DDS leads to an increase in TEER values 
back to the level before the inflammation (Figure 5.5b and Figure 5.5c). That indicates a 
closing of the tight junctions between the Caco-2 cells, which were opened through 
inflammation. In comparison to Figure 5.5a, the uninflamed control show also an increase in 
TEER, which is more slowly than the treated samples and need more than three days to fully 
recovered. Surprisingly, drug free NPs and MPs show also increasing TEER values (Figure 
5.5b and Figure 5.5c).  
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Figure 5.6. IL-8 release after treatment of the triple culture model with drug free (blank) NPs and MPs and BU-NPs 
and BU-MPs in comparison to BU solution in the apical compartment at different time points. 
(  0 h,  24 h,  48 h,  72 h after treatment). The results were presented as mean ± S.D. (n=6; 
** = p<0.001, * = p<0.05 are considered to be significant). 
 
The IL-8 levels decreased after treatment with BU-NPs and BU-MPs (Figure 5.6) in 
comparison to inflamed control. The level of uninflamed control is reached after 24 h. Also the 
application of the drug free particles decreased the IL-8 levels. A significant difference in the 
IL-8 release was determined for the BU-NPs (p<0.001) and BU-MPs (p<0.05) compared to 
drug free NPs and MPs, respectively, at 24 h after treatment. In comparison, the inflamed 
control shows that IL-8 is decreasing more slowly when cells remain untreated (Figure 5.6). 
For all treated groups IL-8 levels increasing slowly at 48 h and 72 h after treatment. 
 
5.4.5. Efficacy studies of cyclosporine A loaded nano- and microparticles on triple
 culture 
The results of efficacy experiments with the CYA-NPs and CYA-MPs were summarized in 
Figure 5.7 for TEER values and in Figure 5.8 for determined IL-8 level. The results were 
compared to an uninflamed and an inflamed triple culture as controls, furthermore, to free 
CYA solution and drug free (blank) NPs and MPs.  
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The TEER values determined for the CYA loaded particles are in accordance with the results 
revealed for the BU loaded particles. CYA solution as well as CYA-NPs and CYA-MPs lead to 
a recovery of the TEER values (Figure 5.7b and Figure 5.7c). Drug free (blank) NPs and MPs 
show also increasing TEER values (Figure 5.7b and Figure 5.7 c). 
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Figure 5.7. TEER measurement during experiments: (a) inflamed control ( ), uninflamed control ( ) and free CYA 
solution ( ); (b) blank NPs ( ), CYA-NPs ( ) and free CYA solution ( );  
(c) blank MPs ( ), CYA-MPs ( ) and free CYA solution ( ). Treatment according to Figure 5.1: Inflammation 
started at day 11 by addition of IL-1ß, which was removed at day 13. Treatment was started on day 13.The results 
were presented as mean ± S.D. (n=6).  
 
The results of IL-8 measurement (Figure 5.8) reveal an anti-inflammatory effect with CYA-
NPs and CYA-MPs. The IL-8 release decreased after treatment with the different 
formulations. A significant difference in the IL-8 release was determined for the CYA-NPs 
(p<0.001) and CYA-MPs (p<0.05) compared to drug free NPs and MPs at 24 h after 
treatment. Furthermore, a significant difference between pure CYA solution and CYA-NPs 
was determined. The increase of IL-8 after 48 h and 72 h was equal to the uninflamed 
control.
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Figure 5.8. IL-8 release after treatment of the triple culture model with drug free (blank) NPs and MPs and CYA-
NPs and CYA-MPs in comparison to CYA solution in the apical compartment at different time points (  0 h, 
 24 h,  48 h,  72 h after treatment). The results were presented as mean ± S.D. (n=6; ** = 
p<0.001, * = p<0.05 are considered to be significant). 
 
5.4.6. Deposition of nano- and microparticles on the triple cell culture model 
The inflamed triple culture model was treated with DID-NPs and DID-MPs to investigate the 
accumulation of particles. Confocal images in Figure 5.9 showed that NPs as well as MPs 
were located and stick on top of the triple culture on the Caco-2 cells, although the cells were 
washed several times after incubation with the particles. In Figure 5.9a and Figure 5.9c the z-
stack demonstrated that the signal from the NPs is located in the Caco-2 monolayer. 
Therefore, it could be assumed NPs were up-taken by Caco-2 cells. Examples were marked 
with an arrow (). Moreover, NPs were detected at the intercellular space.  
The MPs in Figure 5.9b and Figure 5.9 d were distributed over the cell borders (tight junctions 
staining in green) and stick on top of the Caco-2 cells, which was expected due to their bigger 
size. 
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Figure 5.9. Deposition of particles on triple culture model: Representative CLSM images of the inflamed triple 
culture model incubated with DID-NPs and DID-MPs in the apical compartment. On top and at the right side z-
stacks are shown (position marked by red and green line). (a) Shows DID-NPs and (b) DID-MPs referring to the 
used CYA concentration, (c) DID-NPs and (d) DID-MPs a referring to the used BU concentration. Images were 
randomly selected. (scale bar=50 µm;  NPs assumed to be up-taken in Caco-2 cells; blue: DAPI stained nuclei, 
green: tight junctions stained with anti-occludin antibody, red: DID loaded particles). 
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5.5. Discussion 
A triple culture model consisting of intestinal epithelial cells and immune competent cells was 
used to evaluate the anti-inflammatory effect as well as the size-dependent accumulation of 
the developed DDS. Two independent read outs, the TEER values and the IL-8 level, allowed 
to determine the anti-inflammatory efficacy of the particulate DDS. Nevertheless, the TEER 
measurement showed fluctuations and was demonstrated to be a less robust parameter of 
the used model. The triple culture model shows a self-healing process after removal of IL-1ß, 
which can be monitored by a recovery of the TEER in the inflamed control compared to the 
uninflamed control (Figure 5.5 and Figure 5.7) [119]. Therefore, the self-healing process limits 
the timeframe for testing the particles on the triple culture model. 
All loaded DDS showed anti-inflammatory effects, detectable via both markers, with a faster 
recovery of the TEER values compared to the uninflamed control. Interestingly, also for the 
drug free DDS an anti-inflammatory effect measured by TEER values and IL-8 level was 
determined, which was already observed in earlier studies with the triple culture model [119]. 
Additionally, Beloqui et al. determined an anti-inflammatory effect of drug free pH-sensitive 
PLGA/Eudragit®S 100 NPs in a murine DSS-induced colitis model [77]. It can be assumed, 
according to Leonhard et al., that soluble signaling parameters in the inflammatory cascade 
of IL-8 could be adsorbed on the particle surface [119]. Furthermore, it was hypothesized that 
drug free particles could interact with immune cells and lead to a pre-occupation of the 
immune system [119]. A theory which has yet to be confirmed [119]. In addition, a recent 
study could demonstrate that lactate released from PLGA accelerates wound healing, 
including an anti-inflammatory effect, applied as subcutaneous implant or as NPs in different 
mice wound models [186], [187].  
BU-NPs and BU-MPs both showed similar effects in comparison to BU solution on the IL-8 
level. The BU-NPs release nearly 100% of the encapsulated BU in 4 h of incubation time and, 
hence, a similar effect could be expected. In contrast, the BU-MPs release 58% in 4 h in PBS 
(chapter 3, Figure 3.8).  
The CYA loaded NPs and MPs reduce the IL-8 level slightly more after 24 h in comparison to 
the BU loaded DDS with less increased values after 72 h. For the CYA-NPs a significant 
effect, in comparison to CYA solution, could be determined. The release from the CYA-NPs is 
characterized by a low burst release with ~14.0% after 1 h, followed by a very slow sustained 
release with ~28% after 8 h (chapter 3, Figure 3.8). The CYA-MPs, which release 86% in 8 h, 
also showed a reduced IL-8 level, which was not significant compared to drug solution. 
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Therefore, in particular for the BU-MPs, CYA-NPs and CYA-MPs, an additive effect of API 
and carrier can be assumed for improving the anti-inflammatory efficacy. Additive effects 
were reported before and can be material dependent [187] or due to the accumulation on the 
triple culture model in combination with a controlled sustained release [119].  
After the incubation of the different formulations the medium was changed and, hence, free 
drug also released from the DDS was removed.  
The main advantage of the particulate formulations in comparison to the drug solution is that 
they remain on the triple culture as revealed by the CLSM images (Figure 5.9). According to 
the loading the triple culture model was incubated with different concentrations of NPs and 
MPs. Unfortunately, a quantitative analysis of the amount of remaining particles was not 
possible within the used technique, but could be interesting for further investigations. 
Nevertheless, it can be proposed that the remaining particles release the residual 
encapsulated drug leading to the prolonged anti-inflammatory effect. Additionally, from the 
CLSM images an up-take of the NPs in Caco-2 cells could be noted. Recent studies confirm 
this effect demonstrated with 15 nm gold NPs [118] and 183 nm PLGA NPs [71]. 
Furthermore, MPs were detected at the cell walls and NPs, independently of the loading, at 
the intercellular space indicating a size-dependent accumulation/deposition. Trough 
inflammation with IL-1ß the tight junctions between the Caco-2 cells open due to lower 
expression of tight junction proteins ZO-1 and occluding [188]. The pores of the open tight 
junctions, which are between 58-104 nm, are too small to be passed by the used DDS [189]. 
However, the inflammation leads to intercellular spaces in which particles can accumulate 
[119].  
 
5.6. Conclusion 
The anti-inflammatory effect and, furthermore, the deposition of the optimized NPs and MPs 
could be successfully tested on the triple culture model consisting of three cell lines 
(enterocytes, macrophages and dendritic-like cells) using TEER and IL-8 measurement as 
meaningful markers for inflammation. Therefore, the method offers an easier selection of the 
most suitable formulations for progression to in vivo efficacy studies (chapter 7). 
All carrier, interestingly also the drug free DDS, lead to an anti-inflammatory effect with regard 
to investigated parameters, which were improved compared to the inflamed control. 
Furthermore, an improvement in the parameters was determined for the loaded DDS 
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compared to drug free DDS, and to the free drug solution. In particular, for the CYA-NPs 
significantly reduced IL-8 level could be determined in comparison to CYA solution.  
NPs were deposited at the intercellular space and up-taken in Caco-2, whereas MPs were 
detected at the cell walls indicating a size-dependent accumulation/deposition. It can be 
concluded that the deposited particles release the residual encapsulated drug leading to the 
prolonged anti-inflammatory effect. 
Based on tested parameters, CYA-NPs seem to be the most effective formulation on the 
triple culture. The model revealed the effects less time-consuming and less expensively 
compared to in vivo studies in rodent models and, especially without using animals.  
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6.1. Introduction 
The developed DDS should offer a new therapeutical opportunity for IBD and were fabricated 
as carrier to transport the encapsulated API to the inflamed areas of the intestine via the oral 
or the rectal route. As a new therapy opportunity the developed carriers have to be non-
cytotoxic at relevant concentrations e.g. for testing on the triple culture model (chapter 5). 
Although PLGA is a well investigated and established excipient in biomedical applications, 
particles with a size <1000 nm have different physico-chemical properties compared to the 
bulk material [190]. The combination with further excipients and the fabrication process can 
be also of impact for the biocompatibility. Moreover, NPs and MPs can be up-taken by cells 
and facilitate intracellular effects. Of further importance, the particles should not be 
recognized as exogenous material by the innate immune system and antigen presenting 
cells, since an activation of the immune system can decrease the drug effect and lead long-
term medication.  
The WST-1 assay was performed to assess the cytotoxicity of drug free NPs and MPs on 3T3 
mouse fibroblasts and on J774A.1 murine macrophages [23]. The WST-1 assay uses the 
mitochondrial succinate tetrazolium reductase system in metabolic active cells to cleave a 
carbon to carbon bond in the slightly red tetrazolium salt WST-1 and turn it to the dark red 
formazan. The assay was also performed with a macrophage cell line due to their phagocytic 
activity, therefore, their ability to take up and accumulate particles [43], [191]. Additionally, 
macrophages are also involved in the pathogenesis of IBD [69], [117]. 
Furthermore, the potential of NPs and MPs to interfere with reactions of the innate immune 
system were assessed. As crucial parts of the innate immunity, the complement system 
activation and the alteration, activation and suppression, of cytokine secretion of dendritic 
cells were investigated in appropriate in vitro assays. The complement system consists of a 
group of liver synthesized plasma proteins and cell membrane receptors expressed by 
several types of immune cells including macrophages and dendritic cells [191]. Some 
components of the complement system can bind to foreign molecules or particles leading to 
their opsonisation. Such complexes are better phagocyted by macrophages and dendritic 
cells after interaction with their complement receptors. The complement system is also 
involved in chemotaxis, cell lysis of foreign cells or microorganisms, and agglutination of 
pathogens [23]. The complement system can be activated on three pathways, classical, 
alternative and lectin initiating a cascade.  
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The cascade results in massive amplification of response and the formation of the membrane 
attack complex, which causes terminally cell lysis [23]. CH50 (classical pathway) and APH50 
assays (alternative pathway) are diagnostic tests to determine the ability of serum for 
complement activation by measurement of the haemolytic activity. The results of both assays 
(CH50 and APH50) refer to the reciprocal dilution of a serum required to produce 50% 
haemolysis of a standard preparation of erythrocytes. For the classical pathway sheep 
erythrocytes are used, which were sensitized by anti-(red cell) IgG. The classical pathway, 
which requires calcium and magnesium ions, is then initiated by IgM on the surface of the 
antibody sensitized sheep erythrocytes. For the alternative pathway rabbit erythrocytes are 
used as sheep erythrocytes are inefficient at activating this pathway [192]. 
The complement system and dendritic cells in tissues are the first line of defense of the 
innate immune system [191]. Dendritic cells activate cells of the innate immune response, 
e.g. natural killer cells, via secretion of cytokines. Furthermore, dendritic cells are antigen 
presenting cells to T-lymphocytes, thus, allowing the initiation of the specific immune 
response [193]. Therefore, dendritic cells were revealed to be an optimal tool to study the 
impact of DDS on the immune system as demonstrated by Villiers et al. [193]. Drug free NPs 
and MPs were hence incubated with lipopolysaccharides (LPS) activated dendritic and non-
activated dendritic cells to measure the modulation of the cytokine release to test the 
interference with the development of an immune response. 
 
6.2. Methods and Materials 
6.2.1. Particle preparation and characterization 
In the following studies of this chapter drug free NPs and MPs were investigated. Excipients 
for NP and MP preparation and active ingredients were used as described in chapter 2.2 and 
chapter 3.2. The particles were fabricated as described in chapter 3.3.2 for NPs and in 
chapter 3.3.3 for MPs. The size and size distribution of both NPs and MPs were measured as 
described in chapter 3.3.4. 
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6.2.2. In vitro cytotoxicity assay 
In accordance to the International Organization for Standardization recommendation 
n_10993, NIH-3T3 murine fibroblast cells (H-3T3 cell line, adherent cells, American Type 
Culture Collection (ATCC) N°CRL-1658™) and additionally J774A.1 murine macrophages 
were chosen according to the application to perform classical WST-1 cytotoxic assay. The 
cell lines were purchased from the ATCC. The cell viability was determined using a WST-1 
assay (Roche Diagnostics, Germany). The cells were maintained according to routine cell 
culture procedures and seeded at a density of (~5.104/cm²) in 96 well plates (Nunc, Sigma 
Aldrich, Schnelldorf, Germany). After 24 h incubation at 37°C, different concentrations of NPs 
and MPs, ranging from 100 to 1500 µg/ml, were added for 24 h to the culture medium. Each 
test group was performed with n=6. 
Cytotoxicity was assessed for 24 h following the particle removal using the WST-1 assay and 
expressed as cell viability. WST-1 reagent (soluble formazan derivative reagent) was added 
(10%, v/v) to the culture medium and kept in the incubator for 3 h. Cells without particles and 
cells incubated with a solution of H2O2 (10 mM) were used as negative and positive controls, 
respectively. Absorbance was afterwards recorded at 450 nm (soluble formazan titration) and 
690 nm (background subtraction) using a microplate reader (Tecan Infinite M 1000, Tecan 
Deutschland GmbH, Crailsheim, Germany). The absorbance difference (450 nm–690 nm) is 
directly proportional to the number of viable cells. The percentage cell viability is determined 
using the following equation 12 (eq. 12). In this equation AS, APC and ANC represent the 
absorbance of the sample, the positive control (cells treated with H2O2 10 mM) and the 
negative control (only cells), respectively. Furthermore, concentrations of particles showing 
50% reduction in cell viability (IC50 value) were calculated by Sigma Plot 12.5 software (Systat 
Software GmbH, Erkrath, Germany). 
																c ^K ) " =
(Bd − B[G)
(BeG − B[G)
∗ 100 
 
eq. 12 
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6.2.3. Immunotoxicity studies 
6.2.3.1. Activation of complement system by nano- and microparticles  
In order to determine the effect of drug free NPs and MPs on complement system, human 
serum was incubated at 37°C for a maximum of 24 h in the presence of NPs and MPs at 
250 µg/ml, then serum samples were keep frozen before complement pathways activity 
measurement. The human serum contains all components of the complement system. 
The activity was measured using sheep erythrocytes in a medium containing 2.5% glucose, 
5 mM diethylmalonylurea, 142 mM NaCl, 0.05% gelatine, 0.5 mM MgCI2 and 0.15 mM CaCl2 
(pH 7.5). Sheep erythrocytes were previously sensitized with rabbit antiserum to sheep red 
cells, cell suspension was adjusted to 3.7×106 cells/ml (absorbance (A) recorded at 660 nm, 
A660=0.3). Complement alternative pathway was measured in the same medium using rabbit 
erythrocyte at the concentration of 6x106 cells/ml (A660=0.48). Sheep red cells are inefficient 
at activating the alternative pathway, so rabbit erythrocytes are used. In both cases, 1 ml of 
erythrocytes was pre-incubated at 37°C for 5 min before addition of 50 µl of the human serum 
previously incubated in the presence of NPs. After a rapid mixing, the absorbance was 
monitored at 660 nm for classical and alternative pathways, respectively. All the experiments 
were performed at 37°C. Through mixing of the red blood cells an activation of the 
complement system takes place ending in the leakage of haemoglobin. The leakage is 
measured by the absorbance of the haemoglobin in the cell supernatant. Subsequently, the 
modification of the complement activation in the presence of particles is determined. 
Haemolytic activity, CH50 and APH50 for classical and alternative pathway, respectively, was 
determined by measuring the time required for the reduction of absorbance to 50% of its 
initial value (50% lysis). The determination of percentage of complement activity was 
obtained by comparison of the result with those obtained with serum composed of a mixture 
of fully active (positive control) and of fully inactive serum (negative control) to assure the 
functionality of the assay (incubated 30 min at 56°C) mixed with various ratios. An activation 
of the complement system by particles would lead to modification of reduction of absorbance. 
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6.2.3.2. Alteration of cytokine secretions of dendritic cells by nano- and 
  microparticles 
Dendritic cells were generated from bone marrow extracted cells from C57BL/6 mice (Charles 
River, l’Arbresle, France) as previously described by Faure et al. [194]. The bone marrow 
cells were isolated by flushing from the femurs. Erythrocytes and GR1 positives cells were 
removed by magnetic cell sorting, and the remaining negatively sorted cells were re-
suspended at 5x105 cells/ml in complete Iscove’s modified Dubelcco’s medium (IMDM, 
Gibco, Invitrogen, Grand Island, NY, USA) supplemented with factors GM-CSF, FLT-3L and 
IL-6 (Peprotech, Rocky Hill, NJ, USA) and cultured at 37°C in the presence of 5% CO2. GM-
CSF is produced by the GM-CSF-transfected J558 cell line (provided by D. Gray, University 
of Edinburg, UK) and FLT-3 ligand (FLT-3L) is produced by the FLT-3 L-transfected BL16-
F10 cell line (provided by G. DranoV, Boston, USA). The transformation of the progenitors 
into fully active dendritic cells occurs during a 10 days culture. 
Determination of activation of cytokine secretion by particle treatment with unstimulated 
dendritic cells 
After washing, dendritic cells (106 cells/ml) were seeded in 24 well plates. After 24 h drug free 
NPs and MPs were added at concentrations of 0.01-0.5 mg/ml, and the cells were further 
incubated at 37°C for 24 h or 48 h. 
Determination of interference of particles with cytokine secretions of pre-stimulated 
dendritic cells 
After washing, dendritic cells (106 cells/ml) were seeded in 24 well plates and incubated in 
culture medium containing LPS (LPS 2 µg/ml, from Escherichia coli 026:B6, Sigma, St. Louis, 
MI, USA) for 24 h. LPS is a ligand for toll like receptor 4 (TLR 4) expressed by dendritic cells, 
thus, inducing their activation. Afterwards, drug free NPs and MPs were added at 
concentrations of 0.01-0.5 mg/ml, and the cells were further incubated at 37°C for 24 h and 
48 h. 
Cytokines, IL-6 and IL-12, were measured in the supernatant of cell cultures by 
immunoassays using BD OptEIA™ for murine cytokines (BD Bioscience Pharmingen, 
France) according to the procedures recommended by the manufacturer. Each experiment 
was performed at least three times with cells issued from different cultures and each 
measurement is performed in duplicate. The supernatants are harvested after 24 h incubation 
at 37°C. 
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6.3. Results  
6.3.1. In vitro cytotoxicity assay 
The WST-1 assay was performed to assess the cytotoxicity, expressed in Figure 6.1 as cell 
viability, of drug free NPs and MPs on 3T3 mouse fibroblasts and on J774A.1 murine 
macrophages. The NPs in this experiment had a size of 149.8 ± 2.2 nm (PDI: 0.02 ± 0.01, 
ZP:-21.3 ± 1.37 mV) and the MPs a size of 8.4 ± 0.95 µm (width: 4.4 ± 0.17). The results for 
the NPs in Figure 6.1a exhibit at least 80% of cell viability after 24 h incubation, even for 
relatively high concentrations (1500 µg/ml). For both cell lines 3T3 and J774A.1 the IC50 
values are >1500 µg/ml. For MPs in Figure 6.1b a strong decrease in the cell viability was 
observed for concentration >250 µg/ml for the 3T3 (IC50 ~250 µg/ml) and >100 µg/ml for the 
J774A.1 cells (IC50 <100µg/ml).  
Figure 6.1. Cell viability (WST-1 assay) after 24 h incubation of drug free NPs ( ) and MPs ( ) for  
(a) 3T3 cells and (b) J774A.1 cells. Results were presented as mean ± S.D. (n=6). 
 
6.3.2. Immunotoxicity studies 
6.3.2.1. Activation of complement system by nano- and microparticles  
Complement activation via classical or alternative pathway was measured by erythrocyte 
cells lysis. The NPs in this experiment had a size of 141.2 ± 1.6 nm (PDI: 0.05 ± 0.02,  
ZP: -34.6 ± 1.15 mV) and the MPs a size of 7.2 ± 0.35 µm (width: 5.0 ± 0.17). In Figure 6.2a 
as example the absorbance measurement is demonstrated for the classical pathway. The 
negative control shows no change in the absorbance as the components in the human serum 
were inactivated for this control.  
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The positive control demonstrates the activation of the complement system with reduced 
absorption based on the cell lysis. In addition to Figure 6.2a, in Figure 6.2b no modification of 
the CH50 could be determined for NPs and MPs in comparison to positive control. The same 
result was obtained for the alternative pathway demonstrated in Figure 6.2c. Therefore, no 
activation by drug free NPs and MPs was observed, on both pathways, indicating that the 
formulations were not recognized as exogenous material based on this assay.  
Figure 6.2. Determination of activation of complement system. (a) Measurement of the time required for the 
reduction of absorbance to 50% of its initial value, which is equal to 50% lysis, for classical pathway. (b) CH50 and 
(c) APH50 for drug free NPs and MPs in comparison to positive control. Results were presented as mean ± S.D. 
(n=6).  
 
a 
    
 
 
b 
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6.3.3. Alteration of cytokine secretions of dendritic cells by PLGA particles 
The incubation of NPs and MPs with dendritic cells, investigating the activation of immune 
system by these DDS, did not induce secretion of IL-6 or of IL-12, therefore, no graph could 
be shown. Hence, the dendritic cells were not activated by drug free NPs or MPs at the 
different concentrations demonstrating that these DDS do not display pro-inflammatory 
activity themselves.  
Investigating the suppression of immune system (Figure 6.3) by incubating the particles with 
LPS pre-activated dendritic cells, a slight and concentration dependent effect was determined 
on IL-6 secretion in presence of NPs (Figure 6.3a). Therefore, a slight effect can be 
investigated in relevant concentrations e.g. for in vitro efficacy studies on triple culture model 
(chapter 5) as NPs were applied at ~0.0135 mg/ml and ~0.024 mg/ml.  
 
nanoparticles 
 
nanoparticles 
a 
 
b 
 
 
microparticles 
 
microparticles 
c 
 
d 
 
Figure 6.3. IL-6 and IL-12 concentrations after exposure of different concentrations of NPs and MPs to LPS 
activated dendritic cells. (a) IL-6 and (b) IL-12 level after incubation with NPs. (c) IL-6 and (d) IL-12 level after 
incubation with MPs. Results were expressed as mean ± S.D. (n=3;  24 h and  48 h incubation time).  
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No effect on the IL-6 secretion was determined for MPs (Figure 6.3c) and, consequently, no 
effect was investigated in used concentrations (<0.01 mg/ml) for in vitro efficacy studies on 
triple culture model (chapter 5). Depending on the loading MPs were applied at 
concentrations of ~0.0076 mg/ml and ~0.0052 mg/ml. 
The IL-12 secretion in presence of NPs was concentration dependent slightly suppressed 
(Figure 6.3b), but no effect was determined in the used concentrations which are <0.05 mg/ml 
for in vitro efficacy studies. A strong concentration dependent suppression of IL-12 secretion 
by MPs was detected (Figure 6.3 d) also for the lowest concentration with 0.01 mg/ml. No 
differences in results were obtained by prolongation of the incubation time from 24 h to 48 h. 
 
6.4. Discussion  
PLGA was used over decades in the medical field e.g. as suture [195] and has been shown 
to be extremely safe as a material for macroscopic DDS, e.g. implants and also 
microparticulate DDS [61]. Furthermore, it can be suggested that the chemical composition of 
PLGA does not rise toxicity [196]. However, unique effects may occur through preparation of 
novel nano- and microparticulate formulations. Several studies revealed that biodistribution 
and toxicological effects of materials change upon formulating it as NPs [197]. Effects can 
originate due to size, also preparation techniques as well as due to excipients, which differ 
e.g. according to the freeze and spray drying techniques used in this study. NPs were freeze 
dried using the sugar trehalose as cryoprotective agent, while MPs contained Span60 to 
enable re-dispersion after spray drying. The MPs consists to a high value of Span60 
(0.592 mg per mg final formulation) which forms together with the PLGA the matrix system. 
Span60 is widely used in cosmetics, food products, and oral as well as topical pharmaceutical 
formulations [175]. The LD50 value was determined in rats after oral application to be 31 g/kg, 
indicating no toxicity, and the World Health Organization (WHO) assessed in 1974 Span60 as 
safe food additive [198]. The acceptable daily intake of 25 mg/kg bodyweight was evaluated 
as it is metabolized to sorbitol and stearic acid [198]. During the last decades Span60 was 
widely used for the formulation of DDS, in particular niosomes [199] and nanocapsules [200], 
[201]. The disaccharide trehalose is approved for the use as cryoprotective agent for proteins, 
particularly for parenteral administration and liposomes [175]. It is rapidly metabolized to 
glucose by the specific enzyme trehalase and evaluated as nontoxic and non-irritant excipient 
(LD50 in rats after oral administration >5g/kg). 
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The NPs demonstrate marginal to low toxicity with IC50 values >1500 µg/ml. For MPs a strong 
decrease in the cell viability was observed for concentration >250 µg/ml for the 3T3 
(IC50 ~250 µg/ml) and >100 µg/ml for the J774A.1 (IC50 <100µg/ml). Nevertheless, 
macrophages show a higher sensitivity and they have the possibility to phagocyte size-
dependent materials [191], [202]. One other explanation for the enhanced toxicity could be 
the high sedimentation rates that occur during 24 h incubation and, therefore, mechanical 
stress for the cells, which has to further investigated. Additionally, the effect could be cell line 
dependent. To underline this, Semete et al. investigated the toxicity of spray dried PLGA 
particles (300 nm-1 µm) in Caco-2 and HeLa cells, a cervical cancer cell line, in 
concentrations of 0.001-0.1 mg/ml and determined no toxic effect. Furthermore, in the 
present work the cytotoxicity was also determined on the cell lines used for set-up of the triple 
culture model (chapter 5.4.3). The experiments were performed via LDH assay at 
concentrations between 0.006-6.0 mg/ml for NPs and 0.0014-1.4 mg/ml MPs on 
monocultures of Caco-2, THP-1 and Mutz-3 cells. The different concentrations were selected 
according to the different tested concentrations and loading. The cell lines were robust to 
MPs, even at the highest concentration (chapter 5.4.3, Figure 5.4). The NPs show no toxicity 
except for the highest concentration with 40% toxicity for THP-1 and MUTZ-3 cells. In 
general, Caco-2 cells are known to be more resistant to toxic effects, especially when they 
are differentiated to a confluent monolayer. 
Apart from cellular toxicity the particles should stay for a period of time in the living individual, 
e.g. in rodent colitis models for in vivo studies as well as in a future perspective in the human 
patient. Therefore, the particles should not be recognized as exogenous and cause an 
immune reaction including inflammation [190]. The assay used in this immunology study 
represents the investigations of the innate immune response. The innate immune system is 
non-specific, has an immediate response, e.g. for binding compounds of the complement 
system in seconds, and consists of cell-mediated and humoral components (complement 
system). The first line of defense of the innate immune system consists of the complement 
system and dendritic cells in tissues secreting IL-6 and IL-12 [23]. IL-6 is both a pro-
inflammatory and anti-inflammatory cytokine, furthermore it may promote B-cell stimulation. 
IL-6 is secreted in the first phase of the immune response as pro-inflammatory cytokine and 
can cross the blood brain barrier inducing fever. The cytokine IL-12 is the T-cell stimulating 
factor linking innate and adaptive immune responses via the induction and differentiation of 
the TH cells [23].  
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In this study, no activation of the complement system could be measured for NPs as well as 
for MPs and, therefore, both were not recognized as exogenous material. The absence of 
detectable levels of IL-6 and IL-12 is an indicator of safety for these particles as they are not 
activating immune responses by themselves. Interestingly, the particles had concentration 
dependent an effect of the IL-12 secretion of with LPS stimulated dendritic cells. Does a 
modulation of the IL-12 secretion have consequences? IL-12 is a regulator of TH cells and 
important for the cellular defense and adaptive immune system. In the first phase of the 
immune response IL-12 is a key factor for TH1 responses characterized by IFN-γ secretion 
[203]. Suppression of IL-12 secretion of dendritic cells may reduces the crosstalk between 
innate and adaptive immune system, but only in the early stage of TH1 immune response. In 
the following immune response IL-23 plays a more important role and supports the 
inflammatory process [203]. Moreover, in the second phase of the immune response IL-12 
can also be secreted by phagocytes e.g. macrophages. IL-12 is further associated with food 
allergy or autoimmune diseases including psoriasis, multiple sclerosis, rheumatoid arthritis, 
and CD [9], [204]. Several studies aimed to reduce IL-12 levels for these allergies and 
diseases [205]. In a study in human patients Mannon et al. applied successfully an anti-IL-12 
antibody (3 mg/kg, weekly) as co-medication for active CD [206]. In mouse models IL-12 p35 
(IL-12 subunit) deficiency and IL-12Rb1 (part of the IL-12 receptor) deficiency ameliorates the 
induced colitis. Furthermore, IL-12 p40 (IL-12 subunit) deficiency significantly protects the 
rodent models from developing colitis [207]. Other studies in rodent colitis models 
demonstrated that antibodies directed against IL-12 p40 can prevent and/or reverse colitis [9], 
[208]. 
In conclusion, the decrease of IL-12 production by dendritic cells may reduce their potential to 
promote TH1 response, therefore damper further inappropriate response such as those 
observed in autoimmune diseases. 
In the present study the effect of IL-12 suppression was obvious at a concentration of 
0.01 mg/ml for MPs and 0.05 mg/ml for NPs (Figure 6.3). Hence, this effect would not 
influence the dendritic cells in the triple culture model of the in vitro studies in chapter 4, as 
MPs were applied at ~0.0076 mg/ml and ~0.0052 mg/ml and NPs at ~0.0135 mg/ml and of 
~0.024 mg/ml. In a future perspective the question is if it would be possible to reach such 
(high) concentrations in vivo at the side of inflammation influencing the local dendritic cells. 
Therefore, the effective concentration in vivo had to be confirmed first. In the study of Mannon 
et al. the patients received 3 mg of the antibody IL-12 per kg of body weight weekly per 
subcutaneous injection to achieve a significant effect [206].  
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As one of the major goals in the present work was to reduce the applied drug doses by 
accumulation of the DDS in the inflamed areas of the intestine, in a first step this hypothesis 
should be confirmed to reveal the effective concentrations of the loaded DDS. A step towards 
in this direction is the evaluation of efficacy of the formulations in a rodent colitis model as 
followed in chapter 7. However, if a local effect on the immune system could be reached it 
would rather assist the drug effect.  
 
6.5. Conclusion  
The NPs and MPs showed no toxicity in relevant concentration for in vitro testing e.g. on the 
triple culture model of the inflamed intestinal mucosa. No activation of the complement 
system was determined for NPs as well as for MPs, therefore the particles were not 
recognized as exogenous material via the investigated mechanism.  
The absence of detectable levels of cytokines (IL-6 and IL-12) by incubation of dendritic cells 
in presence of the particles underlines the safety of the particles as they are not activating 
immune responses by themselves. Interestingly, the particles suppress concentration 
dependent the IL-12 secretion of stimulated dendritic cells and the effect should be 
considered in further investigations.  
As far as such in vitro results can predict the in vivo effects, there is no result within the 
cytotoxicity and immunotoxicity testing performed here that would raise concerns about the 
safety of NPs as well as of MPs.  
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7.1. Introduction 
The medical treatment of IBD is mostly based on the daily administration of corticosteroids 
and immunosuppressants to induce remission and prevent relapses [17], [37]. The required 
doses of corticosteroid and immunosuppressant drugs can induce severe side effects. Novel 
therapy strategies using nano- and microparticluate DDS aim to improve the treatment by 
local application of the used drugs. Therefore, high drug concentrations in the affected 
tissues could be obtained avoiding their access to the systemic circulation in sufficient 
amount and rate to reduce systemic side effects [4], [43]. In previous studies NPs and MPs 
had shown to be able to remain in the ulcerated areas of the colon for prolonged periods of 
time, where they can control a sustained release of the drug in situ. This accumulation of 
particles can be used for a passive targeting approach [67], [75]–[77]. Furthermore, the 
particles can be entrapped in the mucus layer of the lumen [75]. Through the inflammation an 
increased mucus production is observed, which leads to an thicker mucus layer, in particular 
in the ulcerated areas [72], [79], [80].  
However, following this passive targeting approach the appropriate or optimal size of such 
DDS is not fully clear at the moment. NPs had shown their efficacy in rodent models [67], 
[75], whereas the literature suggests that MPs seem to be more favorable in human patients 
compared to NPs [76]. Therefore, two formulations, PLGA based NPs and MPs, which differ 
in size and in manufacturing technology were compared in the same in vivo model using 
dextran sodium sulfate (DSS) to induce colitis in Balb/C mice [124]. On both processes for 
producing the particles a DOE was before applied in chapter 2 to identify process parameters 
influencing size and size distribution to address reproducibility and controllability of the 
manufacturing processes and, therefore, to achieve consistent quality of the DDS at the early 
state of development. Furthermore, both carriers demonstrated their safety with regard to 
cytotoxicity and immunotoxicity in chapter 5 and chapter 6 with comparable results in different 
in vitro cell culture systems. In this chapter NPs and MPs loaded with CYA were selected 
according to their physico-chemical and biopharmaceutical properties (chapter 3) and in in 
vitro testing on the triple culture model (chapter 5). CYA loaded NPs and MPs demonstrated 
higher encapsulation efficiencies, a more controlled release and significantly better anti-
inflammatory efficacy compared to BU loaded DDS. In general, CYA demonstrated to be 
successful in the treatment of IBD, but also causes several serious side effects through its 
systemic bioavailability [17], [160], [161], which should be decreased by using a suitable 
DDS. 
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Among the chemically induced models of colitis, the DSS model has been extensively 
characterized and is widely used to study epithelial repair mechanisms as well as the 
contribution of innate immune mechanisms [123]. This model shares many of the 
macroscopic, histological and immune characteristics of human IBD and is characterized by 
bloody diarrhoea, ulcerations and infiltrations with granulocytes. The DSS-induced colitis in 
Balb/C mice is further characterized by an inflammation only located in caecum and colon, 
which reflects characteristics of UC [125], [133], [209]. Pathophysiological changes of the 
DSS model can be recorded by clinical parameters: body weight loss, stool consistency, 
blood in stool, colon length, colon weight/length ratio as well as colon histology. In this study 
an acute DSS model was used, which shows an increased mucosal production of 
macrophage-derived cytokines, in particular TNF-ɑ and IL-6 [131]. Hence, inflammation 
markers (IL-1ß, IL-6, TNF-ɑ) and anti-inflammatory cytokines (IL-4, IL-10) in the colon were 
measured. Due to the toxicity to the gut epithelial cells of the basal crypts, DSS affects the 
integrity of the mucosal barrier [123] and allows, therefore, to investigate the passive 
targeting approach by deposition of particles in ulcerated regions of the intestine.  
Before starting the in vivo study the stability with regard to the size of the NPs and MPs was 
investigated and release profiles were performed at pH 3, as the pH in the GIT of mice differs 
from humans [210]. For the in vivo efficacy studies an oral dose of 50 mg/kg referring to the 
weight of the mice was administered, following by a dose response with 25 mg/kg and 
12.5 mg/kg for the NPs [125]. The formulations were compared to the commercially available 
oral CYA formulation (Sandimmun® Neoral) and drug free NPs and MPs in both healthy 
animals and DSS colitis mice.  
 
7.2. Materials 
Excipients for NP and MP preparation and active ingredients were used as described in 
chapter 2.2 and chapter 3.2. Sandimmun® Neoral capsules (Sandimmun) were donated by a 
local pharmacy. 
All solvents were of high-performance liquid chromatography grade and all chemicals met the 
quality requirements of the European Pharmacopoeia 6.0–7.3. 
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7.3. Methods 
7.3.1. Preparation and characterization of cyclosporine A loaded nano- and
 microparticles 
The CYA-NPs and CYA-MPs were prepared with an optimal loading as described in 
chapter 3.3.2 and chapter 3.3.3, respectively. Hence, for CYA a loading of 4/10 (CYA/PLGA, 
wt/wt) for both, NPs (CYA-NP) and MPs (CYA-MP), was used.  
Hydrodynamic diameter and polydispersity index (PDI) were measured by laser light 
scattering and zeta potential (ZP) of NPs were measured by laser light scattering as 
described in chapter 2.3.6. The size and size distribution (width) of MPs were measured by 
laser light diffraction as described in chapter 3.3.4. The encapsulation efficiency (EE) was 
determined as described in chapter 3.3.6.  
 
7.3.2. Stability of particles in simulated gastrointestinal tract of mice 
The stability of particles in the GIT was investigated according to the findings of McConnell et 
al. [210]. Hence, the particles were incubated in simulated gastric fluid (SGF) without pepsin 
according to the United States Pharmacopeia (USP, 2003), and adjusted with 0.1 N NaOH to 
pH 3.0. The experiments were performed in triplicate at room temperature. Drug free NPs 
(freeze dried) or MPs were weighted and incubated in 10.0 ml SGF pH 3.0. The particles 
were shaked at 100 rpm in an incubator (GLF 3031, Germany) and at pre-defined time points 
(0 h, 1 h, 2 h, 4 h, 8 h and 24 h). Size and size distribution were measured as described in 
chapter 2.3.6 for NPs and in chapter 3.3.6 for MPs. An increase in size or size distribution 
indicates an agglomeration of particles and, therefore, instability. The results of size were 
expressed in % referring to the initial size at 0 h (100%). 
 
7.3.3. In vitro release profile in simulated gastric fluid 
According to the pH values in the GIT of mice published by McConnell et al. [210], the 
release of CYA-NPs and CYA-MPs was investigated in SGF (USP, 2003) without pepsin 
adjusted to pH 3.0 with 0.1 N NaOH at room temperature. As SGF does not include a 
buffering system the pH was monitored during the experiment and determined to be pH 3.0 
for the whole experimental time. To increase the solubility of CYA, 0.05% tween®80 (wt/v) 
was added to the SGF.  
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The sink conditions were defined as 30% of the saturation concentration according to the 
USP (USP, 2003). The in vitro release profiles and determination of saturation concentration 
were performed as described in chapter 3.3.8. The saturation concentration was determined 
to be 41.7 ± 0.23 µg/ml (n=3) for CYA. The results were calculated cumulative and expressed 
as percent normalized to the EE. The release was compared to a release in PBS at pH 6.8. 
The experiments were performed in triplicate. 
 
7.3.4. Induction and assessment of DSS-induced colitis and therapeutic efficacy  
Female Balb/C mice (Harlan Interfauna Iberica, Barcelona, Spain), 6-8 weeks old, with 
weights ranging from 18 to 20 g, were acclimatized under a 12 h light/dark cycle at 22 °C and 
60% humidity, fed with a standard laboratory rodent diet and water ad libitum for seven days 
before starting the experiments. All animal care and experimental protocols were approved by 
the Institutional Ethics Committee of the University of Valencia (No. 108), in accordance with 
current Spanish legislation (RD1201/2005) and Helsinki declaration under the procedure 
number of: A1360059439693.  
Animals were randomly assigned to groups (six mice per group, seven mice for blank and 11 
mice for control) distributed as in Table 7.1. Acute colitis was induced by adding 3% (wt/v) 
DSS to the drinking water of Balb/C mice for seven days (Figure 7.1). Blank mice received 
water at libitum. DSS was removed at day seven. 
Table 7.1. Control and treatment groups in DSS colitis mice and in healthy mice. Drug free NPs and MPs were 
applied at a dose referring to 50 mg/kg of loaded particles. 
groups treatment nomenclature 
experiment in DSS colitis 
mice/in healthy mice 
1 blank (healthy mice) blank healthy animals 
2 DSS (colitis mice) control DSS colitis mice 
3 Sandimmun (25 mg/kg) Sandimmun (25 mg/kg) + DSS 
DSS colitis 
mice 
4 Sandimmun (50 mg/kg)  Sandimmun (50 mg/kg) + DSS 
5 drug free NP  NP (50 mg/kg) + DSS 
6 CYA loaded NP (50 mg/kg)  CYA-NP (50 mg/kg) + DSS 
7 CYA loaded NP (25 mg/kg) CYA-NP (25 mg/kg) + DSS 
8 CYA loaded NP (12.5 mg/kg) CYA-NP (12.5 mg/kg) + DSS 
9 drug free MP MP (50 mg/kg) + DSS 
10 CYA loaded MP (50 mg/kg)  CYA-MP (50 mg/kg) + DSS 
11 Sandimmun (50 mg/kg) Sandimmun (50 mg/kg) 
healthy mice 12 drug free NP NP (50 mg/kg) 13 CYA loaded NP (50 mg/kg) CYA-NP (50 mg/kg) 
14 drug free MP MP(50 mg/kg) 
15 CYA loaded MP (50 mg/kg) CYA-MP (50 mg/kg) 
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Concentrations of 50 mg/kg, 25 mg/kg and 12.5 mg/kg CYA-NPs and 50 mg/kg CYA-MPs 
were administered daily, staring with 50 mg/kg and compared to Sandimmun administered at 
50 mg/kg and 25 mg/kg, respectively. Drug free NPs and MPs were administered at a dose 
referring to 50 mg/kg of loaded particles (Table 7.1). Therefore, NPs and MPs were 
suspended and diluted in drinking water, and administered by oral gavage (200 µl/day). 
Sandimmun solution was extracted from Sandimmun® Neoral capsules by washing the 
capsules three times with ethanol. The respective dose was diluted from this stock solution 
directly before administration with PBS pH 7.4. Blank and control mice received daily drinking 
water by oral gavage mimicking the administration stress. The last dose of formulations was 
given at day eight (1.5 h before sacrifice) to measure the CYA levels in blood.  
All groups were also tested at the highest concentration (50 mg/kg) in healthy mice (five to six 
mice per group) to evaluate toxic or side effects of the particles, which can be detected by the 
appearance of the fur and the body weight (indicator for quality of life).  
 
Figure 7.1. Experimental set-up in vivo studies. 
Animals were sacrificed at day eight by heart blood punction after anaestesia of the mice with 
isofluran (CP-Pharma, Germany), and the entire colon (from the caecum to anus) was 
resected. Resected colon tissue samples were rinsed with ice-cooled phosphate buffer to 
remove luminal content. Tissue wet weight and colon length were determined and expressed 
as a colon weight/length quotient. Colon length is shortened under inflammation and colon 
weight is increased due to development of edema in the inflamed areas. The colons of each 
test group were blinded and randomly separated for histological analysis (chapter 7.3.5) and 
measurement of cytokine levels (chapter 7.3.6). The samples for the cytokine measurement 
were frozen immediately and stored at −80 °C until use. 
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Animal body weights (being an indicator for quality of life), stool consistency, rectal bleeding, 
appearance of fur and consumed DSS solution volume, were recorded daily throughout all 
the experiments.  
The disease activity index (DAI) was determined according to Mladenovska et al. [84] 
assessing weight loss, stool consistency and rectal bleeding. No weight loss was counted as 
0 points, 1–5% as 1 point, 5–10% as 2 points, 10–20% as 3 points and >20% as 4 points. For 
stool consistency, 0 points were given for well-formed pellets, 2 points for pasty and semi-
formed stools that did not stick to the anus and 4 points were given for liquid stools that stick 
to the anus. Bleeding was scored as 0 point for no blood, 2 points for positive finding and 
4 points for gross bleeding. The mean of these scores was forming the clinical score ranging 
from 0 (healthy) to 4 (maximal activity of colitis). 
 
7.3.5. Histological analysis 
Colon samples used for histopathology (n=3) were opened longitudinally along the main axis, 
rolled up in a spiral starting from distal to proximal margin (“swiss role”), fixed in 4% 
formaldehyde, paraffin embedded, sectioned and stained with hematoxylin and eosin. The 
“swiss role” allows to the observation of the whole colon, distal and proximal part. The slides 
were analysed by light microscopy and scored as described previously [211] according to the 
criteria listed in Table 7.2. 
Table 7.2. Histopathological scores for DSS-induced colitis. Results were expressed as means of scores [211].  
Grade Severity of inflammation (amount of cell infiltration) 
Extend of inflammation 
(cell infiltration location) Extent of crypt damage 
0 none none no damage 
1 mild mucosa basal one third 
2 moderate mucosa + submucosa basal two third 
3 severe transmural crypt loss/ epithelium 
conserved 
4 n. a. n. a. crypt and epithelium loss 
n. a. = not applicable 
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7.3.6. Cytokine level 
The colons (n≥3) were cut in small pieces and then suspended (20%, w/v) in ice-cold PBS 
containing 0.1% Igepal CA-630, homogenized, sonicated for 30 s and centrifuged at 
20000x g for 10 min at 4°C. Supernatants were collected and protein concentrations were 
determined by Bradford colorimetric method [212].  
Then, IL-1β, IL-4, IL-6, IL-10 and TNF-α concentration in the supernatants were measured by 
ELISA kit for each IL (eBioscience, San Diego, USA) according to the manufacturer's 
instructions and expressed as pg/ml per mg protein. 
 
7.3.7. Cyclosporine A level in plasma 
Plasma samples were analysed by means of an HPLC device (Agilent, Barcelona Spain). 
The analytical conditions were as follows: Column, Kromasil C18 25x4mm; flow: 1.2 ml/min; 
detection wavelength: 210 nm; injection volume: 50 µl; retention time: 3.2 min; temperature of 
analysis: 65ºC. The mobile phase consisted of a mixture of acetonitrile/methanol/purified 
water (7/2/1, v/v/v). Three calibration curves were prepared for inter and intraday validation of 
the method in the concentration range: 5-100 µg/ml. Therefore, 100 µl of plasma samples 
were spiked with different volumes of a CYA standard solution in ethanol at a concentration of 
500 µg/ml, and then mixed (vortex mixer) for 5 min. 500 µl acetonitrile were added and 
samples were mixed (vortex mixer) for 5 min. Samples were then centrifuged again at 
20000x g for 11 min. After sacrifice of the mice by heart puncture, heparinized blood samples 
were centrifuged under the conditions noted above and further prepared following the 
protocol for the standards, except for the addition of CYA standard solution. 
 
7.3.8. Statistical analysis 
The results are expressed as the mean ± standard deviation (S.D.). Statistical significance 
was performed by means of one-way analysis of variance (ANOVA) and Holm-Sidak test for 
multiple comparisons. Sigma Plot 12.5 software (Systat Software GmbH, Erkrath, Germany) 
was used for all calculations. 
 
            Evaluation of cyclosporine A loaded PLGA drug delivery systems in DSS Balb/C mice model 
 
131 
7.4. Results 
7.4.1. Characterization of cyclosporine A loaded nano- and microparticles 
The physico-chemical properties were determined for NPs and MPs and summarized in 
Table 7.3 and Table 7.4, respectively. NPs have a size of 160 nm and CYA-NPs of 158 nm 
with a narrow size distribution and a negative zeta potential, which is typical for PLGA 
particles.  
The MPs have a size of 2.8 µm and the CYA-MPs of 2.7 µm with a wider size distribution, 
which is typical for spray dried products. 
Table 7.3. Physico-chemical characteristics of NPs used for in vivo studies. 
formulation size [nm] PDI zeta potential [mV] EE [%] 
loading 
[µg/mg] 
drug free NP 160.5 ± 2.1 0.03 ± 0.02 -27.8 ± 0.5  - 
CYA-NP 158.1 ± 2.0 0.04 ± 0.04 -31.0 ± 6.1 61.4 ± 2.8 85.3 
 
Table 7.4. Physico-chemical characteristics of MPs used for in vivo studies. 
formulation size [µm] width EE [%] loading [µg/mg] 
drug free MP 2.8 ± 0.06 1.8 ± 0.06 - - 
CYA-MP 2.7 ± 0.02 1.2 ± 0.02 100.5 ± 2.2 142.4 
 
7.4.2. Stability of particles in simulated gastrointestinal tract of mice 
The colloidal stability according to size and size distribution after incubation in SGF at pH 3 is 
summarized in Figure 7.2. During 24 h of incubation no change in size and size distribution 
was determined for the NPs (Figure 7.2a). For the MPs (Figure 7.2b) a reduction of 18.5% 
after 1 h incubation time was observed. A re-dispersibility of the particle aggregates and 
dispersion of Span60 could be assumed. 
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Figure 7.2. Stability measured as size and size distribution of (a) NPs and (b) MPs in SGF at pH 3.0. The data 
were presented as mean ± S.D. (n=3). 
 
7.4.3. In vitro release profile 
The administered particles should be stable following their administration by oral gavage. 
According to the work of Mc Connell et al. [210] the stability can be also assessed by release 
studies at pH 3.0 in SGF (Figure 7.3). The CYA-NPs release the encapsulated CYA slower 
(67.1 ± 8.8 % released CYA after 24 h) compared to the CYA-MPs with 89.0 ± 9.3 % in 24 h. 
Compared to release studies in PBS pH 6.8 showed a minimal change in the release of CYA 
form CYA-MPs, whereas the burst release is reduced for the CYA-NPs at pH 6.8.  
 
Figure 7.3. In vitro release profile over 24 h. (a) CYA-NPs and (b) CYA-MPs in SGF at pH 3.0 in comparison to a 
release in PBS at pH 6.8. The data were presented as mean ± S.D. (n=3).  
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7.4.4. Clinical parameters - Body weight loss and disease activity index 
The monitored body weight loss as indicator for the quality of life is presented in (Figure 7.4). 
Due to the assessed mild colitis a light reduction in the body weight of the control group 
starting at day 6 was determined. For a drastic weight reduction a dose of 5% DSS solution 
should be applied, but often animals die at this concentration. Based on a benefit-risk balance 
and ethical reasons 3% was used as other parameters, in particular, colon length, colon 
weight/ratio, reveal significant results at this concentration. DSS intake was measured and 
ranged between 3.5-4.7 ml/day per mouse, except for CYA-MPs with 2.0 ml/day. 
a experiment in DSS colitis mice b experiment in DSS colitis mice 
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Figure 7.4. Body weight loss of (a) control mice, blank mice and DSS colitis mice receiving drug free NPs and 
MPs, (b) DSS colitis mice receiving Sandimmun, CYA-NPs and CYA-MPs at 50 mg/kg, (c) DSS colitis mice 
receiving Sandimmun (25 mg/kg) and NPs at 25 mg/kg and at 12.5 mg/kg, (d) healthy mice receiving Sandimmun, 
CYA-NPs, CYA-MPs and drug free NPs and MPs at 50 mg/kg. The data were presented as mean ± S.D. (n≥6). 
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Drug free MPs (Figure 7.4a) showed a slight body weight reduction in DSS colitis mice 
compared to the administration in the healthy mice (Figure 7.4d). For the drug free NPs a 
stronger weight reduction starting at day 6 to day 7 was observed. Sandimmun at 50 mg/kg 
(Figure 7.4b) induced body weight reduction starting at day 2 and reduced dramatically the 
body weight after day 5, whereas no change in the body weight was determined for 
administration of 25 mg/kg Sandimmun (Figure 7.4c). The Sandimmun (50 mg/kg) group was 
silent in behaviour and the fur was shaggy. One mouse died at day 3. All groups that received 
Sandimmun were more active than the blank mice.  
For the mice receiving CYA-NPs (50 mg/kg), only a slight reduction, less than for 
Sandimmun, from day 5 to day 8 was determined comparable to control mice (Figure 7.4b). 
One mouse died at day 7, although all mice had a normal behaviour and fur. Unfortunately, 
CYA-MPs administered in DSS colitis mice decreased the body weight dramatically up to 
20% loss of the initial weight starting at day 2 (Figure 7.4b). The group was silent in 
behaviour and the fur was shaggy. Furthermore, a reduced water intake was determined. 
Also CYA-NPs administered at a dose of 25 mg/kg reduced the body weight in a slightly 
higher value starting at day 5 than the control mice and Sandimmun at 25 mg/kg (Figure 
7.4c). The body weight of DSS colitis mice receiving CYA-NPs at a dose of 12.5 mg/kg was 
positively constant over the whole experiment, but the fur of the mice was light shaggy.  
All healthy mice treated with Sandimmun or particles, both drug free and loaded, showed no 
effect on body weight, except the CYA-MPs, which showed a light fluctuation between day 4 
and day 6 (Figure 7.4d). The administration to heathy mice intended to assess the safety of 
the particles as drug vehicle. 
Disease activity index 
The stool consistency and rectal bleeding were recorded daily and scored with the body 
weight as DAI. The mean of these scores was forming the clinical score ranging from 0 
(healthy) to 4 (maximal activity of colitis) as presented in Figure 7.5. No statistical significance 
could be determined. The control mice developed diarrhea stating at day 2, which is typical 
for the colitis model. All other groups receiving DSS started to develop semi-formed stools 
between day three and day four.  
Sandimmun administered at 25 mg/kg and 50 mg/kg, as well as drug free NPs and MPs and 
CYA-NPs at 12.5 mg/kg, showed no improvement in the DAI compared to control mice 
(Figure 7.5).  
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All other groups receiving CYA-NPs showed a reduced DAI, in particular the 25 mg/kg dosing 
regime. CYA-MPs at 50 mg/kg showed a worsening in the DAI compared to the control mice. 
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Figure 7.5. Effect of treatment presented as disease activity index (DAI). DAI is expressed as means of score 
(mean ± S.D.) of body weight loss, stool consistency and rectal bleeding, ranging from 0 (healthy) to 4 (maximal 
activity of colitis) according to Mladenovska et al. [84]. No weight loss was counted as 0 points, 1–5% as 1 point, 
5–10% as 2 points, 10–20% as 3 points and >20% as 4 points. For stool consistency 0 point was given for well-
formed pellets, 2 points for pasty and semi-formed stools that did not stick to the anus and 4 points were given for 
liquid stools that stick to the anus. Bleeding was scored as 0 point for no blood, 2 points for positive finding and 
4 points for gross bleeding.  
 
7.4.5. Clinical parameters - Colon length and weight/length ratio 
For this model, the colon length is the main marker for indicating an efficient developed 
colitis. A shortening of the colon indicates a progression of disease. To test a possible 
negative effect of the particles in the mice, all healthy mice were treated with Sandimmun and 
particles, both drug free and CYA loaded, showing no significant change in colon length 
(Figure 7.6a).  
All results of the colon length for the diseased mice are summarized in Figure 7.6b. 
Sandimmun does not influence the colon length at a dose of 50 mg/kg, whereas an increase 
in colon length was observed for 25 mg/kg. The drug free NPs also showed a slight increase, 
which is not significantly different from the control mice. The CYA-NPs at all concentrations 
increased significantly (p<0.001) the colon length >8.4 cm, compared to Sandimmun at 
50 mg/kg, but no dose dependency was observed.  
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CYA-NPs at 25 mg/kg showed a slight increase, which is not significant (p=0.161), in colon 
length compared to the same dose of Sandimmun.  
 
a experiment in healthy mice b experiment in DSS colitis mice 
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Figure 7.6. Colon length [cm] and colon weight/length ratio [mg/cm] of mice. (a) Colon length [cm] of healthy mice 
treated with NPs and MPs at different doses in comparison to blank mice and treatment with Sandimmun (n≥6). 
(b) Colon length [cm] of diseased mice treated with NPs and MPs at different doses in comparison to blank mice, 
control mice and administration of Sandimmun (n≥6). (c) Colon weight/length ratio [mg/cm] of healthy mice treated 
NPs and MPs in comparison to blank mice and administration of Sandimmun (n≥3). (d) Colon weight/length ratio 
[mg/cm] of diseased mice treated with NPs and MPs at different doses in comparison to blank mice, control mice 
and treatment with Sandimmun. The data were presented as mean ± S.D. Statistical significance was assessed by 
ANOVA using Holm-Sidak for multiple comparison (***p<0.001, p**<0.01, p*<0.05). 
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The drug free MPs had no effect on the colon length. The CYA-MPs showed a significant 
effect compared to Sandimmun (50 mg/kg, p<0.001) and drug free MPs (p=0.012) with an 
increased colon length of 8.8 ± 0.8 cm. CYA-NPs administered at 25 mg/kg showed an 
increase up to 9.9 ± 1.0 cm, which is comparable to the colon length of blank mice 
(10.2 ± 1.1 cm). CYA-NPs at 50 mg/kg increased the colon length to 8.1 ± 1.0 cm and CYA-
NPs at 12.5 mg/kg to 8.7 ±1.2 cm. All with CYA loaded particles treated mice show a 
significant recovery in colon length, CYA-NPs (50 mg/kg p=0.001, 25mg/kg and 12.5 mg/kg 
p<0.001) and CYA-MPs (p=0.001), compared to Sandimmun (50 mg/kg). 
The results for the colon weight/length ratio are summarized in Figure 7.6c for healthy mice 
and Figure 7.6d for DSS colitis mice. The marker combines the two effects, which occur 
under inflammation: shortening of colon length and increasing of colon weight due to 
development of edema. Healthy mice (Figure 7.6c) treated with Sandimmun, CYA-NPs, drug 
free and CYA-MPs show a slight increase, in colon weight/length ratio, which was not 
significant. Only drug free NPs show an increase in the ratio in healthy mice. 
In Figure 7.6d diseased mice treated with Sandimmun, in both concentrations, further drug 
free NPs and MPs, show no significant difference in the weight/length ratio compared to the 
control mice. All CYA-NPs demonstrate values ~25 mg/cm for the colon weight/length ratio, 
which is near to the value of the blank mice (22.5 ± 3.7 mg/cm). Also the CYA-MPs had a 
colon weight/length ratio (23.0 ± 3.7 mg/cm), which is comparable to the blank mice. 
 
7.4.6. Clinical parameter - Cytokine level 
The results of the cytokine level in colon for the different cytokines are presented in 
Figure 7.7. For the pro-inflammatory cytokines no reduction could be reached for both 
concentrations of Sandimmun compared to control mice. CYA-NPs (25 mg/kg) show a 
reduction in IL-6 and TNF-ɑ levels, but not in the IL-1β level. IL-6 is also reduced by drug free 
and CYA-MPs compared to control. IL-4 is upregulated for Sandimmun at 50 mg/kg, drug free 
NPs and MPs and, furthermore, for CYA-MPs. For all concentrations of CYA-NPs IL-4 is 
significant downregulated compared to control mice and Sandimmun at 50 mg/kg. IL-10 is 
upregulated for Sandimmun at 25 mg/kg and CYA-NPs at 12.5 mg/kg compared to control 
mice. 
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Figure 7.7. Cytokine levels in colon: IL-1β, IL-6, TNF-ɑ, IL-4 and IL-10. For the drug free particles an equal amount 
referring to the loaded particles at a dose of 50 mg/kg was used. The data were presented as mean ± S.D. (n≥3). 
Statistical significance was assessed by ANOVA using Holm-Sidak for multiple comparison (***p<0.001, p**<0.01, 
p*<0.05). 
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7.4.7. Histological analysis 
For the histopathological analysis colon samples were randomly investigated and 
representative microscopic images are presented in Figure 7.8 for all treatment groups in 
DSS colitis mice compared to blank mice and control mice. The histopathological score was 
also calculated and is summarized in Figure 7.9. The control mice (Figure 7.8b) show typical 
changes with a total loss of the colon architecture including mucosal ulcerations, crypt 
damage, and complete loss of villis, edema, and cell infiltration into mucosal tissue. 
Furthermore, the major affected part is the distal colon, which is typical for the DSS model. 
These changes resulted in a high histopathological score and reveal the functionality of the 
used DSS model. As expected before drug free NPs and MPs show a high score, which is 
higher in comparison to control mice (Figure 7.9). 
The results demonstrate that all with CYA treated mice, except the CYA-MPs, have 
therapeutic and protective efficacy according to the histological analysis. For Sandimmun 
(50mg/kg) in Figure 7.8c the images reveal a medium destroyed lamina propria with signs of 
lost colon architecture and ulcerations, but some crypts are conserved. Cell infiltration can be 
seen only in the lamina propria and not in the submucosa.  
The results are also comparable for Sandimmun at 25 mg/kg (Figure 7.8d). For CYA-NPs at 
50 mg/kg and 25 mg/kg (Figure 7.8e and Figure 7.8g) only a slight inflammation with highly 
conserved crypts and slightly elongated villis, low cell infiltration and a conserved lamina 
propria could be determined. Both CYA-NP at 50 mg/kg and 25 mg/kg show a significant 
reduction in the histopathological score compared to control mice (p=0.003, p=0.004, 
respectively) and drug free NPs (p<0.001) (Figure 7.9). CYA-NPs (50 mg/kg) further reduce 
significantly (by ~25%) the score compared to Sandimmun (50 mg/kg). The results for CYA-
NP administered at a dose of 25 mg/kg are comparable to a dose of 50 mg/kg, whereas for 
12.5 mg the score increases (Figure 7.9).  
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a blank b control 
 
 
 
 
c Sandimmun (50 mg/kg) d Sandimmun (25 mg/kg) 
 
 
 
 
e CYA-NP (50 mg/kg) f CYA-MP (50 mg/kg) 
 
 
 
 
g CYA-NP (25 mg/kg) h CYA-NP (12.5 mg/kg) 
 
 
 
 
Figure 7.8. Histological manifestation in DSS colitis mice. Hematoxylin and eosin stained images of representative 
colons are shown at the same magnification (10x, scale bar=100 µm). 
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The CYA-NPs at 12.5 mg/kg (Figure 7.8h) showed less anti-inflammatory effectiveness with 
severe inflammation including mild to moderate cell infiltration and mild crypt loss, but 
conserved colon architecture. The results for the CYA-MPs (Figure 7.8f) show a completely 
destroyed mucosa, elongated and destroyed villis and, furthermore, with immune related cells 
highly infiltrated lymph nodes. The CYA-MPs show a histopathological score equal to control. 
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Figure 7.9. Histopathological score. The data were presented as mean ± S.D. (n=3). Statistical significance was 
assessed by ANOVA using Holm-Sidak for multiple comparison (***p<0.001, **p<0.10, *p<0.05). 
 
7.4.8. Cyclosporine A level in plasma 
The method was validated for mouse plasma samples with interday and intraday variation 
coefficient <3% for the concentration range of 5-100 µg/ml (R2=0.9989) with a detection limit 
of 0.31 µg/ml, and a quantification limit of 1.05 µg/ml. For the samples from blank mice and 
control mice, as well as mice treated with drug free NPs and MPs, no CYA peak was 
detected, as it was expected. In the case of the mice treated with the different 
CYA formulations and doses, some differences could be observed. None of the NPs 
formulations provided any detectable CYA peak. Sandimmun at the dose of 25 mg/kg, 
provided detectable, but non-quantifiable concentrations of CYA. For the CYA-MPs and 
Sandimmun at the dose of 50 mg/kg, administered in DSS colitis mice, quantifiable CYA 
amounts were determined, 45.77 ± 0.83 µg/ml and 58.45 ± 0.17 µg/ml, respectively. The 
plasma concentrations were slightly lower in healthy mice with the intact mucosa, 
42.57 ± 0.82 µg/ml for CYA-MPs and 53.71 ± 1.27 µg/ml for Sandimmun, both at 50 mg/kg.  
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7.5. Discussion 
The DSS-induced acute colitis model in rodents is frequently used as a pre-clinical model to 
test drugs for IBD and had also been used to evaluate the efficacy of novel drug delivery 
strategies in recent studies [67], [125]. Among the chemically induced models of colitis, it has 
been extensively characterized and demonstrated to establish a robust colitis within four to 
eight days [123], [213]. Due to the toxicity to the gut epithelial cells of the basal crypts, DSS 
affects the integrity of the mucosal barrier with main features of the macroscopic and 
histological characteristics of human IBD, and is widely used to study epithelial repair 
mechanisms as well as the contribution of innate immune mechanisms [123]. One limitation 
of this model is the lack of involvement of the adaptive immune system in the pathogenesis of 
the inflammation [123], [125], [130]. The model shows inflammation only in caecum and colon 
and resembles to UC [125], [209]. Therefore, the model is the most adequate model among 
the chemically induced models to evaluate the efficacy of CYA loaded particles in this work.  
In general, concentrations from 2-5% [128] of DSS in the drinking water can be applied to 
induce an acute colitis in rodents of different severity, which depends either on the used mice 
strain/breeder, molecular weight of DSS, or the different environmental factors in the 
laboratories [129], [209], [213], [214]. 2% enables to see clear differences, whereas 5% can 
induce colitis of high severity. For our ethical considerations high concentrations of DSS 
induces a too severe disease which is not needed to see the differences, therefore, 3% DSS 
were applied in this study.  
CYA, a immunosuppressive calcineurin inhibitor, is applied to UC patients suffering from 
fulminant colitis and do not respond to intravenous corticosteroids [29]. The therapy is started 
intravenously (i.v.) for three to five days and typically continued with oral CYA often in co-
medication with corticosteroids and azathioprine, or methotrexate for maintenance therapy 
[17]. The CYA therapy is associated with adverse effects when CYA is systemically available 
e.g. neurological toxicity, infections, renal dysfunction, nephrotoxicity and hypertension [17]. 
Therefore, patients would benefit from a drug delivery system that would deliver the 
encapsulated CYA directly to the inflamed areas of the intestine. Such a local treatment 
would ideally allow a dose reduction compared to a systemic application. Furthermore, high 
systemic concentrations would be avoided and, therefore, the side effects of the used drugs 
could be reduced. CYA is at the moment available as oral dosage form and also for i.v. 
injection. Therefore, the NPs and MPs were tested by oral gavage. 
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With the CYA-NPs at all concentrations a significant improvement in the marker colon length 
and colon weight/length ratio could be demonstrated, compared to Sandimmun (50 mg/kg 
and 25 mg/kg, Figure 7.6). The results from the histological analysis reveal that the 
histopathological changes such as total loss of the colon architecture including mucosal 
ulcerations, damage crypts and villis, edema, and cell infiltration are significant reduced 
applying CYA-NPs compared to control and are overall better compared to Sandimmun. 
Interestingly, no dose dependency could be observed for the CYA-NPs, which was also 
reported in previous studies using a CYA solution [215]. Banić et al. demonstrated in a 2, 4-
dinitrofluorobenzene colitis mouse model that CYA administered intraperitoneally had a 
concentration-dependent anti-inflammatory effect in contrast to an intracolonical 
administration. The latter should be addressed with the particles in this study. The CYA-NPs 
does not influence the body weight neither in healthy nor in DSS colitis mice and were, 
therefore, revealed as safe. Drug free NPs reduce the body weight in DSS animals. An effect 
which was not observed applying drug free MPs. Drug free NPs seem to have a negative 
effect on the inflammation, which is compensated by CYA encapsulated in NPs. The toxicity 
and immunotoxicity were tested before (chapter 6) and the performed tests would not raise 
concerns about the safety of the particles. Therefore, a physical effect of the particles could 
be assumed triggering the destruction of the mucosa as also the histopathological score was 
15% higher compared to control. The body weight reduction might be due to the increased 
permeability of the upper intestinal mucosa of the mice based on the inflammation [41], [42]. 
In previous studies of our group, testing BU loaded NPs, such effect was not obvious [67]. 
Depending on the effective dose of CYA ranging in mg/kg, which is much higher as the 
applied BU 0.168 mg/kg, ~36.5 mg of particles had to be applied per day for the highest dose.  
The CYA-MPs decreased strongly the body weight, indicating an intoxication of the animals 
by CYA as also the DSS-water intake was decreased in DSS colitis mice. The applied high 
dose of CYA (50 mg/kg) could lead to toxic effects as reported in previous studies applying 
50 mg/kg [125], [215], and as could be seen in the body weight reduction of Sandimmun at 
50 mg/kg compared to the CYA-MPs. By encapsulating the CYA in MPs and NPs achieving a 
controlled release, the toxicity of CYA should be reduced in this study due to the reduced 
systemic bioavailability of CYA. The CYA-NPs applied at 50 mg/kg show no intoxication and 
seems to have a protective effect, which can be associated with the release. The CYA-MPs 
release the encapsulated drug much faster (89.0 ± 9.3 % in 24 h, Figure 7.3) as compared to 
the CYA-NPs (67.1 ± 8.8 % in 24 h). The slower release demonstrates, therefore, a protective 
effect.  
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Apart from the reduction in body weight the CYA-MPs as well as the drug free MPs show a 
complete destroyed mucosa in the histopathological analysis (Figure 7.8 and Figure 7.9) 
equal to control mice and, therefore, further doses were not tested in this study. 
Nevertheless, the results revealed that both markers, colon weight and colon weight/length 
ratio, were significantly improved compared to control mice and Sandimmun, demonstrating, 
thus, absolute values which were comparable to CYA-NPs. In a future perspective the 
efficacy of MPs should be further investigated with a more slow and controlled release as a 
recent study revealed a high accumulation efficiency for MPs in human patients compared to 
NPs from the same material [76]. The negative effect of the MPs could be dependent on the 
animal species used for the experimental set-up, as suggested by Leonard et al., due to the 
different dimensions (e.g. the length of small intestine was determined to be <50 cm for mice 
compared to humans with 3-4 m) [88]. The MPs might damage the mucosa in the GIT of the 
mice during their transit time due to the inflexible PLGA matrix. Furthermore, particles 
prepared with different preparation processes should be evaluated to have an effect on the 
used model, as the change in the preparation method is often associated with a change in the 
used stabilizer. However, the MPs seems to be a promising approach and a change to a rat 
model with other dimensions would offer the possibility to test the particles with a modified 
release at lower concentrations [216].  
The administration of DSS to the mice leads to an increased immune cell infiltration and, 
therefore, enhanced mucosal production of pro-inflammatory cytokines, IL-1β and IL-6, from 
epithelial cells and immune competent cells, typical for the acute DSS model [130], [131]. IL-6 
presents the intestinal inflammation, and IL-1β and TNF-ɑ are associated with a generic 
inflammation. For the pro-inflammatory TNF-ɑ also an enhanced mucosal production was 
determined, which was also high for the blank mice and, therefore, an effect of the treatment 
groups could not be determined. Furthermore, the anti-inflammatory IL-4 was measured, 
which was equal for control mice and blank mice in this study [133]. CYA can have a 
paradoxic pro-inflammatory effect, which was described by Rafiee et al. and could influence 
the measured cytokine levels [217].  
The model also allowed determining plasma levels to evaluate the systemic bioavailability of 
CYA. Sandimmun showed plasma concentrations only with the highest dose (50 mg/kg), 
being higher in diseased mice in comparison to healthy mice. The CYA-MPs showed 
quantifiable plasma concentrations, which were lower than those obtained for the 
Sandimmun. This is probably due to the controlled release, which was faster than the one 
provided by the NPs.  
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The plasma concentrations obtained from CYA-MPs (50 mg/kg) were also lower in healthy 
mice compared to diseased mice. None of the NPs showed any plasma profile of drug, 
confirming the hypothesis that the slow controlled release formulations reduce the access of 
drug to systemic circulation preventing severe side effects.  
In summary, the DSS-induced colitis could be successfully treated with the CYA-NPs 
according to the data obtained for the investigated markers. Nevertheless, this model allows 
also measuring the CYA plasma levels. Therefore, the systemic bioavailability could be 
investigated, which was significantly reduced by encapsulation of CYA in NPs.  
As Koboziev et al. resumed, a lot of potential drugs for an improved therapy of IBD were 
identified and only a few studies have been able to translate the results demonstrated in 
acute chemically induced models to chronic colitis mouse models [213]. However, testing the 
most promising particles, based on this study the CYA-NPs, in a chronic rodent colitis model 
should be addressed in a future perspective to underline the efficacy. In contrast to acute 
colitis, the chronic DSS-induced colitis is characterized by focal epithelial regeneration due to 
the destabilized intestinal repair mechanism and, moreover, by a TH1 and TH2 cytokine profile 
with increased mucosal IFN-γ and IL-4 levels [133].  
7.6. Conclusion 
CYA-NPs showed efficacy in the investigated parameters, colon length, colon weight/length 
ratio, and in the histological analysis and, moreover, reduced systemic bioavailability. 
Furthermore, they demonstrated a significant improvement compared to control and 
Sandimmun.  
The CYA-MPs demonstrated effectiveness in colon length, colon weight/length ratio, but led 
to increased pathological changes of the mucosa. Furthermore, CYA-MPs led to an 
intoxication of CYA determined by a strong body weight reduction and shaggy fur, whereas 
the CYA-NPs had a protective effect by the encapsulation of the CYA.  
Especially, the CYA-NPs, offer a promising therapeutic alternative for an improved treatment 
of IBD. Further in vivo studies should be performed based on the results of the systemic 
bioavailability (CYA plasma level). These studies should address the determination of the 
lowest effective dose and the evaluation of the CYA-NPs in a chronic model of the DSS-
induced colitis, which is characterized by focal epithelial regeneration, and a TH1 and TH2 
cytokine profile.  
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8. Summary and outlook 
Inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis are 
chronic, episodic, inflammatory disorders of the gastrointestinal tract. The classical medical 
therapy applying corticosteroids or immunosuppressant drugs via tablets or pellet systems is 
often inefficient mainly due to enhanced elimination of the dosage forms by diarrhea and, 
therefore, limited time for drug release. The reduction of dosage form size may help to 
minimize the fast clearance from the gastrointestinal tract increasing local drug 
concentrations in the inflamed tissues [53].  
Nanoparticles (NPs) and microparticles (MPs) had shown to be able to remain in the 
ulcerated areas of the inflamed tissues for prolonged periods of time offering the possibility of 
a passive targeting approach [67], [75]–[77]. Furthermore, they can be entrapped in the 
mucus layer of the lumen [75]. A size-dependent accumulation of particulate drug delivery 
systems (DDS) in inflamed areas of the colonic mucosa in rats was previously demonstrated 
[75]. In contrast, a recent study revealed a higher accumulation efficacy of MPs in 
comparison to NPs in human patients [76]. The mechanism is not yet fully understood and 
has to be further investigated. However, it seems to be supported by an increased 
permeability of the inflamed epithelium and up-take of NPs into invading intestinal 
macrophages [41], [42], [76].  
The major motivation of this work was to develop a small particulate polymeric DDS for 
oral/rectal administration for an improved therapy of IBD using reproducible and controllable 
preparation techniques. To improve the understanding of inflammation targeting by passive 
targeting as well as physico-chemical and biopharmaceutical properties of the DDS on the 
success of IBD therapy, a nanoparticulate and a microparticulate DDS were developed and 
both were compared. In both DDS the immunosuppressive drug cyclosporine A (CYA) and 
the anti-inflammatory drug budesonide (BU) were encapsulated. Both drugs were selected 
due to differences in their pharmacological and physico-chemical properties, and their 
effectiveness in the therapy of IBD.  
This work was performed in the context of the ERA-Net EuroNanoMed project Delivering 
Nanopharmaceuticals through Biological Barriers, acronym ‘BIBA’, with a focus on the 
transfer of the preparation of particulate DDS to lager production scales in a future 
perspective. Therefore, established excipients and scaleable, robust methods for the 
preparation of the DDS were selected. 
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In the first part of this work a design of experiments (DOE) approach was applied to a 
nanoprecipitation method (NPR) and a nano spray drying technique (NSD) as processes for 
preparing poly (lactic-co-glycolic acid) (PLGA) NPs and MPs. In particular, the determination 
of the feasible size range, critical factors influencing particle size, size distribution or yield, 
and the robustness towards variations of the batch size were investigated. A fractional 
factorial design for response surface was applied to study the influence on continuous, 
categorical and discrete factors. The NPR yielded NPs (150-200 nm) with narrow size 
distributions (PDI <0.15). The polymer concentration was the main factor in this process, 
which was found to be very robust towards varying the batch size (0.625-50.0 ml). In contrast, 
the NSD, which yielded MPs (2-163 µm), is influenced by various factors and, therefore, more 
difficult to control and less robust towards varying the batch size (5-40 ml). By a factorial 
design approach to NPR, an equation could be derived, which allowed the prediction of 
several optimal formulations with defined particle sizes and distributions. It could be 
demonstrated that a DOE can be an optimal quality tool to optimize well known systems and 
to understand unknown processes as well as to achieve consistent quality of the DDS.  
In size and size distribution optimized DDS were further improved for drug load for the 
selected lipophilic drugs CYA and BU. The loaded DDS were characterized in size and size 
distribution and in vitro release tests were performed. With the NSD high encapsulation 
efficiencies of ~90% were yielded for both drugs. For the NPR the encapsulation of CYA 
(67%) is more efficient than for BU (37%). From NPs and MPs different release profiles were 
obtained, which can be explained by the amorphous or crystalline status, determined by X-
ray powder diffraction, as well as the lipophilicity of the drugs in the respective particles. In 
particular, both CYA loaded NPs and MPs demonstrated promising release profiles for the 
passive targeting approach. In addition, the CYA loaded MPs demonstrated the best 
controlled release profile. Moreover, a protocol for freeze-drying the nanoparticulate 
formulations was developed to obtain a storable product.  
As the matrix of the spray dried MPs consists of PLGA and the stabilizer Span60, the 
question of the location or spatial distribution of the Span60 was addressed by a small angle 
X-ray scattering study. MPs measured in solid state showed a tension inside the particles, 
whereas in aqueous solution no tension could be detected leading to the conclusion of a 
clustered organisation of Span60 within the particles.  
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Furthermore, the ability to modify the MPs in release by blending the MPs with poly (ethylene 
glycol), using BU as model drug, was investigated. Additionally to modify the MPs in size, low 
molecular weight PLGA (2149 Da in comparison to 40,300 Da) was spray dried for the 
fabrication of MPs. By blending the MPs no improvement in the release could be achieved for 
the application approach. A strong burst release was determined already at small amounts of 
poly (ethylene glycol) and, furthermore, 25-32% of the encapsulated BU remained in the 
MPs. No change in size was determined by spraying PLGA with lower molecular weight due 
to the strong influence of the used stabilizer on size as revealed previously by the DOE. 
The anti-inflammatory efficacy as well as the size-dependent accumulation of all optimal 
loaded NPs and MPs were evaluated on an in vitro three-dimensional cell culture model of 
the inflamed intestinal mucosa (triple culture model), consisting of Caco-2, THP-1 and MUTZ-
3 cell lines. The transepithelial electrical resistance (TEER) and IL-8 levels were measured to 
monitor the anti-inflammatory effect of the particles. Furthermore, particles, which 
incorporated a far-red fluorescent dye (DID), were added to the triple culture model and 
visualized by confocal laser scanning microscopy to investigate the deposition of the 
particles. The anti-inflammatory effect was more significant after treatment with CYA loaded 
NPs and MPs compared to a CYA solution. However, the treatment with BU loaded NPs and 
MPs as well as drug free particles showed also an anti-inflammatory effect. NPs were 
deposited at the intercellular spaces and up-taken in Caco-2 cells, while MPs were detected 
at the cell walls indicating a size-dependent accumulation/deposition. It can be concluded that 
the deposited particles release the residual encapsulated drug leading to the improved anti-
inflammatory effect. 
Cytotoxicity and immunotoxicity studies were further applied on the drug free particles since 
an activation of the immune system by the particles could decrease the drug effect and lead 
to long-term medication. Hence, a WST-1 assay was performed to assess the cytotoxicity of 
particles on 3T3 mouse fibroblasts and on J774A.1 murine macrophages. Additionally, the 
complement system activation and the alteration, activation and suppression, of cytokine 
secretion (IL-6 and IL-12) of dendritic cells were investigated in appropriate in vitro assays to 
test the interference with the development of an immune response. The NPs and MPs show 
no toxicity in relevant concentrations for in vitro testing and no activation of the complement 
system was determined. The absence of detectable levels of IL-6 and IL-12 by incubation of 
dendritic cells in presence of the particles underlines the safety of the particles as they are 
not activating immune responses by themselves.  
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A concentration dependent suppression (NP: <0.05 mg/ml, MP: 0.01-0.5 µg/ml) of the IL-12 
secretion was investigated and should be considered in further investigations. No result within 
the performed cytotoxicity and immunotoxicity testing would raise concerns about the safety 
of NPs and MPs. 
Finally, both CYA loaded DDS were selected as most promising particles with regard to the 
investigated physico-chemical and biopharmaceutical properties, and in vitro parameters to 
enter in vivo studies in a chemically induced dextran sodium sulfate mouse model of acute 
colitis. NPs and MPs both loaded and drug free were orally applied by gavage at different 
concentrations to diseased and healthy mice, and compared to a commercially available 
product (Sandimmun® Neoral, Sandimmun). All particles were tested in healthy mice to 
evaluate the safety of the particles. Pathophysiological changes were recorded by clinical 
parameters: body weight, stool consistency, blood in stool, colon length, and colon 
weight/length ratio as well as colon histology. The CYA levels in plasma after sacrifice at 
day 8 were measured to determine the systemic bioavailability of the CYA from the particles. 
Furthermore, cytokine levels in colon of pro-inflammatory (IL-1ß, IL-6, TNF-ɑ) and anti-
inflammatory cytokines (IL-4, IL-10) were determined as indictors of inflammation status. The 
CYA loaded NPs showed efficacy in the investigated parameters, colon length, and 
colon weight/length ratio, and in the histological analysis, plus a reduced systemic 
bioavailability of the CYA. Furthermore, they showed a significant improvement compared to 
control and Sandimmun. The CYA loaded MPs demonstrated effectiveness in colon length, 
colon weight/length ratio, but led to increased pathological changes of the mucosa. 
Furthermore, the CYA loaded MPs led to intoxication with CYA determined by a strong body 
weight reduction and shaggy fur, whereas the CYA-NPs had a protective effect by the 
encapsulation of the CYA due to the reduced bioavailability.  
Suggestions for future work 
The present work revealed the potential of nano- and microparticulate DDS for an improved 
therapy for IBD demonstrating the need of the characterization of the used preparation 
techniques as well as in vivo and in vitro methods for the evaluation of the efficacy of the drug 
delivery systems. 
Future work should focus on a novel, promising strategy for the encapsulation of BU to 
reduce the high burst release and to facilitate, therefore, the entrance of the BU loaded DDS 
to in vivo efficacy studies.  
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This could be achieved, e.g. (a) using swellable methacrylate copolymers for the 
encapsulation, or (b) by encapsulation in PLGA based nanocapsules consisting of an oily 
core surrounded by the PLGA. With the evaluated knowledge of the used NPR the particulate 
formulations could be easily transferred to the preparation with this method.  
In an in vitro model of the inflamed intestinal mucosa and in vivo model of chemically induced 
colitis, in particular the CYA loaded DDS showed anti-inflammatory efficacy. However, the 
size-dependency could not be fully clarified in the present work. The in vitro triple culture 
model cannot be used to determine a deposition of particles in a mucus layer. In the in vivo 
model the MPs were less tolerated and no accumulation studies with fluorescent particles 
were performed.  
Future work should focus on further in vivo studies in rodent models based on the results of 
the systemic bioavailability (CYA plasma level). These studies should address the 
determination of the lowest effective dose and evaluation of particles deposition using 
fluorescent particles. Furthermore, the DDS should be evaluated in a chronic model of 
chemically induced colitis, which is characterized by focal epithelial regeneration, and a TH1 
and TH2 cytokine profile.  
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9. Zusammenfassung und Ausblick 
Chronisch-entzündliche Darmerkrankungen (IBD) - Morbus Crohn und Colitis ulcerosa - sind 
chronische, episodisch auftretende, entzündliche Veränderungen des Darms. Die klassische 
medikamentöse Therapie mit Tabletten oder Pellet-Systemen, die Kortikosteroide oder 
Immunsuppressiva enthalten, ist oft ineffizient. In Folge des mit den Erkrankungen 
einhergehenden Durchfalls, wird die Transitzeit der Arzneiformen und damit auch der zur 
Verfügung stehende Zeitraum für die Arzneistofffreisetzung reduziert. Mit einer Verkleinerung 
der Arzneiformen könnte eine Verlängerung der Verweildauer im Darm erreicht werden [53].  
Nano- und mikropartikuläre Arzneistoffträgersysteme (NP und MP) können in ulzerierten 
Regionen des entzündeten Darmgewebes akkumulieren und ermöglichen damit ein passives 
Targeting. Zudem können sich die NP und MP an der Mukusschicht des Darms anlagern 
[67], [75]–[77]. Eine optimale Zielgröße der partikulären Arzneistoffträgersysteme konnte 
bislang noch nicht klar definiert werden. Während NP sich in einem chemisch induzierten 
Rattenmodell der Kolitis verstärkt im ulzerierten Gewebe anreicherten, zeigten MP bei an IBD 
leidenden Patienten eine verstärkte Anreicherung in ulzerierten Gewebsläsionen im Vergleich 
zu NP [76]. Der zugrunde liegende Mechanismus ist noch nicht vollständig geklärt. Vermutet 
wird ein Zusammenhang mit der erhöhten Permeabilität des entzündeten Epithels und eine 
damit verbundene Aufnahme der NP in Epithelzellen und Makrophagen, die in das 
entzündete Gewebe einwandern [41], [42], [76]. 
Zielsetzung dieser Arbeit war die Entwicklung von partikulären Arzneistoffträgersystemen, für 
eine verbesserte Therapie von entzündlichen Darmerkrankungen, unter der Verwendung von 
reproduzierbaren und kontrollierbaren Herstellungstechniken. Die partikulären 
Arzneistoffträgersysteme sollten sich vor allem für die orale/rektale Applikation eignen. Um 
ein besseres Verständnis für das Targeting-Prinzip mit NP und MP zu bekommen sowie den 
Einfluss von physikochemischen und biopharmazeutischen Eigenschaften der 
Arzneistoffträgersysteme auf den Erfolg der Therapie von IBD zu untersuchen, wurden 
jeweils ein nano- und ein mikropartikuläres Arzneistoffträgersystem entwickelt und 
miteinander verglichen.  
Die Arzneistoffträgersysteme wurden, aufgrund ihrer bisherigen Effizienz in der Therapie von 
IBD, mit dem Immunsuppressivum Cyclosporin A (CYA) und dem Kortikosteroid Budesonid 
(BU) beladen. 
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Diese Arbeit wurde im Rahmen des ERA-Net EuroNanoMed Projektes Delivering 
Nanopharmaceuticals through Biological Barriers (Akronym „BIBA“) angefertigt, welches den 
Fokus auf eine spätere, potenzielle Übertragbarkeit der Formulierung auf einen industriellen 
Maßstab legte. Daher wurden etablierte Ausgangssubstanzen für die Herstellung der 
Arzneistoffträgersysteme, wie das Polylactid-co-Glycolid (PLGA) ausgewählt sowie 
skalierbare, robuste Herstellungsmethoden angewandt.  
Für die Herstellung der, auf PLGA basierenden, partikulären Arzneistoffträgersysteme 
wurden eine Nanopräzipitationsmethode (NPR) und die Nano-Sprühtrocknung (NSD) 
ausgewählt. Durch Anwendung statistischer Versuchsplanung (DOE) konnte für beide 
Methoden der mögliche Größenbereich, kritische Prozessfaktoren, die Partikelgröße, die 
Partikelgrößenverteilung und Partikelausbeute sowie die Robustheit bei der Variation der 
Chargengröße untersucht werden. Ein fraktioniertes Design (Reponse Surface) ermöglichte 
es zudem, den Einfluss von kontinuierlichen, kategorischen und diskreten Faktoren zu 
bestimmen. Mittels NPR konnten NP (150-200 nm) mit einer engen Größenverteilung 
(PDI <0.15) hergestellt werden, wobei die Polymerkonzentration den Haupteinflussfaktor für 
die Partikelgröße und Partikelgrößenverteilung darstellt. Die NPR zeigte eine große 
Robustheit in der Variation der Chargengröße (0.625-50.0 ml) bei gleichbleibender 
Partikelgröße und Partikelgrößenverteilung. Mit der NSD konnten MP (2-163 µm) hergestellt 
werden, wobei der Prozess durch mehrere der untersuchten Faktoren beeinflusst wurde. In 
der Folge war dieser schwerer zu kontrollieren und zeigte sich zudem weniger robust in der 
Variation der Chargengröße (5-40 ml). Basierend auf den Ergebnissen der statistischen 
Versuchsplanung, konnte für die NPR eine Gleichung erstellt werden, mit deren Hilfe 
definierte Partikelgrößen und Partikelgrößenverteilungen vorausberechnet werden können. 
Somit erwies sich die statistische Versuchsplanung als erfolgreiche Methode zur 
Verbesserung bekannter Herstellungsprozesse wie der NPR und ermöglichte darüber hinaus 
ein besseres Verständnis für neuere und komplexere Methoden wie der NSD. 
Die in Partikelgröße und Partikelgrößenverteilung optimierten partikulären 
Arzneistoffträgersysteme wurden anschließend mit CYA und BU beladen, und in ihrer Größe 
sowie Größenverteilung charakterisiert. Zudem wurden in vitro Freisetzungsprofile der NP 
und MP ermittelt. Um die, sich nach der Herstellung in Suspension befindlichen, NP in eine 
lagerbare Form zu bringen, wurde ergänzend eine Gefriertrocknungsmethode entwickelt. Für 
beide Arzneistoffe konnte bei der Beladung von MP eine hohe Einkapslungseffizienz erreicht 
werden (>90%). Für die NP wurde für die Beladung mit CYA (67%) eine höhere 
Einkapslungseffizienz im Vergleich zu BU (37%) erhalten.  
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Die Arzneistoffträgersysteme weisen für jeden Arzneistoff ein anderes Freisetzungsverhalten 
auf. Die mit CYA beladenen NP zeigen eine langsame Freisetzung des CYA. Die mit CYA 
beladen MP setzen das CYA am besten kontrolliert frei. Dies beruht zum einen auf den 
kristallinen oder amorphen Anteilen des Arzneistoffes in den Arzneistoffträgersystemen, 
welche mit Röntgendiffraktometrie (XRD) bestimmt wurden, und zum anderen auf der 
Lipophilie der verwendeten Arzneistoffe.  
Die Untersuchung der sprühgetrockneten MP mit Röntgenkleinwinkelstreuung (SAXS) sollte 
Aufschluss geben über die Lokalisation des Stabilisator Span 60 in der Matrix der PLGA MP. 
Beim Vergleich der Vermessung der MP in Lösung und in Pulverform ergab sich eine 
Spannung in den Partikeln in Pulverform, die auf eine nicht-homogene Verteilung des 
Span60 zurückzuführen ist. Zudem wurde versucht, die Freisetzung aus den MP am Beispiel 
von BU durch das Verblenden der Partikel mit Polyethylenglykol zu erreichen. Hier konnte 
keine Verbesserung erzielt werden, da eine sehr schnelle Freisetzung des BU innerhalb der 
ersten Stunde erfolgte, und zudem 25-32% des BU nach 24 h in den Partikeln verbleibt. Auch 
eine Verringerung der Größe der MP, unter Verwendung von PLGA eines geringeren 
Molekulargewichtes, führte nicht zum angestrebten Erfolg. 
Die anti-entzündlichen Eigenschaften der Arzneistoffträgersysteme sowie die 
größenabhängige Deposition, wurden in vitro in einem drei-dimensionalen Zellkulturmodell 
der entzündeten Darmmukosa, bestehend aus Caco-2, THP-1 und MUTZ-3 Zelllinien, 
untersucht. Der transendotheliale elektrische Widerstand (TEER) und die IL-8 Level im 
Zellkulturmedium dienten dabei als Marker für anti-entzündliche Effizienz. Die Deposition von 
mit dem Fluoreszenzfarbstoff DID beladenen NP und MP wurde mittels konfokaler Laser-
Scanning-Mikroskopie bestimmt. Beladene und unbeladene Arzneistoffträgersysteme zeigten 
einen anti-entzündlichen Effekt. Dieser war für mit CYA beladene NP und MP signifikant 
besser. Ergänzend konnte gezeigt werden, dass NP in Caco-2 Zellen aufgenommen wurden 
und sich in den Zellzwischenräumen ablagern, wohingegen MP auf den Caco-2 Zellen 
akkumulieren, was auf einen größenabhängigen Effekt hindeutet.  
In einem weiteren Schritt wurde die Zytotoxizität und Immunotoxizität unbeladener NP und 
MP untersucht, da eine Aktivierung des Immunsystems mit Therapieversagen assoziiert sein 
kann. Für die Zytotoxizitätsstudien mittels WST-1 Assay erfolgte die Testung auf murinen 
Makrophagen- (J774A.1) und Fibroblasten-Zelllinien (3T3). Zur Bestimmung der 
Immunotoxizität wurden die Komplementaktivierung sowie die Beeinflussung der 
Zytokinsekretion (IL-6 und IL-12) dendritischer Zellen untersucht.  
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Die NP und MP zeigten weder zytotoxische Effekte auf den getesteten Zelllinien in relevanten 
Konzentrationen, noch eine Aktivierung des Komplementsystems. Die Abwesenheit von 
nicht-detektierbaren Zytokinleveln unterstreicht zudem die Sicherheit der 
Arzneistoffträgersysteme, da sie selbst keine Immunantwort auslösen. Eine 
konzentrationsabhängige Unterdrückung (NP: <0.05 mg/ml, MP: 0.01-0.5 µg/ml) der IL-12 
Ausschüttung konnte festgestellt werden und sollte für weitere Untersuchungen 
berücksichtigt werden.  
In Kombination mit den physikochemischen und biopharmazeutischen Eigenschaften, zeigten 
sich insbesondere die mit CYA beladenen MP und NP am besten geeignet für die in vivo 
Testung in einem Mausmodell der Dextran-Sodium-Sulfat-induzierten, akuten Kolitis. In 
diesem wurden die CYA beladenen NP und MP im Vergleich zu unbeladenen 
Arzneistoffträgersystemen sowie einem kommerziell erhältlichen Produkt (Sandimmun® 
Neoral, Sandimmun) getestet. Die pathophysiologischen Veränderungen des Modells wurden 
anhand der Parameter Köpergewicht, Stuhlkonsistenz, Auftreten von rektalen Blutungen, 
Kolonlänge, Kolon Gewichts/Längenverhältnis und Kolonhistologie untersucht. Zudem 
wurden die CYA Plasmalevel nach der letzten Verabreichung der Formulierungen gemessen. 
Um den Entzündungsstatus zu bestimmen, wurden die Level an pro-inflammatorischen (IL-
1ß, IL-6, TNF-ɑ) und anti-inflammatorischen (IL-4, IL-10) Zytokinen im Kolon gemessen. 
Insbesondere die mit CYA beladenen NP zeigten, durch eine reduzierte systemische 
Verfügbarkeit des Arzneistoffes, eine signifikante Verbesserung in den charakteristischen 
Parametern Kolonlänge, Kolon Gewichts/Längenverhältnis sowie in der histologischen 
Analyse, im Vergleich zu Sandimmun und erkrankten, unbehandelten Mäusen. Die mit CYA 
beladenen MP zeigten eine Verbesserung in den Parametern Kolonlänge, Kolon 
Gewichts/Längenverhältnis, aber auch verstärkte pathophysiologische Veränderungen in der 
histologischen Analyse. Zudem wird bei der Verabreichung der MP durch die schnelle 
systemische Verfügbarkeit von CYA, eine Intoxikation mit CYA vermutet. Dies äußerte sich in 
einer starken Gewichtsveränderung sowie einer Veränderung des Fells der Mäuse. Ein 
protektiver Effekt hingegen zeigte sich, bei den mit CYA beladenen NP, durch die reduzierte 
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Ausblick 
Die vorliegende Arbeit zeigt das Potenzial von nano- und mikropartikulären 
Arzneistoffträgersystemen für eine verbesserte Therapie von IBD. Zudem wird die 
Notwenigkeit der Charakterisierung der verwendeten Herstellungsmethoden sowie die 
Verwendung von in vivo und in vitro Modellen für die Bewertung der Effizienz der 
Arzneistoffträgersysteme verdeutlicht. 
Zukünftige Forschungsanstrengungen sollten sich auf eine verbesserte Strategie der 
Verkapslung von BU z. B. unter der Verwendung von quellbaren Methacrylsäure-
Copolymeren oder durch die Herstellung von Nanokapseln konzentrieren, um eine 
kontrollierte Freisetzung zu erhalten und damit die Testung dieser Formulierungen in in vivo 
Studien zu ermöglichen. Mit dem Wissen über die Kontrollierbarkeit der NPR könnte dieses 
für den Transfer z. B. der Nanokapseln auf eine bestimmte Größe angewendet werden. 
In den verwendeten in vitro und in vivo Modellen zeigten speziell die mit CYA beladenen 
Arzneistoffträgersysteme eine anti-entzündliche Effizienz. Jedoch konnte der 
größenabhängige Effekt nicht weiter bestätigt werden. Daher sollten zukünftige Studien in 
weiteren Nagermodellen durchgeführt werden sowie die niedrigste effektive Dosierung und 
die Deposition der NP und MP im Kolon evaluieren werden. Zudem sollte die Effizienz der 
Arzneistoffträgersysteme in einem chronisch entzündlichen Modell der Kolitis getestet 
werden, welches durch eine Regeneration des Epithels und durch ein TH1 und TH2 
Zytokinprofil charakterisiert ist. 
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10. List of abbreviations 
A   absorbance 
ADME    absorption, distribution, metabolism and excretion 
ANOVA  analysis of variance 
API   active pharmaceutical ingredient 
ATCC   American Type Culture Collection 
BU   budesonide 
Büchi B-90  Büchi Nano Spray Dryer B-90 
CD   Crohn’s disease 
CLSM   confocal laser scanning microscopy 
COX-2   cyclooxygenase-2 
CYA   cyclosporine A 
CYP   cytochrome P450 
Da   Dalton 
DAI    disease activity index  
DCM   dichloromethane 
DDS   drug delivery systems 
DID    1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate 
DOE    design of experiments 
DSMZ   Deutsche Sammlung von Mikroorganismen und Zellkulturen 
DSS   dextran sodium sulfate  
EDTA    ethylenediaminetetraacetic acid  
EE   encapsulation efficiency 
EMA   European Medicines Agency 
FBS   fetal bovine serum  
FDA   Food and Drug Administration 
GIT   gastrointestinal tract 
GWAS   genome wide association studies 
IBD   inflammatory bowel disease 
IL   interleukin 
IFN   interferon 
iNOS   inducible nitric oxide synthases  
i.v.   intravenous 
HPLC   high-performance liquid chromatography 
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LOD   lower limit of detection  
LOQ   lower limit of quantification  
LPS   lipopolysaccharides LPS 
NEAA    non-essential amino acids  
NFAT    nuclear factor of activated T cells 
NF-κB    nuclear transcription factor kappaB  
NP   nanoparticle 
NPR    nanoprecipitation method  
NSD    nano spray drying technique  
MECS   Material Engineering Center Saarland  
MP   microparticle 
MW   molecular weight 
MWCO  molecular weight cut-off 
PEG   polyethylene glycol 
PBS   phosphate buffered saline 
Ph. Eur.  European Pharmacopeia 
PDI    polydispersity index 
Pen/Strep  Penicillin/Streptomycin 
PLGA    poly (lactic-co-glycolic acid)  
PMA   phorbol myristate acetate  
PVA   polyvinyl alcohol 
R   run 
SAXS   small angle x-ray scattering 
S.D.   standard deviation  
SEM   scanning electron microscopy 
SGF   simulated gastric fluid  
Span60  sorbitan monostearate  
TEER   transepithelial electrical resistance 
Tg   glass-transition temperature 
TH   T helper cell 
TNBS    trinitrobenzenesulfonic acid  
TNF-ɑ   tumor necrosis factor-ɑ 
UC   ulcerative colitis 
USP   United States Pharmacopeia 
WHO   World Health Organization 
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XRD   X-ray powder diffraction 
ZP   zeta potential  
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